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ABSTRACT  
Dendritic cells (DCs) constitute a large family of immune cells with a dendritic 
morphology and a critical role in all aspects of an immune response and immune regulation, 
from immunogenicity to tolerance. One of the important characteristic of DCs is maturation, 
during which DCs undergo significant changes in their phenotypic and functional properties and 
change from phagocytic cells to highly efficient antigen presenting cells (APCs). Dendritic cells 
have recently been at the centre of attention as a promising tool in treatment or control of cancer 
and infectious diseases. Accordingly, DCs have been generated, matured, and loaded with tumor-
associated or microbial antigens ex vivo, to be subsequently used as therapeutic tools or vaccine 
carriers.  
Hepatitis C virus (HCV) is a hepatotropic virus, which infects the liver in humans and 
results in a chronic infection in most cases. The persistent infection of the liver eventually results 
in cirrhosis and/or hepatocellular carcinoma in 15-20 years. Chronic hepatitis C (CHC) has 
recently become a serious health concern and the leading cause of liver transplantation. The 
mechanism of persistence of the virus is not clear yet, but as a Th1-type immune response is 
strongly correlated with elimination of HCV in vivo, it is evident that insufficient cellular 
immunity is a contributing factor. Non-cytopathic viruses such as HCV may infect immune cells 
to modify and evade a protective immune response. Dendritic cells, which are the most potent 
APCs, and uniquely capable of initiating a primary immune response, have been considered as a 
target for HCV. Inhibition of DC maturation by HCV has been suggested as a potential 
contributing factor in immune evasion; however, this issue remains controversial as many 
contradictory results have been reported.  
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To investigate this contention, we initially planned to evaluate the effects of HCV on 
DCs of CHC patients; however, due to limited access to patients’ blood, we instead elected to 
examine the effects of HCV genes products on in vitro generated DCs from healthy volunteers. 
Specific attention was paid to the generation, maturation, and transfection of DCs in vitro, as 
variability in procedures might have been responsible for the controversial reports. Viral vectors 
have generally been used to transfect DCs; however, a vector and HCV genes might have 
synergistic effects on DC maturation. Thus, our first objective was to develop an efficient non-
viral transfection method while retaining high viability of the DCs, as previous efforts in this 
regard resulted either in low efficiency or in low viability of DCs after transfection. In order to 
improve the viability of DCs after transfection, we established a new method for fast generation 
of monocyte-derived DCs (Mo-DCs) in two to three days. By performing a comprehensive study 
on transfection reagents, electroporation, and nucleofection with DNA or in vitro transcribed 
(IVT) RNA, we successfully established a new, highly efficient non-viral method for transfection 
of DCs with long-term viability. This method is based on the use of the X1 program of a 
nucleofection device with IVT RNA and results in high transfection efficiency of 93%, with 75% 
viability of DCs 72 h after transfection. 
Subsequently, we performed a comprehensive study on the effects of different maturation 
methods on the phenotype, function and gene expression profile of DCs. Three commonly used 
treatments, TNF-α, LPS and a maturation cocktail (MC) consisting of IL-1β, IL-6, TNF-α, and 
prostaglandin E2 (PGE2) were compared. Our results showed that there is a significant 
difference in the level of maturity between these treatments, and MC generated more 
functionally competent mDCs than TNF-α or LPS. In addition, MC induced Th1-promoting 
changes in the transcriptional profile of mDCs. This observation was important, as the presence 
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of PGE2 in MC was previously challenged based on the potential induction of Th2-biased 
immune responses. However, our results suggest retaining PGE2 in the cocktail because of the 
fact that MC generated highly competent and functional mDCs with a Th1-promoting 
transcriptional profile. 
Finally, Mo-DCs were transfected with IVT HCV RNAs, individually or in combination. 
While HCV genes had no inhibitory effect on DC maturation, transfection of DCs with IVT core 
RNA appeared to result in changes compatible with maturation. To investigate this in more 
detail, the transcriptional profiles of DCs transfected with IVT core, NS3 or green fluorescent 
protein (GFP) RNA were examined using a DC-specific membrane array. Of the 288 genes on 
the array, 46 genes were distinctively up- or down-regulated by transfection with IVT core RNA 
in comparison to NS3 or GFP RNA treatments, 42 of which are involved in DC maturation. The 
effects of core on maturation of DCs were further confirmed by a significant increase in surface 
expression of CD83 and HLA-DR, a reduction of phagocytosis, as well as an increase in 
proliferation and IFN-γ secretion by T cells in a mixed lymphocyte reaction assay. These results 
show that HCV core does not have an inhibitory effect on human DC maturation, but could be a 
target for the immune system.  
The use of a non-viral method of transfection combined with confirmed transcriptional 
profiles of DCs in this study may make these results conclusive for in vitro generated DCs from 
healthy volunteers. However, further investigations are required to confirm the effects on DCs 
from CHC patients.  
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 1 
Introduction and literature review 
 
1.1 Dendritic cells 
Dendritic cells (DCs) are composed of a family of immune cells with a dendritic 
morphology, which was the basis for their designation. The first member of DC was discovered 
by Paul Langerhans in 1868 and thought to be a kind of nerve cell; however, the family of DCs 
was identified and described by Ralph Steinman in 1973 as a part of the immune system 
(Steinman and Cohn 1973; Steinman, Lustig et al. 1974). Over the past few decades, a large 
number of studies established a role for DCs as one of the most important cell types in the 
immune system. DCs are potent antigen-presenting cells (APCs), which play a critical role in all 
aspects of an immune response and immune regulation resulting in immunity or tolerance. 
Accordingly, they became a promising tool for treatment or control of infectious diseases, 
cancers, allergies, and autoimmune disorders. DCs are also of interest in transplantation 
medicine. 
 
1.1.1 Biology of dendritic cells and role in the immune system 
DCs constitute a complex system of cells, with different phenotypes and specific 
functions. They originate from diverse lineages of bone marrow cells, and dispersed throughout 
the body, but localize more specifically at the sentinel barriers, such as skin and respiratory or 
gastrointestinal mucosa, thus providing protection from pathogens. DCs are non-dividing cells 
and need to be continuously re-generated as their in vivo life span is short (Kamath, Pooley et al. 
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2000; Matsuno and Ezaki 2000; O'Keeffe, Hochrein et al. 2002). Dendritic cells residing in non-
lymphoid organs such as lung, intestine, liver, kidney, and heart are called interstitial DCs; while 
those in the skin are known as Langerhans cells (LCs). In general, DCs remain at an immature 
status in peripheral tissues, where they are highly exposed to potentially harmful non-self 
antigens (Cella, Sallusto et al. 1997; Banchereau and Steinman 1998; Mellman and Steinman 
2001) (Fig. 1.1). They take up antigens, change their morphology and marker expression, and 
start the maturation process resulting in different functional capabilities and a directional motility 
toward local lymph nodes (LNs). On their way through afferent lymphatic vessels, they are 
called veiled cells based on their dendritic appearance. Their migration to LNs eventually results 
in effective contact with T cells (Mellman and Steinman 2001), which are also attracted 
selectively to the LNs (Savina and Amigorena 2007). In the T zone area of LNs, DCs are known 
as interdigitating cells where they present antigens to T cells.  
 
Figure 1.1. The biology and life cycle of dendritic cells. 
2 
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T cell 
Local LN 
Bone marrow 
 DC precursors 
 Blood vessel 
1 
3 
4 
Residing iDCs (interstitial DCs) 
Interdigitating DCs 
 3 
Dendritic cells were originally considered to be of myeloid lineage and closely related to 
monocytes, macrophages (MФs) and granulocytes. However, later studies suggested that DCs 
can be generated along distinct developmental pathways and from different haematopoietic 
precursors. There are at least two progenitors, which are called common myeloid progenitor 
(CMP) developing into all myeloid cells including DCs, granulocytes, and MФs (Lotze M. T. 
2001), and common lymphoid progenitor (CLP) developing into DCs, natural killer cells (NKs), 
B cells, and T cells. In most tissues, DCs are normally of CMP origin, whereas in the thymus 
they are of CLP origin and in the spleen they are presumed to be derived from both progenitors. 
However, other studies have questioned this restriction (Manz, Traver et al. 2001; Adolfsson, 
Mansson et al. 2005). There also is a low percentage (less than 1% of peripheral blood 
mononuclear cells [PBMCs]) of DCs in the circulating blood known as circulating DCs (Van 
Voorhis, Hair et al. 1982). Recently, four specialized features have been ascribed for DCs 
(Steinman and Banchereau 2007), including location of DCs (briefly explained above), 
maturation of DCs, antigen presentation by DCs, and subtypes of DCs.  
 
1.1.2 Maturation of dendritic cells 
Maturation is one of the most important features described for the DC family. It indicates 
the conversion of these cells from immature sentinels to mature immunostimulatory cells. In the 
process of maturation, DCs lose most of their endocytotic ability (although it is increased in the 
first few hours of this process), gain a higher capacity of antigen presentation, and switch their 
migratory potential toward the LNs in response to a high concentration of specific chemokines 
for mature DCs (mDCs) (Willimann, Legler et al. 1998; Ohl, Mohaupt et al. 2004). These 
chemokines consist of CCL19, CCL21, and CXCL12, which are constitutively secreted in LNs, 
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where DCs interact with naïve T cells. During maturation, DCs reduce the expression of uptake 
molecules and immature (i)DC-specific chemokine receptors such as CCR5 and CCR6. In 
contrast, the cell surface expression of antigen-presenting molecules such as CD83, co-
stimulatory molecules such as CD80 and CD86, MHC molecules, and mDC-specific chemokine 
receptors such as CCR7 and CXCR4 is increased, and the secretion of cytokines and chemokines 
enhanced. Cluster of differentiation 83 molecule (CD83) is the best known and studied 
functional marker for mDCs as it is critical for antigen presentation (Lechmann, Krooshoop et al. 
2001; Lechmann, Berchtold et al. 2002; Lechmann, Zinser et al. 2002; Fedele, Frasca et al. 2004; 
Kotzor, Lechmann et al. 2004; Zinser, Lechmann et al. 2004). Following contact with T cells, 
DCs are licensed to express cytokines such as IL-12 to presumably determine the type of 
immune response and polarize the response based on the characteristics of the antigen. Finally, T 
cells need to be released or de-attached from mDCs in order to be activated and to proliferate. 
DCs also play a role in this de-attachment step by expression of pleckstrin homology, Sec7 and 
coiled-coil domains, binding protein (PSCDBP), which mediates this process. As mDCs are not 
seen to leave LNs via efferent lymphatic vessels (Matsuno and Ezaki 2000), the maturation 
process appears to be irreversible and presumably ends with apoptotic death after antigen 
presentation within LNs. Nowadays, maturation is a subject of controversy as impairment of DC 
maturation may result in chronicity of infectious diseases or escape of tumoral cells from the 
immune response. However, it is clear that in order to achieve strong immunity against non-self 
antigens, DCs need to be mature at the time of antigen presentation to T cells. Indeed, it is well 
known that iDCs expressing low levels of MHC class I and II and co-stimulatory molecules are 
involved in peripheral tolerance (Sallusto, Cella et al. 1995), and by presenting antigens may 
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induce tolerance instead of immunity (Jonuleit, Schmitt et al. 2001; Moser 2003). In general, 
three functional characteristics of DCs dramatically change during DC maturation. 
 
1.1.2.1 Phagocytosis 
Phagocytosis is a process by which particles, microorganisms, or dead cells are taken up, 
usually through receptors on the cell surface, and then destroyed within the phagocytic cell. This 
is part of the innate immune response facilitating the clearance of pathogens. The most important 
phagocytic cells are MФs and neutrophils, which are components of the innate immune system. 
Dendritic cells were originally assumed to be a type of MФs. However, subsequent studies 
showed that the phagocytosis is quite different in DCs, as they are not directly involved in the 
clearance of pathogens. The key difference is that MФs degrade the pathogen to the smallest 
particles possible to be destroyed and cleared from the body, whereas DCs process the pathogen 
in a strictly controlled manner to specific peptides, which are then presented to T helper (Th) 
cells. This is called antigen processing, which makes DCs unique among phagocytic cells. 
Although other phagocytes are also capable of antigen presentation, this is an inefficient process. 
Most importantly, as they cannot present antigens to naïve T cells, other phagocytes are not 
capable of initiating a primary immune response. Phagocytosis is one of the characteristics that 
are lost during DC maturation, and its loss is considered an indicator of the level of maturity in 
DCs. 
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1.1.2.2 Antigen presentation 
Antigen presentation is likely the most important function of DCs, being the final stage in 
immune recognition and the start of an immune response. It determines the outcome of a non-self 
invasive or self-compromising response. DCs are very well programmed for this function and 
most of the immune-related diseases presumably correlate to unsuccessful or improper antigen 
presentation. For this purpose, DCs process and present the antigens through different 
intracellular pathways, eventually resulting in presentation of the target antigen on MHC class I 
or II molecules resulting in a Th1- and Th2-type immune response, respectively. While iDCs are 
not efficient APCs, antigen presentation becomes much more efficient during DC maturation and 
thus is the most important functional property of mDCs. Consequently, maturation is probably 
the most important characteristic of DCs resulting in proper antigen presentation, which in turn, 
is considered another specialized feature of DCs.  
 
1.1.2.2.1 Th1 and Th2 decision 
Appropriate antigen presentation is assumed to be accomplished through three signals. 
The first signal is delivered through contact between MHC molecules on the APCs and the T cell 
receptors (TCRs) which provides information about the identity of the pathogen. The second 
signal is facilitated by the co-stimulatory molecules (CD80 and CD86) on the APCs through 
contact with CD28 on T cells; this provides the activation signal for T cells (Lotze M. T. 2001), 
while the absence of this signal results in T cell anergy (Sallusto, Cella et al. 1995). The third 
signal, which presumably determines the type of the immune response (Sad and Mosmann 1994; 
Dustin and Shaw 1999; Kalinski, Hilkens et al. 1999; Lanzavecchia, Lezzi et al. 1999), depends 
on the polarizing cytokines and microenvironment at the time of antigen presentation in a step 
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called licensing. Successful antigen presentation by DCs results in an optimal combination of 
Th1- and Th2-type immune responses based on the pathogen involved. It could be Th1-biased 
for intracellular pathogens such as viruses and some types of bacteria or Th2-biased for 
extracellular pathogens such as helminth.  
The flexibility and heterogenicity of DCs play a unique role in this process, which may 
be mediated by the type of cytokine secreted or present in the microenvironment (Macatonia, 
Hosken et al. 1995; Heufler, Koch et al. 1996). Interleukin (IL)-12 and IL-4 are the two main 
cytokines responsible for Th1- and Th2-type immune responses, respectively. In the presence of 
IL-12, emerging Th1-type cells secrete interferon (IFN)-γ, which promotes additional secretion 
of IL-12 by DCs eventually resulting in a cellular immune response. There are not enough 
studies on Th2-type immune responses, although IL-4 is known as the main cytokine driving the 
response toward a Th2 bias. In the presence of IL-4 developing Th2-type cells secrete IL-4, IL-5 
and IL-13 facilitating a humoral immune response (Kopf, Le Gros et al. 1993; Magram, 
Connaughton et al. 1996; Murphy and Reiner 2002; O'Garra and Robinson 2004). Type 1 Th 
cells are directly cytotoxic against infected or transformed cells, and more importantly, provide 
helper signals to cytotoxic CD8
+
 T lymphocytes (CTLs), and non-specific killer cells, such as 
NKs, natural killer T cells (NKTs), and MФs. In contrast, Th2 cells produce B cell-stimulatory 
factors and promote the proliferation, survival, cytokine production and immunoglobulin (Ig) 
class switch in B cells.  
Generally, the effect of DCs on the type of immune response is mainly based on their 
capability to secrete IL-12, which is associated with a Th1 response (Cella, Scheidegger et al. 
1996; Cella, Jarrossay et al. 1999; Kalinski, Hilkens et al. 1999). In addition, since DCs are not 
documented to be IL-4 secreting cells, it is believed that the absence of IL-12 secretion by DCs 
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may, by default, drive the immune response toward Th2. However, DCs are capable of 
expressing the ligand for the OX40 molecule (a member of TNF receptor family), which has 
been suggested to be involved in promoting a Th2-type response through induction of IL-4 
secretion upon stimulation of the OX40 receptor (CD134) on naïve T cells (Flynn, Toellner et al. 
1998; Ohshima, Yang et al. 1998). There also is evidence based on in vitro experiments that the 
DC:T cell ratio determines the type of immune response, as high ratios of DC to T cells favor a 
Th1 response (Tanaka, Demeure et al. 2000). Furthermore, the antigen dose presented to T cells 
has been reported to play a role in the type of immune response induced; however, linking the 
dose level of an antigen to a specific type of immune response is controversial (Hosken, Shibuya 
et al. 1995; Menon and Bretscher 1998; Power, Wei et al. 1998; Ruedl, Bachmann et al. 2000; 
Boonstra, Asselin-Paturel et al. 2003). Recently, another type of T cells has been described as 
regulatory T cells (Tregs). The balance between Tregs and T effector cells may determine the 
outcome of an immune response. Regulatory T cells are mainly involved in tolerance against self 
antigens (natural Tregs) (Levings, Sangregorio et al. 2002; Bach 2003) or harmless non-self 
antigens (adaptive Tregs) such as intestinal flora (Khoo, Proctor et al. 1997; Bluestone and 
Abbas 2003). However, whether Tregs have any role in Th1 and Th2 decision is not yet clear. 
In summary, as a non-optimal combination of cellular and humoral immunity may result 
in chronic disease, the balance between Th1- and Th2-type immune responses is likely the most 
critical aspect of immunity. To prevent chronic disease due to uncontrolled spread of the 
pathogen or autoimmune damage to the host tissues and immunopathology, the Th1:Th2 ratio of 
the immune responses needs to be properly matched to a particular type of pathogen.  
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1.1.2.2.2 Cross-presentation 
In general, extracellular antigens are processed and presented through the MHC class II 
pathway driving a Th2 response, which results in antibody production (humoral immunity), 
whereas processing and presentation of intracellular antigens is handled via the MHC class I 
pathway driving a Th1 response, which results in a CTL response (cellular immunity). Cross-
presentation could be defined as the potential of an APC to switch this process to a pathway that 
is not the default for that antigen; for instance, presentation of an extracellularly obtained antigen 
through the MHC class I pathway. The switch to the MHC class I pathway could happen by 
destruction of endocytic compartments and release of an extracellular antigen to the cytoplasm 
favoring cytosol delivery resulting in cross-presentation. The other potential mechanism is the 
entry and involvement of MHC class I molecules in endosomes and lysosomes during recycling 
in the cells, as these cellular compartments are carrying antigens, which are usually processed 
through the MHC class II pathway (Gromme, Uytdehaag et al. 1999; Kleijmeer, Escola et al. 
2001). Cross-presentation is a critical aspect of immunity as it provides flexibility for APCs to 
properly present antigens of pathogens such as cytomegalovirus (CMV), which escape the usual 
presentation pathways as an immune evasion mechanism (Lutz 2006). Moreover, if an 
intracellular pathogen does not normally infect immune cells, APCs would still be able to present 
antigens obtained from an extracellular source to the proper pathway. It is also important for the 
presentation of tumor-associated antigens (TAAs) in the MHC class I pathway (Berard, Blanco 
et al. 2000; Nouri-Shirazi, Banchereau et al. 2000; Russo, Tanzarella et al. 2000), as tumoral 
cells usually break down outside the APCs. Although the capability of cross-presentation was 
initially assumed to be a characteristic of all APCs, it was later shown to be mainly a DC-specific 
property (Yrlid and Wick 2000; Jung, Unutmaz et al. 2002). This has given DCs a unique role in 
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the immune system as decision-making cells. Detailed knowledge of this capacity of DCs may 
lead to innovation of in vitro techniques in order to manipulate DCs for clinical purposes, in 
order to switch undesired types of immune responses into appropriate ones.  
 
1.1.2.3 Migration  
Migration primarily refers to the movement of mDCs toward the regional LNs, in order 
to present antigens to T cells, which then initiate an immune response. DC motility and 
migration is a strictly controlled process depending on the expression of chemokine receptors 
and chemokine production by DCs.  Studies in mice and rats have shown that DCs constitutively 
migrate toward LNs even in the absence of pathogens or any damage to tissues (Pugh, 
MacPherson et al. 1983; Wu, Vremec et al. 1995; Liu, Zhang et al. 1998; Kamath, Pooley et al. 
2000). In fact, this is part of their role in inducing T cell tolerance to self-antigens. However, 
when this motility is induced due to maturation of DCs after detection of non-self antigens, it 
results in immunogenicity.  
In theory, without migration to the LNs, an immune response would be aborted or ended, 
followed by presentation of antigens in the periphery, which may result in tolerance. Chemokine 
receptors CCR7 and CXCR4 are two important receptors as their ligands, CCL19, CCL21, and 
CXCL12, are present in high concentrations in the LNs. In general, mDCs without these 
receptors fail to reach the LNs to deliver their message, resulting in inappropriate or inefficient 
immune responses. 
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1.1.3 Subtypes of dendritic cells 
Different subtypes of DCs have been described based on their location, the type of 
pathogens they are exposed to, the type of immunity expected, or tolerance as their main 
function. It has been suggested that the existence of diverse subtypes of DCs could explain 
dissimilar or sometimes controversial functions of DCs observed in the immune system, as each 
subtype could behave differently in promoting or regulating an immune response.  
Studies on DC subtypes have been largely performed in mice; however, murine DCs are 
not necessarily comparable to human DCs. A simplified and useful categorization of human 
DCs, based on limited studies on blood DCs or in vitro generated DCs, includes two types of 
conventional myeloid DCs (cDCs) originated from CMPs, and plasmacytoid lymphoid DCs 
(pDCs) originated from CLPs. Although there is considerable similarity and flexibility in these 
two subtypes of DCs, they show important differences in their phenotypes, surface markers and 
functions.  
Conventional DCs are considered classic DCs with dendritic morphology and primarily 
located at sentinel barriers in an immature state with high phagocytic ability. They patrol tissues 
for pathogens, endocytose them, proceed with the maturation process, migrate to LNs, and 
introduce the antigens to T cells to initiate an immune response. They are capable of producing 
normal amounts of IFN-α/β and high amounts of IL-12 (Ito, Amakawa et al. 2004), and of 
inducing Th1- as well as Th2-type immune responses. Conventional DCs express most myeloid 
lineage receptors such as CD11b, CD11c, CD13, and CD33 and most TLRs (TLR1-6, and 
TLR8) with exception of TLR9, and are dependent on both GM-CSF and IL-4 for in vitro 
differentiation. In contrast, pDCs are round cells without dendrites and similar to plasma cells, 
more resembling a DC-precursor than a DC. In contrast to cDCs, pDCs are not phagocytic cells, 
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mainly located in lymphoid tissues and not normally seen in peripheral non-lymphoid tissues 
except at a time of inflammation. This occurrence is reported to be associated with inflammatory 
situations seen in autoimmune, allergic, or tumoral diseases (Farkas, Beiske et al. 2001; 
Wollenberg, Wagner et al. 2002; Hartmann, Wollenberg et al. 2003; Vermi, Bonecchi et al. 
2003; Lande, Giacomini et al. 2004). Plasmacytoid DCs have limited potential for IL-12 
secretion (Kadowaki, Ho et al. 2001; Krug, Towarowski et al. 2001) and high capacity of type I 
IFN production, as they were originally known as IFN-producing cells (IPCs) (Svensson, 
Johannisson et al. 1996; Grouard, Rissoan et al. 1997; Siegal, Kadowaki et al. 1999). 
Plasmacytoid DCs were first considered to be Th2-biased DCs (Rissoan, Soumelis et al. 1999); 
however, it was later shown that they can normally mature and induce both Th1- and Th2-type 
immune responses, although the Th1 response was IL-12-independent (Kadowaki, Antonenko et 
al. 2000; Fonteneau, Gilliet et al. 2003). In contrast to cDCs, pDCs do not express the surface 
markers related to the myeloid lineage; instead, they express CD2, CD4, CD5, CD7, and CD123
+
 
(IL-3Rα), which is the characteristic marker for isolation of pDCs from peripheral blood. They 
also  express TLR1, 6, 10 and specifically TLR 7 and 9, which makes them responsive to single-
strand (ss)RNA and CpG oligonucleotides (ODN) (Kadowaki, Ho et al. 2001). The 
differentiation of pDCs in in vitro cultures is highly dependent on IL-3, while addition of IL-4 to 
the culture may kill them. Of the two major subtypes of DCs in humans, cDCs seemed to be 
more efficient in cross-presentation than pDCs (Albert, Pearce et al. 1998; Albert, Sauter et al. 
1998; Schnurr, Chen et al. 2005). 
Langerhans cells are a well-characterized subtype of DCs. They are located in the 
epidermis with a specific structural characteristic of rod- or tennis racket-shaped Birbeck 
granules (Wolff 1967). Their most selective marker is CD207 or langerin (Valladeau, Ravel et al. 
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2000; Valladeau, Clair-Moninot et al. 2002). In comparison to other DCs, LCs have a longer life 
span, replenish themselves, and do not constitutively migrate toward LNs under steady state 
(Lucas and MacPherson 2002; Merad, Manz et al. 2002). Because of their similarities to residing 
iDCs in peripheral tissues, they are considered to be a member of the cDC family, although there 
are some arguments for recognizing them as a local variant of cDCs (Wolff 1972; Rowden 1981; 
Romani, Holzmann et al. 2003; Wilson and Villadangos 2004). Langerhans cells initially known 
as a nervous system-related cell, is the oldest known member of the DC family,  and was placed 
in this family by Schuler and Steinman (Schuler and Steinman 1985; Romani, Holzmann et al. 
2003).  
There also is a population of DC-like cells in the germinal centre and primary B-cell 
follicles of all secondary lymphoid tissues known as follicular DCs (FDCs). Although FDCs 
share some aspects of morphology with DCs, they are different from T cell-priming DCs, belong 
to the stromal cells of lymphoid organs, and are closely related to fibroblast-like cells. 
Tolerogenic DCs are suggested to be a subtype of DCs with a role in tolerance against 
self-antigens. However, they could be considered as a double-edge sword, because they can be 
used as a target by pathogens to evade immunogenicity or as a tool in the clinic to control 
autoimmune diseases (Steinman, Hawiger et al. 2003). It is still questionable whether tolerogenic 
DCs exist as an intrinsic subtype of DCs or are just generated by inhibition of DC maturation and 
modification to tolerogenic DCs under certain environmental signals.  
 
1.1.4 Cytokine secretion by dendritic cells 
Cytokine secretion is an important aspect of DCs and may determine the outcome of an 
immune response. As the component of the third signal in antigen presentation, cytokines can 
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switch the immune response toward Th1 or Th2 type of immunity or even create tolerance. 
Although the secretion of other cytokines has been reported for DCs, the most important 
cytokines secreted by DCs are type I IFN α/β, IL-1β, IL-6, IL-12, IL-23, IL-27, IL-18, TNF-α, 
IL-15, and IL-10. 
 Type I IFNs are a part of the innate antiviral response and have immunomodulatory 
capacities (Muller, Steinhoff et al. 1994; Roberts, Liu et al. 1998; Oritani, Medina et al. 2000; 
Tough 2004). Most nucleated cells can secrete type I IFNs but pDCs have a high natural capacity 
to secrete IFNs, and they were previously known as IPCs. Other types of DCs are also capable of 
secreting type I IFNs, but at lower levels, in response to TLR ligands such as LPS and poly I:C. 
Secretion of type I IFNs may promote the maturation of DCs toward Th1-polarized DCs. 
 Interleukin-1 consists of two different molecules, IL-1a and Il-1β, which both are pro-
inflammatory cytokines with similar biological activities conducted via the IL-1 receptor (IL-1R) 
(Dinarello 1998; Dinarello 1998; Sims 2002). Although the role of IL-1 secreted by DCs is not 
understood yet, there is evidence that the administration of IL-1α may result in increased Th1- 
and strikingly decreased Th2-cytokine production in mice (Von Stebut, Ehrchen et al. 2003). In 
combination with other agents, IL-1 induces maturation and migration of DCs in vitro (Heufler, 
Koch et al. 1988; Roake, Rao et al. 1995; Cumberbatch, Dearman et al. 1997; Cumberbatch, 
Dearman et al. 1997; Stoitzner, Zanella et al. 1999; Kruse, Meinl et al. 2001; Guo, Zhang et al. 
2003).   
 Interleukin-6 is a cytokine secreted by DCs in response to several maturation factors 
(Hope, Cumberbatch et al. 1995; Verhasselt, Buelens et al. 1997; Josien, Wong et al. 1999; 
Morelli, Zahorchak et al. 2001). It was demonstrated that it could have completely opposite roles 
in promoting or inhibiting a Th1-type immune response (Dodge, Carr et al. 2003; Pasare and 
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Medzhitov 2003; Fehervari and Sakaguchi 2004; Kubo, Hatton et al. 2004). Interleukin-6 can 
also affect the role of DC in antigen presentation as suggested elsewhere (Ming, Steinman et al. 
1992; Akira, Taga et al. 1993; Gajewski, Renauld et al. 1995; Jonuleit, Kuhn et al. 1997; 
Drakesmith, O'Neil et al. 1998).  
 Interleukin-12 cytokine family consists of three structurally-related cytokines (Trinchieri, 
Pflanz et al. 2003), which play a role in the induction of Th1-type responses by promoting the 
production of IFN-γ by T cells. Each cytokine consists of two subunits (IL-12 [p35 and p40], IL-
23 [p19 and p40], and IL-27 [p28 and EBI3]). Interleukin-12 induces both naïve and memory T 
cells while IL-23 and IL-27 have selective effects on stimulation of memory T cells and naive T 
cells, respectively. Interleukin-12 secretion by DCs is tightly correlated to induction of Th1-type 
immune responses (Macatonia, Hosken et al. 1995; Koch, Stanzl et al. 1996; Berberich, 
Ramirez-Pineda et al. 2003). Most DC maturation stimuli, such as LPS, poly I:C, CD40L and 
TLR ligands, are inducing secretion of IL-12 (Cella, Scheidegger et al. 1996; Verhasselt, 
Buelens et al. 1997; Thoma-Uszynski, Kiertscher et al. 2000; Morelli, Zahorchak et al. 2001; 
Doxsee, Riter et al. 2003). Dendritic cells also produce high levels of IL-23 and IL-27 in 
response to induction of maturation (Oppmann, Lesley et al. 2000; Pflanz, Timans et al. 2002; 
Nagai, Devergne et al. 2003; Sheibanie, Tadmori et al. 2004; Smits, van Beelen et al. 2004; 
Veckman, Miettinen et al. 2004). Overall, it seems that these three cytokines may play a similar 
role in the induction of a Th1-type immune response. However, the involvement of each may 
depend on the targets.  
 Interleukin-18 is a member of the IL-1 family and plays role in regulation of the type of 
immune response. Like IL-12, IL-18 activates NKs, stimulates T cells to proliferate and secrete 
IFN-γ and is considered a Th1-type cytokine (Zhang, Kawakami et al. 1997; Stoll, Jonuleit et al. 
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1998; Okamoto, Kohno et al. 1999; Kawakami, Qureshi et al. 2000; Pien, Satoskar et al. 2000). 
Interleukin-18 is secreted by DCs activated by microbial agents and DC maturation stimuli 
(Gardella, Andrei et al. 1999; Demeure, Tanaka et al. 2000; Giacomini, Iona et al. 2001; Dreher, 
Kok et al. 2002; Kolb-Maurer, Kammerer et al. 2003; Nagai, Devergne et al. 2003). 
Tumor necrosis factor alpha is a well-known powerful cytokine having profound effects 
on both the innate and adaptive arms of the immune system (McDevitt, Munson et al. 2002). It is 
one of the most common agents used to mature DCs in vitro (Jonuleit, Kuhn et al. 1997; Rieser, 
Bock et al. 1997; Zhang, Mukaida et al. 1997; Schnurr, Then et al. 2000; Yu, Gu et al. 2003), 
while it is also a product of the maturation process in in vitro generated DCs (Lotze M. T. 2001). 
Interleukin-15 is a cytokine structurally and functionally similar to IL-2, which binds to 
IL-2 receptors on T cells (Burton, Bamford et al. 1994; Grabstein, Eisenman et al. 1994). It has 
been reported to be secreted by LCs (Blauvelt, Asada et al. 1996) and in vitro generated mDCs 
(Jonuleit, Wiedemann et al. 1997) and promotes Th1-type immune responses through induction 
of CTL activity (Kuniyoshi, Kuniyoshi et al. 1999).    
Interleukin-10 is a Th2-type cytokine, which is not usually secreted by DCs. However, 
there are reports showing the secretion of IL-10 by some DCs specifically localized in mouse 
bronchi and Peyer’s patches corresponding to induction of a Th2-type immune response 
(Stumbles, Thomas et al. 1998; Iwasaki and Kelsall 1999). 
 
1.1.5 Chemokine and chemokine receptors in dendritic cells 
Chemokines represent a family of low-molecular weight cytokines involved in directional 
movement of leukocytes under physiological and pathological conditions. One group of 
chemokines is constitutively secreted in the LNs under physiological conditions and is 
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responsible for regular trafficking of lymphocytes such as mDCs and T cells toward LNs, 
whereas others are secreted in peripheral tissues to retain resident immune cells (such as iDCs) 
responsible for immune surveillance. Moreover, there are inflammatory chemokines, which are 
expressed in response to damage in tissues in order to recruit cells involved in inflammation such 
as neutrophils. Each chemokine acts as a ligand delivering its effect on target cells via a specific 
chemokine receptor; however, with exception of a few chemokine receptors, there is a high level 
of overlap and flexibility in this specificity. Different tissues secrete basal levels of diverse sets 
of chemokines, and the chemokine surface receptors on the cells influence the type of cells 
entering tissues.  
Because of the nature of their life cycle, the function of DCs is highly dependent on the 
expression of different chemokine receptors mobilizing them toward the required location. 
Immature DCs express high levels of CCR1, CCR2, CCR4, CCR5, and CCR6 (Sozzani, 
Allavena et al. 1999; Sozzani, Mantovani et al. 1999; Allavena, Sica et al. 2000; Cavanagh and 
Von Andrian 2002), which direct them toward peripheral tissues. Upon infection and tissue 
damage, followed by DC maturation, the secretion of iDC ligands (CCL2, CCL3, CCL4, CCL5, 
CCL20, and IL-8) is increased by other cells in tissues, such as MФs, resulting in attraction of 
more iDCs in order to retain the density of iDCs in the periphery. This helps with the 
phagocytosis process and compensates for the number of maturing and migrating iDCs. 
Throughout the maturation process, iDCs down-regulate the expression of CCR1, CCR2, CCR4, 
CCR5, and CCR6 (particularly in lung iDCs and LCs), and instead, up-regulate the expression of 
CCR7 and CXCR4 (Lin, Suri et al. 1998; Sallusto, Schaerli et al. 1998; Sozzani, Allavena et al. 
1998; Yanagihara, Komura et al. 1998) facilitating the continuous flow of mDCs from peripheral 
tissues toward the constitutive secretion of CCL19, CCL21, and CXCL12 in the LNs 
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(Willimann, Legler et al. 1998; Forster, Schubel et al. 1999; Saeki, Moore et al. 1999; Arai, 
Yasukawa et al. 2000; Baekkevold, Yamanaka et al. 2001; Blades, Manzo et al. 2002; Scimone, 
Felbinger et al. 2004). Once in the LNs, mDCs themselves have the capability of secreting 
CCL19 to attract naïve T cells and central memory T cells, which both are also expressing high 
levels of CCR7. In contrast, iDCs secrete a profile of inflammatory chemokines such as IL8, 
CCL3, CCL4, and CCL5 in the periphery to recruit more immune cells to the site of infection 
(Foti, Granucci et al. 1999; Sallusto, Palermo et al. 1999; Padovan, Spagnoli et al. 2002). 
However, this profile is switched to chemokines such as CCL17, CCL18, CCL19, and CCL22, a 
mDC-specific profile attracting T cells, NKs, and B cells to the LNs (Imai, Nagira et al. 1999; 
Sallusto, Palermo et al. 1999; Vulcano, Albanesi et al. 2001). 
With respect to circulating DCs, cDCs and pDCs both express high levels of chemokine 
receptors CCR2 and CXCR4, while the expression of CCR5 and CXCR3 (receptor for CXCL9, 
CXCL10, and CXCL11 chemokines) is high in pDCs and low in cDCs (Penna, Sozzani et al. 
2001; Kohrgruber, Groger et al. 2004). However, in contrast to cDCs, pDCs do not respond to 
the chemoattractant effects of CXCL12 through CXCR4 unless in the presence of CXCR3 
ligands (Krug, Uppaluri et al. 2002; Vanbervliet, Bendriss-Vermare et al. 2003).  
In brief, chemokines play a critical role in DC motility, a crucial characteristic of DCs. 
As a result, a detailed understanding of chemokines and their receptors on DCs would improve 
the use of DCs in medicine as therapeutic tools.   
 
1.1.6 Dendritic cells and tolerance 
In general, there are two types of central and peripheral tolerance, which are mediated 
through four different mechanisms. Dendritic cells were demonstrated to play important roles in 
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both types of tolerance using different mechanisms (Finkelman, Lees et al. 1996; Adler, Marsh et 
al. 1998; Heath and Carbone 2001; Steinman, Hawiger et al. 2003). Central tolerance is mainly 
achieved in the thymus; resting DCs in the medulla of the thymus are involved in this process 
through a mechanism called negative clonal selection of auto-reactive T cells (Brocker, 
Riedinger et al. 1997; Volkmann, Zal et al. 1997; Fujimoto, Tu et al. 2002). However, tolerance 
against escaped self-antigens or harmless non-self antigens such as intestinal flora needs to be 
achieved in the periphery. The continuous migration of iDCs in steady state in absence of any 
inflammatory signal plays an important role in peripheral tolerance as they express low levels of 
MHC class I and II and co-stimulatory molecules resulting in T cell anergy, which is another 
mechanism for tolerance. With their cross-presentation potential, DCs could also induce 
tolerance by skewing the immune response toward a Th2 type as the third tolerance mechanism. 
Finally, DCs may promote peripheral tolerance by a mechanism called ignorance, where they 
keep the organ antigens away from their specific T cells in the periphery. Recently, it was 
suggested that DCs might also participate in suppression of immune responses and tolerance by 
inducing the generation of Tregs. 
 
1.1.7 Dendritic cells and disease 
The role of DCs in presentation of microbial antigens is obvious. They recognize diverse 
pathogens via pattern recognition receptors (PRRs) such as TLRs and undergo a distinct process 
of maturation based on the type of microorganism they are exposed to, leading to antigen 
presentation. In contrast, infectious agents may develop different mechanisms to evade the 
immune system through modulating DC functions. They can directly destroy DCs by injecting 
toxin (Steinman and Banchereau 2007), inducing apoptosis (Albert, Sauter et al. 1998) or 
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affecting different aspects of DC biology. One of the most prevalent mechanisms used to impair 
DCs is to completely or partially inhibit the maturation process in DCs. This mechanism has 
been reported for several viruses such as HCV, herpes simples virus, vaccinia virus (VV), human 
immunodeficiency virus (HIV), respiratory syncytial virus, CMV, varicella zoster, ebola, 
measles, and  a number of non-viral pathogens such as Coxiella burnettii, Salmonella typhi, 
Bacillus anthracis, Mycobacterium tuberculosis, and Borrelia garinii (Salio, Cella et al. 1999; 
Granelli-Piperno, Golebiowska et al. 2004; de Graaff, de Jong et al. 2005; Khader, Partida-
Sanchez et al. 2006; Coutanceau, Decalf et al. 2007; Hartiala, Hytonen et al. 2007; Steinman and 
Banchereau 2007; Yao, Li et al. 2007; Munir, Le Nouen et al. 2008). Several pathogens only 
affect and prevent the proper migration of mDCs toward the LNs by hampering the expression of 
CCR7 (Khader, Partida-Sanchez et al. 2006). They may also switch a Th1 protective immune 
response to a Th2 non-protective response (Steinman and Banchereau 2007).     
With improvement in human life expectancy around the world, cancer is becoming one of 
the most significant health concerns. In parallel with a better understanding of the role of the 
immune system in controlling the growth of tumor cells, DCs as the main players in the initiation 
and coordination of an immune response, are a promising tool in cancer immunotherapy. In 
addition, as the number of circulating DCs may be reduced, the maturation process inhibited, or 
the expression of co-stimulatory molecules on DCs affected (Nestle, Burg et al. 1997; Troy, 
Davidson et al. 1998; Almand, Resser et al. 2000; Hoffmann, Muller-Berghaus et al. 2002; Della 
Bella, Gennaro et al. 2003; Wojas, Tabarkiewicz et al. 2004), DCs might be a target in cancer 
pathogenesis. In other studies, the migration of mDCs to the tumor site was reported to be 
inhibited, while iDCs were attracted to the site due to secretion of iDC-specific chemokines 
(Tsuge, Yamakawa et al. 2000; Vicari, Treilleux et al. 2004). Conclusively, mDCs loaded with 
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TAAs appear to be an efficient tool in cancer immunotherapy; however, several barriers have 
limited these efforts.  
DCs are responsible for inducing tolerance to harmless environmental antigens such as 
pollens and foods. In allergic reactions, a Th2-type immune response develops involving Th2 
cells expressing IL-4, IL-5, and IL-13, which in turn results in secretion of IgE. The generation 
of this complex is responsible for most allergic symptoms. The mechanism by which this 
immune response pathway is activated is not clear, but inhibitory effects of pollen on the 
secretion of IL-12 by DCs has been suggested to be a contributing factor (Traidl-Hoffmann, 
Mariani et al. 2005). If this mechanism would be elucidated, it might lead to manipulation and 
application of DCs as an approach to control allergies. 
Since DCs are responsible for both immunity against pathogens and tolerance to self- 
antigens, they have been at the center of attention with respect to autoimmune diseases. 
Impairment of DCs in generating tolerance may potentially cause auto-reactions due to excessive 
presentation of self-peptides by DCs or defects in down-regulation of activated DCs (Lutz 2006). 
In addition, other studies recently suggested overproduction of certain cytokines by DCs such as 
TNF-α, type I IFNs, and IL-23, to be a contributing factor (Asselin-Paturel and Trinchieri 2005; 
Lowes, Chamian et al. 2005; Banchereau and Pascual 2006; Hue, Ahern et al. 2006). However, 
more studies should be designed to clarify the exact process, in which DCs may be involved. 
This might eventually lead to a treatment for autoimmune disorders by manipulation of DCs. 
Dendritic cells from a graft can migrate to the recipient and activate an allo-stimulatory 
immune response; in contrast, DCs from the recipient can also induce a graft-versus-host disease 
by presenting antigens to the donor organ’s T cells. The focus in transplant immunology could be 
to deplete graft DCs, which would avoid rejection, or to induce tolerance against the donor’s 
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antigens by the recipient’s DCs. In other words, if the host’s DCs could induce tolerance against 
the donor antigens similar to self-antigen, a graft can be protected; however, DCs from the donor 
organ may need to be manipulated or depleted as well to protect the host. One approach might be 
the in vitro generation of tolerogenic DCs by using the recipient’s iDCs carrying the donor’s 
antigen, which could result in anergy following antigen presentation to the recipient’s T cells. 
Another strategy can be the generation of iDCs with reduced capacity for production of 
cytokines such as IL-12.  
 
1.1.8 Dendritic cell applications in medicine and challenges 
In an era when immunology plays a significant role in almost any disease, DCs as the 
main player in the initiation of an immune response have attracted remarkable attention. Indeed, 
they are responsible for most of the adaptive response outcomes such as specific 
immunogenicity, tolerance, and allergy. In addition, their unique role in cross-switching antigens 
between class I and class II pathways has given them the capability of skewing the immune 
response toward a Th1- or Th2-type response as required.  
With respect to cancer and infectious diseases, the goal is to generate an enhanced Th1-
type immune response against TAAs and microbial targets, which have escaped from or weakly 
presented to the immune system, resulting in unsuccessful destruction of the tumor or infected 
cells. However, in autoimmune diseases and transplant rejection, manipulation of DCs in order to 
switch back or induce tolerance toward self and donor or recipient’s antigens is the objective. 
Finally, DCs could be a useful tool to control the Th2-type immune response in allergic diseases.  
 23 
The use of DCs in immunotherapy of cancer has been at the centre of attention in recent 
years. However, the clinical application of DCs, regardless of all their capabilities, has been a big 
challenge and encountered numerous barriers and obstacles, which are discussed below. 
 
1.1.8.1 Dendritic cell generation and maturation 
By introducing a specific antigen from tumor cells or infectious pathogens to DCs, we 
expect to see proper antigen processing, optimal DC maturation, migration of DCs toward LNs, 
and finally effective antigen presentation leading to a qualitatively distinct immune response.  
To achieve this goal, the first step would be the in vitro generation of DCs, which still 
needs to be improved and evaluated in more detail. In the context of DC generation, maturation 
is important and crucial in DC therapy against cancer and infectious diseases as mDCs induce 
stronger immune responses than iDCs. 
In humans, there are four sources for in vitro generation of DCs. The most commonly 
used cells are circulating CD14
+ 
monocytes in peripheral blood typically converting to cDCs. 
The other source is CD34
+
 stem cells, which are primarily present in cord blood and considered 
precursors for pDCs. Circulating DCs consisting of both kinds of cDCs (CD11c
+, CD123ˉ) and 
pDCs (CD11cˉ, CD123+) (MacDonald, Munster et al. 2002) are the third constitutive source, but 
represent a very small pool of DCs. They are usually characterized and isolated based on surface 
marker expression. The recently used source for generating DCs in cancer patients is bone 
marrow-originated CD34
+
 cells, which can be differentiated into both types of cDCs and pDCs.  
To generate DCs in vitro different cytokines have been used. Granulocyte macrophage-
colony stimulating factor (GM-CSF) in combination with IL-4  is the most common cocktail 
applied to generate human cDCs from monocytes (Rossi, Heveker et al. 1992; Sallusto and 
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Lanzavecchia 1994; Akagawa, Takasuka et al. 1996). Granulocyte macrophage-CSF is a 
cytokine produced by many cell types such as MФs, T cells, and fibroblasts. It promotes the 
development and differentiation of murine bone marrow stem cells to DCs (Inaba, Inaba et al. 
1992); however, it has to be combined with IL-4 to generate cDCs from human monocytes. 
Interleukin-4 is a multifunctional cytokine, which is crucial in generating human cDCs, as it 
inhibits differentiation to MФs and skews the process towards generation of DCs (Sallusto and 
Lanzavecchia 1994). Interleukin-3 is a cytokine used for generation of pDCs; however, in 
monocyte culture it induces the generation of Th2-biased DCs (Ebner, Hofer et al. 2002). 
Interleukin-15 and transforming growth factor beta-1 (TGF-β1) are two cytokines generating 
Mo-DCs with LC features; nevertheless, LC-like cells generated by IL-15 lack the Birbeck 
granules (Mohamadzadeh, Berard et al. 2001; Guironnet, Dezutter-Dambuyant et al. 2002). Of 
other cytokines involved in DC generation, feline McDonough sarcoma (a family of DNA 
sequences; fms)-like tyrosine kinase ligand (Flt3L) is generally used in vivo to expand the 
population of circulating DCs in human blood before isolation of DCs (Maraskovsky, Daro et al. 
2000; Pulendran, Banchereau et al. 2000) or in in vitro culture of human CD34
+
 progenitors to 
pre-expand DC precursors (Arrighi, Hauser et al. 1999). Plasmacytoid DCs can be isolated from 
PBMCs as CD11cˉ CD123+ cells; however, they can be generated in vitro by culturing CD34+, 
isolated from cord blood or bone marrow, with a cytokine cocktail mainly including GM-CSF, 
Flt3L, and IL-3. As fully matured DCs are required for clinical applications, TNF-α is the most 
common cytokine added to DC cultures in order to mature iDCs in vitro. TNF-α is involved in 
many common immune reactions in vivo such as inflammation, apoptosis, and stress response.  
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Finally, specific attention should be paid to the protocol of DC generation and 
maturation, as subtype, level of maturity, and cytokine profile of generated DCs may determine 
the type of immune response they induce.  
 
1.1.8.2 Dendritic cell transfection 
In theory, if microbial antigens or TAAs are properly presented to T cells such that a 
Th1-type immune response is induced, the pathogen or tumor cells are specifically eliminated by 
the immune system. Based on this fact, DCs were generated in vitro, loaded by target antigens, 
and re-injected to the host to elicit a specific cellular immune response. However, loading DCs 
with nucleic acids was a serious challenge and although several new protocols were established, 
it is still a significant obstacle. Viral vectors initially thought to be the best tools to transfect 
DCs, as they mimic the natural course of infection. However, their use in clinical applications 
was hampered by the need to avoid introducing viral genes into individuals. Even with respect to 
in vitro studies of specific target genes, the presence of viral vector genes may synergistically 
enhance or reduce the intrinsic effect of the target protein. In contrast, the use of non-viral 
methods such as chemical reagents in combination with DNA plasmids generally resulted in 
unacceptable transfection efficiency in DCs. When electroporation in combination with plasmid 
DNA was used, the viability of DCs was significantly reduced, while with other protocols 
insufficient transfection efficiency was reported. To date, the highest non-viral transfection 
efficiency of plasmid DNA has been achieved by nucleofection. This method resulted in up to 
56% efficiency but only 37% viability of the transfected DCs after 24 h (Lenz, Bacot et al. 2003) 
to almost 0% after 48 h. In contrast, several studies have demonstrated efficient transfection of 
DCs with mRNA (Van Tendeloo, Ponsaerts et al. 2001; Lundqvist, Noffz et al. 2002; Mu, 
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Gaudernack et al. 2003; Ueno, Tcherepanova et al. 2004; Michiels, Tuyaerts et al. 2005). 
However, protein expression levels were generally either low or not discussed, and little 
information was provided with respect to short- and long-term cell viability; as was recently 
concluded in an extensive review on this subject, strategies for efficient transfection still need to 
be established for human DCs (Grunebach, Muller et al. 2005), and in particular Mo-DCs.  
The in vitro generation and transfection of DCs can also determine the type of immune 
response induced; thus these manipulations should be well designed to achieve the appropriate 
type of the immune response. If a Th1-type immune response is dominant and protective, the 
antigen should be generated endogenously, by transfecting DCs with nucleic acids. Conversely, 
for a Th2-type immune response, in vitro produced proteins should be transferred into DCs, 
usually resulting in a better chance of processing through the MHC class II pathway.  
 
1.1.8.3 Dendritic cell delivery 
The ultimate goal for DCs applied in the clinic would be the successful delivery to the 
local LNs. The route of administration is an important variable in this regard for in vitro 
generated DCs. In addition to other standard routes of vaccine administration, intranodal delivery 
or release of DCs to the LN-rich areas could have particular significance for the efficiency of 
immunotherapy. Indeed, many studies are currently focused on in vivo migratory capacities of 
DCs injected into animals (Bedrosian, Mick et al. 2003; Yoneyama, Matsuno et al. 2004; Huck, 
Tang et al. 2008).  
In spite of all challenges, DC immunotherapy has already been tested in the clinic 
because of an urgent need for treatment of cancer; however, not many promising results have 
been achieved yet, with exception of occasional tumor regression, particularly in patients with 
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melanoma (Steinman and Banchereau 2007). This indeed led researchers to reassess the barriers 
to be overcome; the key ones are the problems discussed above (Figdor, de Vries et al. 2004; 
Melief and van der Burg 2008). Finally, it is important to state that in infectious diseases, a DC 
vaccine can only be applied for prevention or at early stages of infection, as the induction of a 
strong Th1 response in a chronic disease may result in massive destruction of the chronically 
infected organ.   
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1.2 Hepatitis C 
 
1.2.1 General considerations and epidemiology 
Hepatitis C is a blood-borne infection of the liver that was known as a non-A, non-B 
transfusion-associated hepatitis until 1989, when the causative agent was cloned and named 
hepatitis C virus (HCV) (Choo, Kuo et al. 1989). Acute HCV infection is usually a benign 
asymptomatic disease with no or non-specific symptoms. However, a low percentage of infected 
cases (20-25%) clears the virus (Alter 2005) and in more than 70%, the infection becomes 
persistent (Liang, Rehermann et al. 2000; Lauer and Walker 2001) and continues as a chronic-
active hepatitis causing a progressive liver fibrosis. Chronic hepatitis C (CHC) infection results 
in cirrhosis in 15-30% of cases (Tremolada, Casarin et al. 1992; Tong, el-Farra et al. 1995) 
and/or hepatocellular carcinoma (HCC) in 1-5% of cases (Lauer and Walker 2001). 
Hepatocellular carcinoma is responsible for half of the liver cancers, which is the third killer 
cancer in the world (8.8% of all cancers) (WHO) (Alter 1997; Alter and Seeff 2000). After the 
development of a hepatitis B vaccine, HCV, one of the confirmed oncogenic viruses is becoming 
the leading cause of HCC and liver transplantation (El-Serag and Mason 2000; Hassan, Hwang 
et al. 2002; Rosen 2002; Koike 2005). According to a WHO report in 1999 
(http://www.who.int/en/), at least 3.1% of the world population is chronically infected with this 
virus. The prevalence rate differs from 0.1% in Iceland and Norway to 18.1% in Egypt (WHO). 
It is estimated that each year 3 to 4 million people are newly infected (WHO, 2000 report), and 
then play important roles as carriers and reservoirs of the disease (Major and Feinstone 1997; 
Moradpour, Brass et al. 2002; Meylan, Curran et al. 2005). In Canada, it is estimated that about 
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250,000 people are currently infected with HCV, with an estimated 8000 new cases each year, of 
which only 30% know they have the virus (http://www.hc-sc.gc.ca); thus, virus transmission 
remains a significant health concern.  
Hepatitis C virus spreads primarily by direct contact with human blood. Transfusion-
associated infection was the main cause of infection before HCV testing became available. 
However, the major causes of infection worldwide are different today. In developed countries, 
use of injection drugs and much more rarely, high-risk sexual activities or medical (acupuncture) 
and cosmetic (tattoos and piercing) procedures are important sources of infection (Craxi and 
Licata 2006), while in developing countries, unsafe therapeutic injections and contaminated 
blood are the most common cause of new infections (2004). The other lower-risk methods of 
transmission are needle sticks in health workers and perinatal or vertical transmission (children 
born from HCV positive mothers; 4-7%).  
Difficulties in in vitro culture of the virus and lack of a good animal model have 
hampered research on HCV. Chimpanzee is the only good animal model available; however, 
costs and ethical issues have limited the use of this model (Bartenschlager and Lohmann 2000; 
Moradpour, Brass et al. 2002). Another animal model is the severe combined immunodeficiency 
(SCID) mouse engrafted with human liver tissue (Ilan, Burakova et al. 1999) and transgenic 
mice; however, the replication of the virus in these models is limited (Moradpour, Brass et al. 
2002).  
Overall, with a five times higher prevalence (3.1%) in comparison to HIV infection 
(0.6%; UNAIDS 2008 Report), lack of vaccine, inefficient therapy, and limitations in research, a 
further increased rate in mortality from HCC associated with CHC can be expected during the 
next 20-25 years. 
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1.2.2 Hepatitis C virus 
Hepatitis C virus is a hepatotropic virus, which primarily attacks the liver and 
hepatocytes. Other extrahepatic compartments are also presumed to be potential infection sites, 
which could act as hidden locations for the virus. Hepatitis C virus is the sole member of the 
genus Hepaciviruses within the family of Flaviviridae. It is a small (30-80 nm), enveloped plus-
sense ssRNA virus, with a narrow host range consisting of humans and chimpanzees.  
The virus life cycle is entirely cytoplasmic and starts by entering the cytoplasm through a 
receptor binding process. The RNA is then uncoated and all viral proteins are translated using the 
cellular machinery. The viral RNA replicates to a negative-strand RNA, and non-structural (NS) 
proteins promote the generation of a new positive strand, resulting in more viral RNA via double 
strand (ds)RNA intermediates (Moradpour, Brass et al. 2004). Subsequently, the viral RNA is 
packed into core protein forming viral capsids, enveloped, and released from the endoplasmic 
reticulum (ER)-Golgi system into the cytoplasm. Finally, the packaged virus is released from the 
cells.  
 
1.2.2.1 Virus genome 
The genome is about 9.6 kb in length and contains an open reading frame (ORF) flanked 
by 5’- and 3’-untranslated regions (UTRs) (Choo, Kuo et al. 1989). The highly conserved 5’UTR 
contains an internal ribosomal entry site (IRES), which mediates cap-independent translation of 
the ORF (Brown, Zhang et al. 1992; Rijnbrand and Lemon 2000). The 3’UTR is also a highly 
conserved RNA element and is essential for viral replication in vivo (Kolykhalov, Feinstone et al. 
1996). It interacts with several cellular proteins including polypyrimidine tract binding protein 
(PTB), which may contribute to the enhanced translational efficiency observed for RNAs 
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containing 5’IRES and the HCV 3’UTR; the X-tail portion at the very 3’ end appears to enhance 
IRES-dependent translation (Cheng, Chang et al. 1999; Oh, Sheu et al. 2000). The HCV ORF 
codes for a polyprotein of 3011-3022 amino acids that is co- and post-translationally cleaved by 
viral and cellular proteases (Major and Feinstone 1997) into four structural (core, E1, E2, and p7) 
and six non-structural (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) proteins (Shimotohno, Tanji 
et al. 1995; Tanji, Kaneko et al. 1995; Lohmann, Koch et al. 1996; Major and Feinstone 1997; 
Penin, Dubuisson et al. 2004) (Fig. 1.2). The proteolytic process at the junctions between 
structural proteins and p7-NS2 is mediated by cellular signal peptidase, while NS2/NS3 protease 
activity is responsible for cleavage between NS2 and NS3 (Hussy, Langen et al. 1996; Pallaoro, 
Lahm et al. 2001; Lemberg and Martoglio 2002; Weihofen, Binns et al. 2002; Okamoto, 
Moriishi et al. 2004). Finally, NS3 cleaves the remaining four junctions between NS proteins 
(Bartenschlager, Ahlborn-Laake et al. 1994; Lin, Pragai et al. 1994). It has later been reported 
that one protein can also be translated in a second reading frame by a frameshift event in the core 
region of the HCV genome (Walewski, Keller et al. 2001; Xu, Choi et al. 2001). This protein 
was named alternative reading frameshift protein (ARFP) and might be considered a structural 
protein. 
 
 
 
Figure 1.2. The schematic orientation of the HCV genome and proteins. 
C   E1       E2    P7   NS2               NS3                NS4A   NS4B      NS5A            NS5B 
ARFP 
Structural Non-structural 
IRES 
5’ UTR 3’ UTR 
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1.2.2.2 Structural proteins 
Core: The core protein located at the N-terminus of the polypeptide is one of the most 
conserved proteins of HCV. It interacts with viral RNA and constitutes the viral capsid 
(Baumert, Ito et al. 1998; Yasui, Wakita et al. 1998). The C-terminal end of core is critical for 
correct folding of protein. Core protein in mature form may contain secondary structures and 
exists as a large multimer, which is likely involved in the virus assembly process (Matsumoto, 
Hwang et al. 1996; Nolandt, Kern et al. 1997; Irshad and Dhar 2006). Core can be efficiently 
self-assembled in vitro along with envelope proteins to form virus-like particles (VLPs) 
(Nolandt, Kern et al. 1997), while in combination with the viral genome it is encapsulated in a 
lipid envelope containing two envelope proteins 1 and 2 (E1 and E2) to form the infective virion 
(Kunkel, Lorinczi et al. 2001; Acosta-Rivero, Rodriguez et al. 2004). In addition, core interacts 
with several cellular proteins including the cytoplasmic domain of the TNF receptor, 
lymphotoxin-β receptor, protein 53, and RNA helicase (Chen, You et al. 1997; Zhu, Khoshnan et 
al. 1998; Lu, Lo et al. 1999; Mamiya and Worman 1999). It also plays a regulatory role in viral 
and cellular gene expression resulting in  steatosis and oncogenesis through a number of cellular 
signalling pathways (Ray, Lagging et al. 1996; Moriya, Yotsuyanagi et al. 1997; Chang, Yang et 
al. 1998; Marusawa, Hijikata et al. 1999; Hahn, Cho et al. 2000; Lai 2002; Yamaguchi, Tazuma 
et al. 2005). The lipid droplet formation in hepatocytes of transgenic mice expressing core 
protein is compatible with observations in HCV-infected livers with HCC (Knipe D. M. 2001). 
This fact proposes a potential role for core protein in HCC through interference with the lipid 
metabolism pathway. Core also has dual roles with opposite actions on apoptosis favouring viral 
immune evasion (Marusawa, Hijikata et al. 1999; Hahn, Cho et al. 2000; Siavoshian, Abraham et 
al. 2004; Nguyen, Sankaran et al. 2006), and plays an inhibitory role in production of IFN-α by 
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pDCs (Dolganiuc, Chang et al. 2006). Furthermore, the presence of high levels of core protein 
circulating in peripheral blood during the early stage of the infection suggests a role for core in 
suppression of the immune response (Urushihara, Sodeyama et al. 1994; Aoyagi, Ohue et al. 
1999).    
Alternative reading frame protein (ARFP) or frameshift (F) Protein: Alternative 
reading frame protein (ARFP) or F protein is encoded by a reading frame overlapping the core 
sequence and expressed by a frameshift during translation (Walewski, Keller et al. 2001; Xu, 
Choi et al. 2001; Varaklioti, Vassilaki et al. 2002; Xu, Choi et al. 2003). It is a labile protein, 
consisting of up to 160 amino acids. Similar to core, ARFP protein is associated with the ER, 
suggesting that it may participate in HCV morphogenesis (Xu, Choi et al. 2003). The ARFP is a 
potential target for cell-mediated immunity in hepatitis C patients (Bain, Parroche et al. 2004).  
Envelope proteins: Envelope proteins 1 and 2 are highly glycosylated type-1 
transmembrane proteins on the virions’ surface and responsible for binding and entry of the virus 
(Knipe D. M. 2001). They form a non-covalent heterodimer (Deleersnyder, Pillez et al. 1997), 
and in contrast to most viral envelope proteins, both have an ER retention signal (Cocquerel, 
Meunier et al. 1998). This feature may help the virus escape from immune attack. There is 
evidence that E2 modulates the IFN-α response (Taylor, Shi et al. 1999) and mediates viral 
attachment (Rosa, Campagnoli et al. 1996). The N-terminus of E2 contains a hypervariable 
region (HVR1) (Kato, Ootsuyama et al. 1992), which is likely to reflect adaptation of the virus to 
the host immune responses and selection of immune escape variants (Weiner, Geysen et al. 
1992). The HVR1 region of E2 is not identical in any of the virus isolates, and is a target for 
neutralizing antibodies (Knipe D. M. 2001).  
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To date, several receptors for virus entry have been identified, which are involved in 
virus entry mostly through interaction with envelope proteins, especially E2. This list includes 
CD81 (Pileri, Uematsu et al. 1998), low density lipoprotein (LDL) receptor (Agnello, Abel et al. 
1999), claudin-1 (CLDN1) (Evans, von Hahn et al. 2007), occludin (OCLN), scavenger receptor 
class B type I (SR-BI) (Scarselli, Ansuini et al. 2002), mannose-binding lectins DC-specific 
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) for DCs and liver SIGN (L-
SIGN) for hepatocytes (Lozach, Lortat-Jacob et al. 2003). In the blood stream, virions combine 
with LDL, which covers their surface, protects them against antibodies and facilitates a viral 
glycoprotein-independent entry process through cellular LDL receptors (Agnello, Abel et al. 
1999). Claudin-1 is highly expressed in the liver and essential for HCV entry. Occludin is an 
essential HCV cell entry factor as its expression in non-permissive murine cells enhances the 
uptake of HCV-VLPs, whereas its silence in permissive cells inhibits the infection by HCV-
VLPs (Ploss, Evans et al. 2009). The interaction between the highly selective human SR-BI and 
E2 has been shown to be specific (Barth, Cerino et al. 2005); however, direct interaction between 
SR-BI and the E1/E2 heterodimer has not been reported yet.  
Protein 7: Protein 7 is a small membrane-spanning protein, the exact role of which is not 
known; however, it may function as an ion channel (Griffin, Beales et al. 2003). In addition, it 
may mediate cation permeability across membranes, an important event for virus release or 
maturation (Carrere-Kremer, Montpellier-Pala et al. 2002), which is essential to viral infectivity 
(Sakai, Claire et al. 2003). 
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1.2.2.3 Non-structural proteins 
Non-structural proteins play an important role in viral RNA replication and proteolytic 
processing of the polyprotein (De Francesco, Neddermann et al. 2000). There are six NS proteins 
in HCV. 
Non-structural proteins 2 and 3: The NS2/NS3 complex is a metalloprotease that 
cleaves NS2 from NS3, which subsequently is responsible for cleavage of other NS proteins 
(Grakoui, McCourt et al. 1993; Hijikata, Mizushima et al. 1993; Pieroni, Santolini et al. 1997). 
This cleavage is shown to be essential for in vivo replication of HCV and persistent infection  of 
HCV in chimpanzees (Kolykhalov, Mihalik et al. 2000). Non-structural protein 2, an integral 
membrane protein targeted to the ER, is inserted into the membrane only when expressed in the 
form of NS2/NS3 and subsequently cleaved from NS3 (Santolini, Pacini et al. 1995; Yamaga and 
Ou 2002). Although it is not required for RNA replication, in vitro interaction of NS2 with other 
HCV proteins has suggested a potential role of the NS2 complex in RNA replication (Dimitrova, 
Imbert et al. 2003; Welbourn, Green et al. 2005; Kiiver, Merits et al. 2006; Welbourn and Pause 
2007). Recently, a role for NS2 in up-regulation of IL-8 through the nuclear factor-kappa B 
(NFKB) pathway was described (Oem, Jackel-Cram et al. 2008). In addition, the effect of NS2 in 
up-regulation of sterol regulatory element-binding protein 1c (SREBP-1c) and fatty acid 
synthase (a well established target gene of SREBP-1c) transcription has been suggested to be a 
contributing factor in liver steatosis (Oem, Jackel-Cram et al. 2008).  
Non-structural protein 3 is a highly conserved 630-amino-acid protein, which has two 
domains with serine protease (N-terminal) and helicase activity (C-terminal). The NS3 protease 
activity is most efficient when combined with NS4A and is responsible for all of the downstream 
cleavages of the NS proteins (Grakoui, McCourt et al. 1993). The helicase activity is presumably 
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involved in unwinding of duplex RNA during replication (Kim, Morgenstern et al. 1998). The 
NS3 enzymatic activities are used as targets to develop anti-HCV drugs. 
Non-structural proteins 4A and 4B: Non-structural protein 4A is a small protein 
containing three distinct domains. The N-terminal and central domains of NS4A form a dimer 
with NS3 and are a co-factor for NS3 serine protease activity as well as recruitment of NS3 to 
membranes (Failla, Tomei et al. 1994; Glenn 2005). The C-terminal acidic domain of NS4A has 
been recently shown to be critical in viral replication (Lindenbach, Pragai et al. 2007). It has also 
been suggested that NS4A in a complex with NS4B may be involved in inhibition of transport of 
newly synthesized MHC class I molecules to the cell surface (Konan, Giddings et al. 2003). The 
NS4B is a larger protein in comparison to NS4A but its role in the HCV life cycle was unknown 
for a long time. However, a role for NS4B in membrane-associated replication of virus was 
suggested (Hugle, Fehrmann et al. 2001). This observation was then supported by reporting a 
critical role for NS4B in inducing the formation of an intracellular membrane, called 
membranous web, as potential site for virus assembly (Gosert, Egger et al. 2003). In addition, 
NS4B, in combination with NS3,  may indirectly influence the function of NS5B and regulate 
HCV replication, according to the stage of the viral life cycle (Piccininni, Varaklioti et al. 2002; 
Gosert, Egger et al. 2003; Einav, Elazar et al. 2004).  
Non-structural proteins 5A and 5B: Non-structural protein 5A is a serine 
phosphoprotein (Koch and Bartenschlager 1999) localized to the periplasmic membrane fraction 
(Tanji, Kaneko et al. 1995; Tarr, Lin et al. 1996). A role in membrane-associated RNA 
replication was suggested for NS5A, which is likely involved in resistance against IFN therapy 
via inhibition of protein kinase R (PKR) (Koch and Bartenschlager 1999). NS5B is a well-
studied protein known as the viral RNA-dependent RNA polymerase (RdRp), which lacks a 
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proof-reading function (Oh, Ito et al. 1999). It has a hydrophilic domain at its C-terminal 
mediating insertion into membranes (Yamashita, Kaneko et al. 1998). Since the specific viral 
polymerization activity of NS5B does not exist in humans, this protein is another target for anti-
HCV drugs. Regardless of the unique enzymatic activity of NS5B, in vivo studies in 
chimpanzees have shown a combined requirement of the NS2/NS3 protease, NS3/NS4A serine 
protease, NS3 NTPase and helicase, and NS5B polymerase activities for viral infectivity. These 
reports agreed with in vitro studies (Knipe D. M. 2001).  
The core, E1, and NS5 proteins, which are all well-conserved, have been used as the 
basis for classification of HCV isolates to six distinct genotypes, 1 (a, b, c), 2 (a, b, c), 3 (a, b), 
4a, 5a, and 6a, and more than fifty subtypes (Simmonds, Alberti et al. 1994; Bukh, Miller et al. 
1995; Major and Feinstone 1997). 
 
1.2.3 Immunovirology and immune evasion strategies 
A viral infection could result in elimination of the host, elimination of the virus, or 
persistence of the infection. From a philosophical point of view, the latter could be the ideal 
situation for the virus in order to continue its presence while the host also survives, although not 
in an entirely healthy condition with long-term complications. In general, in the case of a 
cytopathic virus, one of the first two happens, whereas for a non-cytopathic virus (such as HCV) 
persistence is the choice.  
The first line of defense to a viral infection is a non-specific innate antiviral immune 
response. This step involves IFNs, NKs, MФs, and apoptosis. In the next step, as the adaptive 
responses require specific antigen presentation to effector cells, DCs, monocytes, MФs, B cells, 
and T cells are involved. The end result of antigen presentation to T cells would be the secretion 
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of antibodies (humoral immunity) and/or a broad multi-specific CD4
+
 and CD8
+
 T cell response 
(cellular immunity). Concerning HCV infection, the interaction of the host’s immune response 
and HCV is very complex resulting in an acute resolving or a chronic persistent infection. For 
the first two weeks, the virus replicates quickly followed by a period of slower or stable 
replication (Hoofnagle 2002; Bertoletti and Ferrari 2003). The specific humoral and cellular 
responses start 1-3 months after exposure to the virus (Bertoletti and Ferrari 2003; Rehermann 
and Nascimbeni 2005), while at the same time virus disappears from the serum, followed by 
viral clearance from the liver (Heller and Rehermann 2005). However, virus clearance might 
never happen even in so-called resolved infection (Bertoletti and Ferrari 2003; Pham, 
MacParland et al. 2004). The cellular immune response usually starts earlier than the antibody 
response and it is believed that early and strong responses by CD4
+
 and CD8
+
 T lymphocytes is 
correlated to viral clearance (Gruner, Gerlach et al. 2000; Orland, Wright et al. 2001; Thimme, 
Oldach et al. 2001; Wodarz 2003; Heller and Rehermann 2005; Sarobe, Lasarte et al. 2006). 
Accordingly, Th1 cytokine secretion is associated with recovery from infection, as it stimulates a 
CTL response (Afdhal 2004; Mondelli, Cerino et al. 2005). Overall, the main strategy that HCV 
uses to evade the immune system is not clear yet, but there is evidence that most immune defense 
components are compromised.  
 
1.2.3.1 Innate immunity 
As a component of innate immunity, NKs are capable of eliminating virus through direct 
killing and cytokine production. Inhibition of NKs due to the binding of HCV E2 protein to 
CD81 on the cell surface was one of the earliest reported possible mechanism resulting in the 
failed immune response to HCV (Corado, Toro et al. 1997; Crotta, Stilla et al. 2002; Tseng and 
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Klimpel 2002). Accordingly, the decrease of NKs and NKTs in the liver was shown to favor 
histological progression of disease (Kawarabayashi, Seki et al. 2000; Deignan, Curry et al. 
2002). The role of NKs and NKTs has been highlighted as HCV-infected chimpanzees eliminate 
the virus through an innate immune response without any detectable T-cell response (Thomson, 
Nascimbeni et al. 2003). However, the in vitro cytolytic function of NKs does not appear to be 
impaired in CHC patients, while higher levels cytolytic activity of NKs are associated with less 
liver fibrosis (Morishima, Paschal et al. 2006). In contrast, impaired NKs derived from CHC 
patients could modify DCs to generate IL-10 producing CD4
+
 T cells, which in turn, skews the 
immune response toward a Th2 type, enabling virus to evade cellular responses (Jinushi, 
Takehara et al. 2004). By taking their role in activation of DCs (Piccioli, Sbrana et al. 2002) into 
account, it seems that dysfunction of NKs is involved in evasion of HCV and not just because of 
its role in innate immunity, but also due to its role in the modulation of adaptive immunity.  
Interferons constitute another important component of the innate anti-viral defense 
system. Type I IFNs are secreted by almost every nucleated cell but most commonly by pDCs. 
After binding to their receptor, IFNs promote the phosphorylation of tyrosine kinase (Tyk)-2 and 
Janus Kinase (Jak)-1 (Honda, Yanai et al. 2005). This, in turn, causes phosphorylation of signal 
transducers and activators of transcription (STAT)-1 and STAT-2, which after translocation to 
the nucleus and combination with other proteins leads to activation of IFN-stimulated genes 
(ISGs)(Taniguchi, Ogasawara et al. 2001). Interferon-stimulated gene products impart antiviral 
and immunomodulatory activities that limit virus replication and spread (Sen 2001; Katze, He et 
al. 2002). Interferons also play a role in activation of other cells such as MФs and NKs, 
maturation of DCs, bias of the immune response toward Th1, and enhancement of MHC-I and II 
expression on the cell surface.  
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Hepatitis C virus directly interferes with intracellular pathways and inhibits the activation 
of cellular genes including type I IFN genes (Foy, Li et al. 2003; Duong, Filipowicz et al. 2004). 
The HCV NS3/4A can attenuate the signaling mediated through retinoic acid-inducible gene 1 
(RIG-1) and TLR-3 pathways by cleaving their adaptor proteins, caspase recruitment domain 
adaptor inducing IFN-β (CARDIF) and Toll/IL1 receptor (TIR) domain-containing adaptor 
protein inducing IFN-β (TRIF) (Li, Foy et al. 2005; Meylan, Curran et al. 2005). It can also 
disrupt the process of STAT1 phosphorylation (Helbig, Yip et al. 2008). Inhibition of these 
pathways inhibits the expression of IFN-α and IFN-β as well as IFN-independent activation of 
ISGs. Core protein is reported to have an inhibitory effect on the Jak-STAT signaling pathway 
through inducing the expression of suppressor of cytokine signaling-3 (SOCS-3) (Bode, Ludwig 
et al. 2003). Likewise, an inhibitory role of core in production of IFN-α by pDCs was suggested 
in one study (Dolganiuc, Chang et al. 2006). In a normal course of viral infection, IFNs shut off 
the translation of viral proteins through a protein kinase called PKR. PKR is one of the ISGs, 
which is induced by IFN and can be activated by ds-RNA. After activation, it undergoes an 
autophosphorylation process and then phosphorylates other substrates such as eukaryotic 
initiation factor 2-α (eIf2-α) and the inhibitor of NFKB (IκB). This effect results in the inhibition 
of protein translation. Hepatitis C virus E2 and NS5A can bind to PKR and inhibit this function 
leading to production of viral proteins (Taylor, Shi et al. 1999; Podevin, Sabile et al. 2001; 
Xiang, Martinez-Smith et al. 2005). Non-structural protein 5A also induces production of IL-8, 
which, in turn, partially inhibits the IFN-induced antiviral response (Polyak, Khabar et al. 2001; 
Girard, Shalhoub et al. 2002). In addition, it binds to myeloid differentiation protein 88 (MyD88; 
the major TLR adaptor molecule) and modulates the TLR signaling pathways in immune cells 
(Abe, Kaname et al. 2007).  
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Apoptosis is another innate defense mechanism occurring when host cells are infected 
with a non-cytopathic virus. Although different reports on the HCV core protein effects indicate 
controversial anti-apoptotic or pro-apoptotic consequences, it seems that both are in favor of 
viral evasion, as anti-apoptotic effects are reported in liver cells or cell lines (Marusawa, Hijikata 
et al. 1999; Nguyen, Sankaran et al. 2006) and pro-apoptotic effects are observed in immune 
cells such as DCs and T cells (Hahn, Cho et al. 2000; Siavoshian, Abraham et al. 2004). Similar 
observations for HCV NS3 have been reported (Fujita, Ishido et al. 1996; Nguyen, Sankaran et 
al. 2006). Thus, HCV may affect this defense mechanism in opposite directions, depending on 
the type of the infected cells. 
Dendritic cells as an intermediate element between innate and adaptive immunity are 
considered another target for HCV leading to impairment of effective antigen presentation. The 
effects of HCV on DCs as the main base for the hypothesis of this study are discussed in more 
detail in section 1.3.  
 
1.2.3.2 Adaptive immunity 
The effects on some components of the innate arm of the immune system could indirectly 
affect the adaptive arm of the immune response, as described above. However, HCV may also 
directly affect the adaptive immune response to evade the immune defense. 
The presence of anti-HCV antibodies during CHC (Farci, Alter et al. 1992; Logvinoff, 
Major et al. 2004; von Hahn, Yoon et al. 2007) indicates that antibodies do not play a significant 
role in viral clearance and that HCV has developed very effective strategies to escape 
neutralizing antibodies. This capability is most likely due to the high rate of mutation resulting in 
large genetic heterogenicity and quasispecies of the virus. The lack of proofreading activity in 
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HCV NS5B protein (RdRps) combined with a high viral replication rate could be the reason for 
the high mutation rate. As a result, HCV is presented as a pool of viruses with diverse B and T 
cell epitopes, which makes it difficult for the adaptive immune response to overcome the rapidly 
changing epitopes. One of the regions frequently changing is HVR1 located on glycoprotein E2. 
If the pattern of quasispecies in HVR1 during the acute phase of infection continues to evolve, 
chronic infection occurs (Farci, Shimoda et al. 2000). There is evidence that the target epitopes 
of the virus escape from neutralizing antibodies through association of HCV with lipoproteins 
(Thomssen, Bonk et al. 1992; Nielsen, Bassendine et al. 2006). Shielding of epitopes by 
glycosylation of defined amino acids of E2 protein could also be responsible for virus escape 
(Falkowska, Kajumo et al. 2007; Helle, Goffard et al. 2007). And finally, direct cell to cell 
passage is suggested to be a mechanism to avoid exposure of the virus to neutralizing antibodies 
(Timpe, Stamataki et al. 2008). In summary, it seems that HCV has developed several efficient 
strategies to escape the neutralizing effects of antibodies. 
Similar to humoral immunity, a high rate of viral mutation and diversity of CTL epitopes 
plays an important role in viral evasion from cellular immunity, as the virus is under selective 
pressure and continually modifies its CTL epitopes. In chronic patients, a CTL response was 
observed in the liver but not in the peripheral circulation, and this seems to be insufficient to 
eliminate the infected cells (He, Rehermann et al. 1999). Since HCV-specific CTLs are rather 
inactive in comparison to HBV-specific CTLs this raises the possibility of low antigenicity of 
HCV as an evasion mechanism (Kita, Hiroishi et al. 1995). The newly discovered natural 
subgenomic deletion mutants  of HCV (Iwai, Marusawa et al. 2006; Bernardin, Stramer et al. 
2007; Noppornpanth, Smits et al. 2007; Pacini, Graziani et al. 2009) may be involved in the low 
antigenicity of HCV, since they do not express the structural proteins. However, they contain all 
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regions of the viral genome that are essential for RNA replication, including the 5’UTR, the 
3’UTR, and the region coding from NS3 to NS5B. This fact may indeed be similar to the core 
effect in reducing the viral load to maintain a low steady state of HCV in infected cells in order 
to escape from antigen presentation (Kato 2001). 
There is evidence that HCV core protein plays a role in switching the immune response 
toward Th2 as the production of IL-12 by MФs may be suppressed due to HCV core expression 
(Lee, Choi et al. 2001). In addition, core could limit the induction of Th1 responses by 
interaction with the globular domain of the C1q (a complement soluble molecule) receptor 
(gC1qR) on DCs leading to inhibition of TLR-induced IL-12 production (Waggoner, Hall et al. 
2007). Through ligation to gC1qR on T cells, core also suppresses T cell responses by lowering 
IL-2 production and IL-2 receptor expression (Yao, Nguyen et al. 2001; Yao, Waggoner et al. 
2005) and down-regulates T cell proliferation (Kittlesen, Chianese-Bullock et al. 2000; Yao, 
Nguyen et al. 2001). Moreover, other extensive studies also revealed defects in the HCV-specific 
CD8
+
 cell differentiation from central memory CCR7
+
CD8
+
 cells to effector CCR7ˉCD8+ cells 
due to HCV core protein (Accapezzato, Francavilla et al. 2004; Francavilla, Accapezzato et al. 
2004). Nonstructural protein 4A and NS5B also showed potential to down-regulate the surface 
expression of MHC class I molecules, preventing the elimination of infected cells by CTLs (Tu, 
Gao et al. 1999).  
A direct association was reported between the frequency of Tregs and CHC (Sugimoto, 
Ikeda et al. 2003; Accapezzato, Francavilla et al. 2004; Cabrera, Tu et al. 2004); however, it is 
not clear if this is a cause or a consequence of the disease. In addition, involvement of viral 
proteins in this mechanism has not been reported yet. Depletion of Tregs in vitro increases virus-
specific CD4
+
 and CD8
+
 T cells, and addition of purified Tregs in cell culture suppresses T cell 
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effector mechanisms (Boettler, Spangenberg et al. 2005; Chang 2007; Manigold and Racanelli 
2007; Ebinuma, Nakamoto et al. 2008); however, this effect was not observed in in vivo studies 
(Manigold, Shin et al. 2006). Nevertheless, considering the higher number of Tregs in CHC 
patients (Dolganiuc, Paek et al. 2008; Smyk-Pearson, Golden-Mason et al. 2008), there may be a 
contributing role for Tregs in the viral immune evasion. 
  Finally, it is worth mentioning that HCV can hide in extra-hepatic locations as a possible 
evasion mechanism. Although this may not be a specific immune evasion mechanism, it could 
still be the reason for recurrence of infection in newly transplanted livers (Araya, Rakela et al. 
1997; Garcia-Retortillo, Forns et al. 2002). One of these locations is assumed to be the PBMCs 
such as monocytes or DCs.  
Taken together, although defects in the innate immune response play an important role, it 
could be the magnitude and quality of the adaptive immune response that determines the 
outcome of HCV infection. Indeed, many evasion strategies affecting innate immunity indirectly 
result in defects in adaptive cellular immunity. However, if the immune system has not been 
broadly compromised by HCV, infection might simply resolve by the potency of either the 
innate or the adaptive arm of the immune system.  
 
1.2.4 Vaccine  
At present, there is no vaccine to prevent HCV infection. However, the presence of 
protective immunity against re-infection in previously infected people or chimpanzees (Bassett, 
Guerra et al. 2001; Mehta, Cox et al. 2002; Nascimbeni, Mizukoshi et al. 2003) has kept this 
promise alive. In addition, recent studies showed different levels of protection against HCV in 
chimpanzees by using different approaches such as T-cell-based vaccines (Capone, Meola et al. 
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2006; Capone, Zampaglione et al. 2006; Folgori, Capone et al. 2006), or VLPs containing HCV 
structural proteins (Elmowalid, Qiao et al. 2007). Interestingly, transfer of DCs loaded with HCV 
proteins in mice have shown protection against VV expressing HCV NS3/4a or NS5a proteins 
(Yu, Huang et al. 2006; Yu, Babiuk et al. 2007; Yu, Babiuk et al. 2008). A good candidate for 
this purpose can be core protein, which has proven to be a well-conserved HCV protein inducing 
both humoral and cellular immunity (Iwata, Wakita et al. 1995; Lasarte, Garcia-Granero et al. 
1998; Davis 1999). A HCV vaccine, if it becomes available, is considered to be used as a 
therapeutic tool besides being a preventive means. 
 
1.2.5 Therapy 
1.2.5.1 Existing therapy 
Treatment of CHC has been a challenge for a long time, since IFN-α was first used in an 
attempt to cure the disease in 1986 (Hoofnagle, Mullen et al. 1986). With not very much change 
in content, the most effective therapy available today is still a combination of pegylated (a large 
poly ethylene glycol molecule; PEG) IFN-α-2a or -2b with ribavirin (Strader, Wright et al. 2004; 
Yee, Currie et al. 2006; Farrell 2007). This treatment is expensive, and not effective against all 
subtypes of HCV, and has serious side effects in many cases. With respect to the clinical and 
para-clinical effects of the treatment, after IFN therapy the level of HCV RNA in the serum 
rapidly decreases, followed by complete disappearance of the virus from serum and liver and 
healing of the liver (Lau, Kleiner et al. 1998).  
The other component of the existing therapy for HCV, the broad-spectrum antiviral effect 
of ribavirin, has been already demonstrated to be effective in other viral diseases (Hruska, 
Bernstein et al. 1980; Hruska, Morrow et al. 1982; 1983). Ribavirin, a synthetic purine 
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nucleoside, which is an analog to guanosine ribonucleoside, was added to the HCV therapy in 
1998 (McHutchison, Gordon et al. 1998; Poynard, Marcellin et al. 1998), and enhanced the 
antiviral response via inhibition of HCV replication (Pawlotsky, Dahari et al. 2004) and 
prevention of recurrence of infection (Dusheiko, Nelson et al. 2008). Interestingly, ribavirin 
enhances the production of Th1 cytokines, while it suppresses the production of Th2 cytokines, 
resulting in a polarizing T cell response toward Th1 (Hultgren, Milich et al. 1998; Ning, Brown 
et al. 1998; Tam, Pai et al. 1999).  
The use of PEG-IFN started in 2000 (Manns, McHutchison et al. 2001; Fried, Shiffman 
et al. 2002), and improved the pharmacokinetics of IFN therapy, since it has a lower renal 
clearance (Rajender Reddy, Modi et al. 2002) and longer half-life, which results in sustained 
exposure leading to a more effective antiviral response. This combination also showed fewer side 
effects (Kozlowski, Charles et al. 2001), making it useful for patients who were not tolerant to 
the side effects of the conventional IFN-α therapy.  
In addition to virus genotype as a major determinant for the success rate, there are several 
host factors such as race, age, gender, obesity, and the level of hepatic fibrosis, which are 
important to a lesser extent for the success rate of treatment.  
Finally, for end-stage liver disease due to HCV, liver transplantation is the treatment of 
choice. However, in spite of a relatively acceptable survival rate of 65% for seven years, the new 
grafts are always re-infected.  
 
1.2.5.2 Future therapies 
Because of the disadvantages of the current therapy, there is an urgent need for discovery 
of new drugs. Several approaches are targeting the NS3 helicase activity (Borowski, Deinert et 
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al. 2003; Kim, Seo et al. 2003; Lamarre, Anderson et al. 2003; Perni, Pitlik et al. 2004) or NS5B 
enzymatic properties (Shim, Larson et al. 2003; Beaulieu, Bos et al. 2004; Chan, Das et al. 2004; 
Chan, Pereira et al. 2004; Eldrup, Allerson et al. 2004; Eldrup, Prhavc et al. 2004). Other 
approaches are based on synthetically produced nucleic acids in order to target the translation 
process. The use of small interfering RNAs (siRNAs) to target the IRES (Sioud and Iversen 
2005) or synthesized oligonucleotides (anti-sense technology) to interfere with translation of 
certain mRNAs (Crooke 2004) are two examples of these strategies. The use of RNA 
interference (RNAi) (Kapadia, Brideau-Andersen et al. 2003; Wilson, Jayasena et al. 2003), and 
micro RNAs (miRNAs) are examples of other potential therapeutic tools for the future. 
Immunomodulatory molecules like those stimulating TLRs such as CpG ODN are promising as 
well. However, immunotherapy strategies including preventive and therapeutic vaccine strategies 
(Houghton and Abrignani 2005) such as DC-vaccines are still potential choices for this purpose. 
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1.3 Effects of hepatitis C virus on the function and maturation of human 
dendritic cells 
In general, viruses use multiple mechanisms, such as infection of immune cells, to evade 
the host’s immune defense to become persistent. Dendritic cells have been suggested to be major 
targets for viruses. Viruses can infect DCs and induce apoptotic cell death, inhibit the maturation 
process, or interfere with antigen processing and presentation resulting in inhibition or switch of 
the immune response to a non-protective one (Jenne, Schuler et al. 2001). In addition, they may 
indirectly inhibit maturation by synthesis of homologs for receptors involved in the induction of 
danger signals by viruses (Alcami and Koszinowski 2000). I summarized different strategies 
used by HCV to evade the immune system in section 1.2.3. One of the most important strategies 
HCV presumably uses to establish chronic disease could be the infection of DCs. Although pro-
apoptic effects due to HCV core, NS3, NS5A and NS5B have been observed in DCs (Siavoshian, 
Abraham et al. 2005), most of the effects of HCV on DCs were suggested to be related to 
inhibition of DC activation and maturation. Dendritic cell activation can be inhibited or the type 
of immunity induced can be switched to Th2, because of impairment in DC activation by NKs as 
mentioned previously (Piccioli, Sbrana et al. 2002; Jinushi, Takehara et al. 2004); in turn, 
defective DCs expressing low level of MHC class I molecules on the surface are incompetent to 
activate the NKs (Jinushi, Takehara et al. 2003), resulting in a vicious cycle. Interference by 
HCV proteins with production of IFNs (Dolganiuc, Chang et al. 2006) is another possible 
mechanism, which may inhibit DC maturation. In addition, core can inhibit TLR-induced IL-12 
secretion by DCs, as well as their ability to stimulate T cells to proliferate and secrete IFN-γ in 
an allo-stimulatory mixed leukocyte reaction (MLR) assay (Waggoner, Hall et al. 2007). 
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Although the role of DCs in generation of Tregs is suggested to be an evasion mechanism 
during HCV infection (Pachiadakis, Pollara et al. 2005), it may be a consequence of inhibition of 
DC maturation as it could be due to the presentation of HCV antigens by non-matured iDCs 
(Jonuleit, Schmitt et al. 2001).  
The first studies on the effects of HCV on human DCs reported a diminished ability of 
DCs from chronic HCV carriers to properly mature and stimulate allogenic MLR in comparison 
to DCs from healthy individuals or patients who cleared viral infection (Kanto, Hayashi et al. 
1999; Auffermann-Gretzinger, Keeffe et al. 2001; Bain, Fatmi et al. 2001). These observations 
were later supported by reports on a reduced number and functional impairment of circulating 
cDCs and pDCs, or in vitro generated Mo-DCs in CHC patients (Kanto, Inoue et al. 2004; 
Tsubouchi, Akbar et al. 2004; Tsubouchi, Akbar et al. 2004; Szabo and Dolganiuc 2005; Kanto, 
Inoue et al. 2006; Averill, Lee et al. 2007; Della Bella, Crosignani et al. 2007; MacDonald, 
Semper et al. 2007; Miyatake, Kanto et al. 2007; Miyazaki, Kanto et al. 2008). These DCs were 
also reported to be impaired in secreting IL-12 and inducing IFN-γ secretion by T cells. 
Furthermore, inhibition of maturation or allostimulatory ability of in vitro generated Mo-DCs 
from healthy donors transfected with HCV genes or exposed to HCV proteins was demonstrated 
(Sarobe, Lasarte et al. 2002; Dolganiuc, Kodys et al. 2003; Waggoner, Hall et al. 2007; Saito, 
Ait-Goughoulte et al. 2008; Zimmermann, Flechsig et al. 2008). These observations were 
confirmed in murine models (Hiasa, Horiike et al. 1998; Large, Kittlesen et al. 1999; Kim, Lee et 
al. 2002; Sarobe, Lasarte et al. 2003) and supported by evidence of infection of PBMCs (Sarih, 
Bouchrit et al. 2000), monocytes (Muratori, Gibellini et al. 1996; Lerat, Rumin et al. 1998; 
Garcia, Garcia et al. 2000), circulating DCs (Navas, Fuchs et al. 2002; Goutagny, Fatmi et al. 
2003; Pham, MacParland et al. 2004), and Mo-DCs by HCV (Bain, Fatmi et al. 2001; Navas, 
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Fuchs et al. 2002). In most of theses studies, the focus was on the maturation process and 
impairment of mDC-specific functions such as antigen presentation. In several studies, this 
impairment was suggested to be specifically related to the function of pDCs, based on evidence 
that the decrease in the number and ability of pDCs to secrete IFN-α is a more prominent effect 
than that on cDCs (Szabo and Dolganiuc 2005; Ulsenheimer, Gerlach et al. 2005; Dolganiuc, 
Chang et al. 2006; Decalf, Fernandes et al. 2007).  
Regardless of the type of affected DCs, other studies produced contradictory results 
showing normal functional properties of DCs in chronic HCV patients or DCs expressing HCV 
genes (Sun, Bodola et al. 2001; Longman, Talal et al. 2004; Longman, Talal et al. 2005; Piccioli, 
Tavarini et al. 2005; Li, Krishnadas et al. 2006; Li, Li et al. 2006; Zhou, Lukes et al. 2007; 
Barnes, Salio et al. 2008; Thumann, Schvoerer et al. 2008). Inhibition of maturation and function 
of DCs has also been suggested to be a consequence of HCV chronic infection, not the cause 
(Rollier, Drexhage et al. 2003). In addition, the inhibition of function of pDCs in CHC patients 
has recently been argued, although the number of pDCs might reduce (Albert, Decalf et al. 
2008). Furthermore, DCs transfected with HCV genes were shown to be good candidate vaccines 
because of their in vitro and in vivo stimulatory effects (Li, Krishnadas et al. 2006; Li, Li et al. 
2006; Yu, Huang et al. 2006; Yu, Babiuk et al. 2007; Yu, Babiuk et al. 2008). However, the 
inhibition of DCs in CHC might be indisputable as it is evident that the protective Th1-type 
immune response, a decision mediated by DCs, is weak in chronic HCV infection. Indeed, the 
inhibitory effects on DCs may merely happen in vivo during the normal course of infection. 
Accordingly, reduced expression and functional impairment of TLR2 was recently reported in 
CHC patients (Yakushijin, Kanto et al. 2006). Based on this fact and a report of impairment of 
DCs in cross-presentation due to the systemic activation of DCs via TLR2 (Wilson, Behrens et 
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al. 2006), HCV may use this mechanism to skew the immune response away from a Th1 bias. 
The impaired IL-15 production by DCs is also supportive of a possible defect in generation of a 
Th1-type immune response, as IL-15 is required for type I IFN-mediated expression of MHC 
class I molecules on DCs (Jinushi, Takehara et al. 2003). Taken together, while the effect of 
HCV on the inhibition of DC maturation remains controversial, the fact that in contrast to MHC 
class II molecules, MHC class I synthesis and transportation to the surface of the DCs is 
continued after maturation (Rescigno, Citterio et al. 1998; Cella, Salio et al. 1999) may still 
support this mechanism as a possible hypothesis to be more extensively investigated.  
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2 Hypothesis and objectives 
Our hypothesis was that “HCV inhibits maturation of DCs leading to impairment of their 
functional capacity” based on evidence suggesting inhibitory effects of HCV on human DC 
maturation.  
According to the hypothesis, we performed a comprehensive study of the effects of HCV 
gene products on DCs focusing on the maturation process, based on marker expressions, 
functional properties, and gene expression profiles of DCs.  
To achieve this goal, the first objective was to optimize the generation of DCs and study 
the maturation process in detail. In order to achieve this objective, the progression of the 
maturation process needed to be carefully monitored and evaluated in detail by using different 
maturation agents such as TNF-α, LPS, and a maturation cocktail containing IL-1β, IL-6, TNF-α, 
and prostaglandin E2. 
The second objective was to efficiently transfect DCs while retaining high viability, since 
transfection of DCs was problematic and the originally planned nucleofection method had an 
efficiency rate of 45%, while having significant negative effects on DC viability. 
The third objective was the evaluation of the effects of expression of HCV genes on 
marker expression, phagocytosis, and antigen presentation of DCs, and the evaluation of the 
effects of some of these genes at the molecular level by gene expression profiling.  
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3 High transfection efficiency, gene expression and viability of 
monocyte-derived human dendritic cells after non-viral gene 
transfer 
 
Published in Journal of Leukocyte Biology (Landi et al, 2007). 
 
3.1 Abstract 
Dendritic cells (DCs) are bone marrow-originated professional antigen-capturing and -
presenting cells, which can function as vaccine carriers.  Although efficient transfection of 
human DCs has been achieved with viral vectors, viral gene products may influence cellular 
functions. In contrast, non-viral methods have generally resulted in inefficient gene transfer, low 
levels of gene expression and/or low cell viability. Monocyte-derived DCs (Mo-DCs) are the 
most common source of DCs both for in vitro studies and for in vivo applications. We 
hypothesized that reduction of the time to generate immature DCs (iDCs) might result in higher 
viability after transfection. Therefore, we established a protocol to generate human iDCs from 
CD14
+
 monocytes within three days. These “fast” iDCs were phenotypically and functionally 
indistinguishable from conventional iDCs, showing high endocytic ability and low antigen-
presenting capacity. Furthermore, the “fast” iDCs matured normally and had similar antigen 
presenting capacity to conventional mDCs. To optimize transfection of iDCs, we compared non-
viral transfection of plasmid DNA and in vitro transcribed (IVT) RNA with transfection 
reagents, electroporation and nucleofection. Nucleofection of IVT RNA with the X1 program of 
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an Amaxa Nucleofector resulted in the most efficient transfection with an average of 93% 
transfected iDCs, excellent long-term viability and strong protein expression.  Furthermore, the 
IVT RNA transfected iDCs retained all phenotypic and functional characteristics of iDCs. This 
method is applicable to most purposes including in vitro functional assays, in vivo DC 
immunotherapy and DC-based vaccines.  
 
3.2 Introduction 
Dendritic cells (DCs) are bone-marrow-originated professional antigen-capturing and -
presenting cells, which initiate primary immune responses in vivo.  DCs have unique functions, 
as they are capable of priming naïve T cells and cross-presenting antigens. One of the 
characteristics of the DC family is maturation, a process during which they change both 
morphologically and functionally. Immature DCs (iDCs) are phagocytic cells capable of 
sampling antigens at the site of injury or infection. Phagocytosis by DCs is a process that is much 
more complicated than that of other phagocytic cells and allows them to present the correct 
antigenic peptides on the MHC-I and II molecules. After processing the antigen, they mature, 
migrate toward local lymph nodes, and present the antigen to naïve T cells. This central role in 
cell-mediated immunity has made them attractive targets for cancer immunotherapy (Koido, 
Kashiwaba et al. 2000; Rughetti, Biffoni et al. 2000; Heiser, Maurice et al. 2001; Heiser, 
Maurice et al. 2001; Heiser, Coleman et al. 2002; Grunebach, Muller et al. 2003). DCs loaded 
with TAAs and injected into patients induce anti-tumor responses, which do not occur under 
natural conditions because of low tumor antigen expression or inaccessibility of the antigen to 
DCs. DCs are also potential vectors for the treatment of chronic infectious diseases, which evade 
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the immune system. Moreover, recent advances in generating DCs have provided strategies for 
the design of DC-based vaccines (Grunebach, Muller et al. 2005).       
Because of their unique properties, DCs are of interest for studies on the mechanisms of 
antigen processing and presentation. Since DCs are professional cells and strictly control the 
trafficking of molecules across their cell membranes, it is difficult to transfer genes into the 
nucleus. Many studies have been performed on loading DCs with different antigens for in vitro 
assays or cancer immunotherapy and efficient transfection has been achieved with viral vectors 
(Hiasa, Horiike et al. 1998; Jooss, Yang et al. 1998; Ponnazhagan, Mahendra et al. 2001; 
Dullaers, Breckpot et al. 2004; Siavoshian, Abraham et al. 2005). However, the viral vectors may 
influence DC functions and interact with the host immune system (Engelmayer, Larsson et al. 
1999; Salio, Cella et al. 1999; Drillien, Spehner et al. 2000; Jenne, Hauser et al. 2000; Kruse, 
Rosorius et al. 2000; Tortorella, Gewurz et al. 2000), which may affect the interpretation of in 
vitro studies. Furthermore, there is a need for DC-based immunotherapy without risk of exposing 
individuals to other viral genes or integration of the viral genome, which supports the importance 
of establishing an effective and safe non-viral method for DC transfection. However, inefficient 
gene transfer to DCs, low levels of gene expression or low cell viability by non-viral transfection 
methods have limited studies on DCs (Van Tendeloo, Snoeck et al. 1998; Irvine, Trinder et al. 
2000; Haines, Irvine et al. 2001; Kalady, Onaitis et al. 2002; Lundqvist, Noffz et al. 2002; 
Chamarthy, Jia et al. 2004; Dullaers, Breckpot et al. 2004; Erhardt, Gorschluter et al. 2005; Tan, 
Beutelspacher et al. 2005). To date, the highest non-viral transfection efficiency of plasmid DNA 
has been achieved by nucleofection. This method resulted in up to 56% efficiency but only 37% 
viability of the transfected DCs after 24 h (Lenz, Bacot et al. 2003). In contrast, several studies 
have demonstrated efficient transfection of DCs with mRNA (Van Tendeloo, Ponsaerts et al. 
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2001; Lundqvist, Noffz et al. 2002; Mu, Gaudernack et al. 2003; Ueno, Tcherepanova et al. 
2004; Michiels, Tuyaerts et al. 2005). However, protein expression levels were generally either 
low or not discussed, and little information was provided with respect to short- and long-term 
cell viability. As was recently concluded in an extensive recent review on this subject, strategies 
for efficient transfection still need to be established for human DCs (Grunebach, Muller et al. 
2005), and in particular monocyte-derived DCs (Mo-DCs). 
In this study, we first established a protocol to generate monocyte-derived iDCs (Mo-
iDCs) in three days and then carried out an extensive comparison of non-viral transfection 
methods, including transfection of plasmid DNA and in vitro transcribed (IVT) RNA with 
transfection reagents, conventional electroporation, and nucleofection. Finally, we optimized 
some protocols as the methods of choice for transfecting human DCs for in vitro studies and in 
vivo trials.  
 
3.3 Materials and methods 
3.3.1 In vitro generation of monocyte-derived dendritic cells 
Human venous blood was obtained following informed consent through the protocol 
approved by the Biomedical Research Ethics Board at the University of Saskatchewan. 
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient separation using 
Lymphocyte Separation Medium (LSM) (MP Biomedicals, LLC, Irvine, CA, USA). Briefly, 4 
ml blood diluted 1:2 in endotoxin-free phosphate buffered saline pH 7.2 (PBS; Invitrogen 
Canada Inc., Burlington, ON, Canada) was layered on 3 ml of LSM and centrifuged at 400 x g 
for 25 min.  PBMCs were collected, washed and incubated with human CD14-specific antibody 
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conjugated to paramagnetic MicroBeads (Miltenyi Biotech, Auburn, CA, USA). The CD14
+
 
monocytes were isolated on LS columns (Miltenyi). Conventional iDCs were generated by 
resuspending monocytes at 1×10
6
 cells/ml in complete RPMI (CRPMI; RPMI 1640 [Invitrogen] 
supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 μM non-essential amino 
acids, 1 mM sodium pyruvate, 50 μM 2ME, 10 mM HEPES, and 50 μg/ml gentamycin). 
Recombinant human (rh)GM-CSF (100 ng/ml, Peprotech Inc., NJ, USA) and rhIL-4 (≤100 
ng/ml, Peprotech) were added and then the CD14
+
 monocytes were dispensed into the wells of a 
24- or 12-well plate (Corning Incorporated, Corning, NY, USA). To generate “fast” iDCs, the 
monocytes were resuspended at 1×10
6
 cells/ml in CRPMI made with phenol-red-free RPMI 
1640 [Invitrogen], a lower concentration of heat-inactivated FBS (5%) and a higher amount of L-
glutamine (4 mM).  In addition, the concentration of IL-4 was increased to 200 ng/ml. In 
conventionally generated iDC cultures the media was replaced with fresh media containing 
cytokines every second day. Cultured CD14
+
 cells were checked daily for marker expression by 
flow cytometry. The phagocytic and antigen-presentation capacities of the monocytes and DCs 
were examined at different time points to confirm the exact times of differentiation and 
maturation. Conventional iDCs collected on day 7 and fast iDCs collected on day 3 were 
evaluated in functional assays, and the fast iDCs were used for transfections. To mature the 
iDCs, a cocktail of 10 ng/ml rhIL-1β (Peprotech), 10 ng/ml rhIL-6 (Peprotech), 20 ng/ml rhTNF-
α (Peprotech) and 500 ng/ml PGE2 (Sigma-Aldrich Canada Ltd., Oakville, ON, Canada) was 
used for 16-48 h.  
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3.3.2 Flow cytometry 
PBMCs, monocytes and DCs were washed twice in PBS and resuspended in FACS buffer 
(PBS, pH 7.2 with 0.2% gelatin and 0.03% sodium azide) at 10
5
 cells/100 μl in a round-bottom 
96-well plate (Corning Incorporated). Subsequently, 2 μl of FITC- or PE-conjugated monoclonal 
antibodies (Becton Dickinson Biosciences, Oakville, ON, Canada) were added to each well and 
the plate was incubated on ice for 15-30 min. After incubation, cells were washed three times 
with FACS buffer, fixed with 2% formaldehyde in PBS and analyzed by FACScan (BD 
Biosciences).   
To check the transfection efficiency and intensity, iDCs transfected with plasmid 
encoding GFP (pmaxGFP, Amaxa Company, Köln, Germany) were washed once in PBS and 
analyzed by flow cytometry. The cells were gated electronically according to the control, non-
transfected cells for Forward Scatter (FSC) and Side Scatter (SSC) properties to include the main 
population of the cells and exclude dead cells. To check the cell viability, the cells were stained 
with Propidium Iodide (PI) (Sigma-Aldrich) and more than 10,000 events were analyzed by 
FACScan without gating. Cell Quest software (BD Biosciences) was used for analysis of flow 
cytometry data.  
 
3.3.3 Phagocytosis assay 
A phagocytosis assay was performed as described elsewhere (Sallusto, Nicolo et al. 
1996) with minor modifications. Immature and mature DCs were collected, washed once in PBS, 
and resuspended in CRPMI at 1×10
6
 cells/ml. Two hundred μl of cell suspension were cultured 
in a 24-well plate and 200 μl of FITC-conjugated dextran (FITC-DX, Sigma-Aldrich) in PBS (1 
mg/ml) was added to the DCs. The treatment plate was incubated at 37ºC and the control plate 
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was incubated on ice for 1-2 h in the dark. After incubation, the cells were collected, washed 
three times with cold PBS, and checked by flow cytometry for FITC-DX fluorescence as an 
indicator of phagocytosis. 
 
3.3.4 Allostimulatory mixed leukocyte reaction (MLR) 
Immature and mature DCs were collected, washed in PBS once, and resuspended at 
1×10
6
 cells/ml in CRPMI. One hundred μl of cell suspension was dispensed in the wells of a flat-
bottom 96-well ELISA plate (Corning Incorporated). Subsequently, 3×10
5
 CD14-negative cells 
(70-80% CD3
+
 cells) in 100 μl CRPMI from a different, HLA-mismatched healthy donor was 
added to each well followed by addition of 50 μl of CRPMI. The plate was incubated at 37ºC and 
5% CO2. After 48-72 h, 20-40 μl of MTT (Sigma-Aldrich) at a concentration of 5 mg/ml in PBS 
was added to each well and the cells were incubated for an additional 30-60 min until the uptake 
of dye by the cells was visible under the light microscope. Subsequently, the plates were 
centrifuged at 400 x g for 10 min and 150 μl of supernatant was replaced with 100 μl of acidified 
isopropanol (0.375% HCl in isopropanol). The plates were mixed for 4 min and read by an 
ELISA Reader (Molecular Devices Corporation, Sunnyvale, CA, USA) at a wavelength of 595 
nm. 
 
3.3.5 Transfection with plasmid DNA 
ExGen 500 (Fermentas, Burlington, ON, Canada), FuGene 6 (Roche Diagnostics, Laval, 
QC, Canada), GeneJuice (EMD Biosciences, Novagen Brand, Madison, WI, USA), SuperFect 
(QIAGEN Inc., Mississauga, ON, Canada), and TransFast Transfection Reagent (Promega 
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Corporation, Madison, WI, USA) were used to transfect DCs with pmaxGFP. Since no protocols 
were available for human DCs, optimized protocols were developed. Electroporation of DNA 
was performed according to a previously described protocol (Strobel, Berchtold et al. 2000). 
 
3.3.6 Transfection with IVT RNA 
The pGEM4Z-5’UT-eGFP-3UT-64A vector was kindly provided by Dr. E. Gilboa (Duke 
University Medical Centre, Durham, NC, USA). This plasmid contains the GFP gene flanked by 
the 5’ and 3’ un-translated regions and a poly A tail. There is a SpeI site after the poly A stretch 
to allow linearization of plasmid for in vitro transcription. In vitro transcription and purification 
was performed by using the mMESSAGE mMACHINE Kit (Ambion, Austin, TX, USA). This 
kit uses a T7 RNA polymerase to transcribe RNA from the plasmid, which has a T7 RNA 
polymerase promoter site before 5’ untranslated region. In vitro transcribed IVT RNA was stored 
at -70ºC until use.  
For electroporation, iDCs were collected on day 3 and washed with PBS followed by 
serum-free Opti-MEM. Subsequently, 3×10
6
 cells were resuspended in 200 μl serum-free Opti-
MEM. IVT RNA was added to the cell suspension at different concentrations and the mixtures 
were transferred into a 4 mm cuvette and electroporated at different conditions (250-400 V 
voltage, 125-960 μF capacitance, and 100-1000 Ω resistance) in an electroporation apparatus 
(Bio-Rad Laboratories, GenePulser
TM
 Model 1652076, Mississauga, ON, Canada). Immediately 
after transfection, the DCs were resuspended at 5×10
5
/ml in 37ºC CRPMI supplemented with 50 
ng/ml rhGM-CSF and 100 ng/ml rhIL-4 and incubated at 37ºC until FACS analysis. 
Transfection with TransMessenger Transfection Reagent (TTR) (Qiagen, Mississauga, 
ON, Canada) was performed according to the manufacturer’s instructions with some 
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modifications. TTR is based on a lipid formulation and is used in conjunction with a specific 
RNA-condensing reagent (Enhancer R) and an RNA-condensing buffer (Buffer EC-R).     
Immature DCs were collected on day 3, and washed with PBS. The Enhancer R Solution and 
different amounts of IVT RNA were diluted in an appropriate amount of Buffer EC-R and 
incubated for 5 min at room temperature (RT). TTR was added to the mixtures and the 
complexes were incubated for 10 min at RT. RPMI 1640 was added to the IVT RNA-TTR 
complexes, which were then immediately added to the iDCs. Finally, the iDCs were transferred 
to a 24-well plate, and incubated at 37ºC. After 1 h the iDCs were washed with PBS, fresh 
CRPMI supplemented with 50 ng/ml rhGM-CSF and 100 ng/ml rhIL-4 was added, and the plate 
was incubated again until analysis by flow cytometry. 
 
3.3.7 Nucleofection of DNA and IVT RNA 
Nucleofection of iDCs was performed according to the manufacturer’s instructions with 
some modifications, by using the Nucleofector Machine (Amaxa). The iDCs were collected on 
day 3, and washed twice in PBS. Subsequently, 2×10
6
 cells were resuspended in 100 μl of 
Human Dendritic Cell Nucleofection Solution (Amaxa). Five μg pmaxGFP were added per 
2×10
6 
cells and the samples were transferred into certified cuvettes (Amaxa) and transfected by 
using programs K2, M2, Q2, T2, U1, U2, U8, X1, or X10. The same programs were used for 
transfection of IVT RNA at a concentration of 5-10 μg per 1×106 cells. RPMI-1640 
supplemented with 10% heat inactivated FBS, 2mM L-glutamine, 1 mM sodium pyruvate, 100 
μg/ml streptomycin and 100 μg/ml penicillin was warmed to 37ºC and 500 μl was added 
immediately after transfection to each cuvette. The iDCs were collected, dispensed in the wells 
of a 24-well plate containing 2.2 ml pre-warmed SRPMI supplemented with 50 ng/ml rhGM-
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CSF and 100 ng/ml rhIL-4  and divided into four wells to be analyzed at 8, 24, 48 and 72 h. The 
plate was incubated at 37ºC until analysis by flow cytometry. All samples were checked for 
transfection efficiency and intensity as well as cell viability with an Axiovert 200M fluorescent 
microscope (Carl Zeiss Canada Ltd., Toronto, ON, Canada) and a FACScan. 
 
3.3.8 Stimulation of dendritic cells and cytokine secretion 
Four hours after nucleofection with GFP IVT mRNA, iDCs were stimulated for 20 h in 
the presence of LPS (Sigma-Aldrich) at a final concentration of 10 μg/ml and supernatants were 
checked for IL-12 (p70), IFN-γ and IL-10 production by using a BD OptEIA Human ELISA Set 
(BD Biosciences) according to the instructions provided by the manufacturer. Non-nucleofected 
iDCs as well as iDCs nucleoporated without genetic material were used as controls. 
 
3.3.9 Statistical analysis 
Data were analyzed using statistical software (GraphPad Prism Version 4.00). As outcome 
variables were not normally distributed, differences among all groups were examined using the 
Kruskal-Wallis test. If a significant difference was found among the groups, the medians 
between pairs of groups were compared using the Mann-Whitney U test. Differences were 
considered significant if the two-tailed P value was lower than 0.05 with the confidence intervals 
of 95%. All transfection results are shown as mean ± SEM of at least four independent 
experiments performed with different donors.  
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3.4 Results 
3.4.1 In vitro generation of immature and mature dendritic cells 
Transfection of Mo-iDCs generated over a period of 7 to 14 days as described previously 
(Sallusto, Cella et al. 1995; Zhou and Tedder 1996; Cella, Sallusto et al. 1997; Brossart, 
Grunebach et al. 1998; Yang, Howard et al. 1999) resulted in progressively reduced viability 
over time (data not shown). We hypothesized that generation of DCs in a shorter period of time 
would result in higher viability and thus we established a protocol to differentiate monocytes into 
iDCs more rapidly. CD14
+
 monocytes were isolated from PBMCs by magnetic activated cell 
sorting (MACS), which routinely resulted in at least 95% pure populations (Fig. 3.1a). 
Subsequently, the CD14
+
 monocytes were cultured with different concentrations of rhGM-CSF 
and rhIL-4 and checked daily for changes in CD1a, CD14, CD209 (DC-SIGN), CD83 and CD86 
expression to identify the exact time of differentiation and maturation. When the CD14
+
 cells 
were cultured in medium supplemented with 100 ng/ml rhGM-CSF and 200 ng/ml rhIL-4 on day 
0, they differentiated into iDCs in three days (Fig. 3.1b) without further addition of cytokines. 
The expression of CD14, which is a specific monocyte marker, decreased to 5%, CD209 or DC-
SIGN as an interstitial DC marker increased from 0% to 92%, CD1a a MHC-I-like molecule 
increased to 71%, CD86 as a co-stimulatory receptor decreased from 95% to 57% and CD83 was 
expressed at less than 4% confirming the immature status of the iDCs. When the iDCs were 
cultured with a cocktail of rhIL-1β, rhIL-6, rhTNF-α and prostaglandin E2, CD83, the well-
defined marker for maturation (Lechmann, Krooshoop et al. 2001; Lechmann, Berchtold et al. 
2002; Lechmann, Zinser et al. 2002), increased to 89%, so they became fully mature on day 5 
(Fig. 3.1c). In addition, the morphology of these iDCs and mature (m)DCs was as expected (Fig. 
3.2c,d). Similar but slower marker changes were observed with the conventional method (Fig. 
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3.1b,c). As shown in Figure 3.1, the expression of CD1a, CD209, CD83 and CD86 was very 
similar on “fast” iDCs and conventionally generated iDCs, as well as on the mDCs after 
maturation. To further characterize the iDCs and mDCs, their phagocytic ability, and antigen-
presenting capacity were evaluated and compared to conventionally generated DCs. Fast iDCs 
showed strong phagocytic ability, which decreased upon maturation to mDCs, similar to 
conventionally generated iDCs (Fig. 3.3a). The mDCs, regardless of whether they were 
generated from onventionally or fast-generated iDCs, had increased antigen-presenting capacity 
(Fig. 3.3b). Overall, this approach generated iDCs more rapidly than previously reported 
methods using only one treatment with rhGM-CSF and rhIL-4. These data demonstrate that the 
conventional and fast DCs were phenotypically and functionally indistinguishable, both before 
and after maturation.  
Due to the fact that GM-CSF alone drives monocytes toward macrophages, we 
hypothesized that IL-4 might play a key role in promoting differentiation toward DCs and that an 
increase in IL-4 concentration might be responsible for the expedited differentiation of fast DCs. 
To investigate this, we checked the effects of GM-CSF or IL-4 on expression of key phenotypic 
markers. The results indicate that IL-4 is the main cytokine for reduction of CD14 expression, 
which is a specific marker for monocytes also present on macrophages (Fig. 3.4a). Moreover, 
CD209 (DC-SIGN), an important marker for DCs, increased more dramatically in the presence 
of IL-4 than with GM-CSF (Fig. 3.4b). We also showed that IL-4 was responsible for 
maintaining stable levels of MHC-II expression during differentiation (Fig. 3.4c). These 
observations support the contention that IL-4 plays a major role in the differentiation of 
monocytes to iDCs and rationalize the use of high IL-4 concentrations during this process. 
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Figure 3.1. Phenotypic characterization of fast and conventionally generated monocyte-derived DCs. a. 
Expression of cell surface markers on monocytes isolated by anti-CD14 antibody conjugated to 
paramagnetic MicroBeads. b. Differentiation of monocytes to iDCs. c. Maturation of iDCs. Monocytes 
were differentiated into iDCs with 100 ng/ml rhGM-CSF and ≤100 ng/ml (conventional) or 200 ng/ml 
(fast) rhIL-4 and matured to mDCs by adding a maturation cocktail (IL-1β, IL-6, TNF-α, and PGE2) on 
day 3 (fast) or 7 (conventional). The phenotypes of monocytes, iDCs, and mDCs were monitored by flow 
cytometry. Numbers in the upper right quadrants represent the percentage of positive cells for each 
marker and are representative of eight experiments.  
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Figure 3.2. Morphology of monocytes, iDCs and mDCs after fast differentiation and maturation. a. 
Lymphocytes (80% of CD14-negative cells flowing through the MACS column); this population was 
used for MLR assays as responder cells; (× 100) b. Monocytes (CD14
+
 cells) isolated from PBMCs by 
MACS; (× 100) c. iDCs three days after culturing monocytes with rhGM-CSF and rhIL-4, and d. mDCs 
one day after addition of maturation cocktail (IL-1β, IL-6, TNF-α, and PGE2) to the iDC cultures. Left 
iDC and mDC panels show the cells in the culture (× 40) and right iDC and mDC panels show the cells 
stained by modified Wright’s stain (HemaTek Stain, Bayer Corporation, Tarrytown, NY, USA) (× 100). 
(MC = maturation cocktail). 
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Figiure 3.3. Functional evaluation of fast and conventional DCs a. Phagocytosis assay showing similar 
uptake of FITC-conjugated dextran (FITC-DX) in fast and conventional iDCs. Numbers in the upper right 
quadrants represent the percentage of phagocytic cells and are representative for three experiments. b. 
Antigen-presenting abilities in fast and conventional mDCs measured by MTT MLR assay (P<0.05 is 
shown as *). (MC = maturation cocktail, Black arrows = MC added, and white arrows = No MC). 
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Figure 3.4. Effects of GM-CSF and IL-4 on expression of three key markers during differentiation from 
monocytes into iDCs. a. CD14. b. CD209. c. HLA-DR. Nil = Monocytes cultured without any cytokines. 
GM-CSF = Monocytes cultured with 100 ng/ml of GM-CSF. IL-4 = Monocytes cultured with 100 ng/ml 
of IL-4. Numbers in the upper right quadrants represent the percentage of positive cells for each marker 
and are representative of at least four experiments. 
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3.4.2 Transfection with plasmid DNA 
To develop an optimal non-viral transfection method that would result in high gene 
expression levels and long-term viability and thus allow functional studies, the iDCs were 
transfected on day 3 with pmaxGFP and various transfection reagents or conventional 
electroporation. The transfection efficiency, GFP intensity, and cell viability were evaluated at 
different time points after transfection. Regardless of the reagent selected, the transfection 
efficiency was low. The highest efficiency was obtained with FuGene 6, with 20% of the iDCs 
transfected. However, although to our knowledge this was the highest efficiency reported for any 
transfection reagent with plasmid DNA, this was still not sufficient for either in vitro or in vivo 
studies. The other transfection reagents tested, ExGen 500, GeneJuice, SuperFect and TransFast 
Transfection Reagent, resulted in less than 10% efficiency and low intensity. Electroporation 
also resulted in less than 10% transfection efficiency, as well as low viability (data not shown). 
Overall, this demonstrated that regardless of the method or reagent used, transfection with 
plasmid DNA was inefficient. 
 
3.4.3 Transfection with IVT RNA 
Since we did not achieve acceptable transfection efficiencies with fore-mentioned 
methods, we considered IVT RNA as the next approach to transfect DCs.  After generating IVT 
RNA from the pGEM4Z-5’UT-eGFP-3UT-64A vector, iDCs were transfected with the GFP IVT 
RNA (10 μg per 1 × 106 cells) by conventional electroporation with different settings in terms of 
voltage, capacitance, and resistance. In comparison to transfection with plasmid DNA, this 
method was less toxic to the DCs and more effective, resulting in more than 80% transfection 
efficiency (data not shown), which is comparable to previous reports on RNA electroporation 
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(Van Tendeloo, Ponsaerts et al. 2001). Some electroporation conditions resulted in high 
transfection efficiency, but the cell viability was not high enough for further in vitro studies or in 
vivo applications (data not shown). Five electroporation conditions resulted in both acceptable 
efficiency and viability after 72 h (Fig. 3.5a, c). However, the intensity was very low (Fig. 3.5b), 
so although electroporation could be useful for transfection with genes that need to be expressed 
at low levels, the protein expression was considered insufficient for most applications.   
Since TTR is a novel transfection reagent recommended for use with IVT RNA, we 
subsequently tested the efficacy of this reagent with GFP IVT RNA. When the TTR and IVT  
RNA were incubated for 2 h, up to 61% of the iDCs became transfected, but the viability was 
very low (data not shown). Therefore, we reduced the incubation time to 1 h, which resulted in 
40% efficiency, high levels of GFP expression and 69% viability after 72 h (Fig. 3.5). 
Interestingly, after transfection of iDCs with TTR the CD83 expression increased (Fig. 3.7a) and 
the cell morphology changed (Fig. 3.9c), indicating that TTR induced the iDCs to become 
mature. Thus, transfection of DCs with TTR may have effects on the functional properties of the 
DCs.  
 
 
 
 
 71 
Efficiency
8h 24h 48h 72h
0
25
50
75
100
R-ELA
R-ELB
R-ELC
R-ELD
R-ELE
R-TTR
a
Time after Trasfection
P
er
ce
n
t 
(%
)
Intensity
8h 24h 48h 72h
0
25
50
75
100
125 R-ELA
R-ELB
R-ELC
R-ELD
R-ELE
R-TTR
b
Time after Trasfection
P
er
ce
n
t 
(%
) 
to
 R
X
1
Viability
8h 24h 48h 72h
0
25
50
75
100
R-ELA
R-ELB
R-ELC
R-ELD
R-ELE
R-TTR
c
Time after Trasfection
P
er
ce
n
t 
(%
)
 
Figure 3.5.  Transfection efficiency, transfection intensity, and cell viability after transfection of in vitro 
transcribed GFP IVT RNA. Immature DCs were either transfected by electroporation using five different 
settings (R-ELA = 300 V, 125 μF, and 100 Ω; R-ELB = 300 V, 250 μF, and 100Ω; R-ELC = 300 V, 500 
μF, and 200 Ω; R-ELD = 300 V, 500 μF, and 400 Ω; and R-ELE = 350 V, 250 μF, and 200 Ω) or with 
TTR (R-TTR). a. Transfection efficiency expressed as percentage of iDCs expressing GFP. b. Intensity 
expressed as a percentage of the strongest fluorescence achieved with the most effective method, the 
Nucleofector program X1 with GFP IVT RNA. The geometric mean intensity was calculated based on 
FACS results and expressed as a percentage of the highest intensity obtained with program X1 and IVT 
RNA, which was calculated as 100%. c. Cell viability expressed as percentage of live iDCs. 
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3.4.4 Nucleofection of DNA 
Since there is a report on nucleoporation of human DCs with a Nucleofector (Lenz, Bacot 
et al. 2003), we evaluated this approach as an alternative for transfection of iDCs with plasmid 
DNA. To optimize the protocol, we screened nine different programs and further evaluated the 
five most promising programs with respect to efficiency, level of protein expression, and 
viability after nucleofection with pmaxGFP. Reasonably high transfection efficiency and protein 
expression levels were achieved (Fig. 3.6a,b), as well as good viability for up to 24 h (Fig. 3.6c) 
with some of the programs, in particular U2, and X1, which led to significantly better 
transfection efficiencies than K2 and M2 (P<0.05). However, with the U2 and X1 programs, the 
viability decreased significantly between 24 and 48 h. Program X1 was comparable to program 
U2, which is recommended by Amaxa for nucleofecting DCs with DNA (Fig. 3.6a-c).   
 
3.4.5 Nucleofection of IVT RNA 
Since the transfection efficiency achieved by nucleofection of plasmid DNA was at most 
50% and the viability of the iDCs decreased significantly between 24 and 48 h, we subsequently 
used the same programs with GFP IVT RNA. Nucleofection with IVT RNA resulted in higher 
efficiency regardless of the program used (Fig. 3.6d), as well as good viability after 72 h (Fig. 
3.6f).  The iDCs expressed higher levels of protein when transfected with program X1 than with 
any other transfection method (Fig. 3.6e), while the other programs resulted in comparable levels 
of protein expression to DNA nucleofection (Fig. 3.6b, e). The transfection efficiency obtained 
with program X1 varied between 90 and 98%, with a mean of 93% 8 h after transfection, while 
after 72 h the mean efficiency was 78% and the mean viability was 75%. Furthermore, high 
protein expression was observed 8 h after transfection and although there was some decrease, the 
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protein expression level was still reasonably high at 72 h after transfection. In fact, GFP could be 
detected as early as 1 h and as long as five days after transfection (data not shown). In addition, 
there was less variability in protein expression levels between cells within one experiment (Fig. 
3.9a, b) and less variation between experiments (Fig. 3.6b, e) when iDCs were transfected with 
IVT RNA instead of DNA. Interestingly, at 8 h after transfection the GFP intensity in the RNA 
transfected iDCs was higher than that obtained after DNA nucleofection, whereas long-term 
protein expression was equivalent. To check if the nucleofection has any effect on the functional 
properties of DCs, iDCs were checked for their antigen presentation ability as well as CD83 
expression after nucleofection and addition of maturation cocktail. Normal maturation similar to 
that of non-transfected DCs and comparable antigen presentation ability were observed after 
nucleofection with the X1 program (Fig. 3.7a, b). 
Since DCs may lose their capacity to produce IL-12 p70 after electroporation, iDCs were 
stimulated with LPS at 10 μg/ml. Supernatants were collected and checked for the presence of 
IFN-γ, IL-12p70, and IL-10. The results demonstrate that DCs nucleofected with mRNA using 
the X1 program were capable of secreting significant amounts of cytokines in comparison to 
non-nucleofected DCs (Fig. 3.8a-c). Nucleofection had no effect on IFN-γ and IL-10 secretion, 
and although the ability of the nucleofected iDCs to secrete IL-12, was reduced, about 200 pg/ml 
was still detected, which is a significant amount.  
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Figure 3.6.  Transfection efficiency, transfection intensity, and cell viability after nucleofection of GFP 
plasmid DNA or GFP IVT RNA. a, b, c: Nucleofection with 2.5 μg of GFP plasmid DNA per 1×106 
cells, using programs K2 (D-K2), M2 (D-M2), Q2 (D-Q2), U2 (D-U2) and X1 (D-X1). d, e, f: 
Nucleofection with 10 μg of GFP IVT RNA per 1×106 cells, using programs K2 (R-K2), M2 (R-M2), Q2 
(R-Q2), U2 (R-U2) and X1 (R-X1). a and d: Transfection efficiency expressed as percentage of iDCs 
expressing GFP. b and e: Intensity calculated as for Fig. 3.4 and expressed as a percentage of the 
strongest fluorescence achieved with the Nucleofector program X1 with GFP IVT RNA. c and f: Cell 
viability expressed as percentage of live iDCs.  
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Figure 3.7. Investigation of the effects of transfection on the maturation and antigen presentation ability 
of DCs. a. Comparison of the expression of CD83 on non-transfected, nucleofected, and TTR transfected 
iDCs and mDCs.  Numbers in the upper right quadrants represent the percentage of DCs expressing 
CD83. b. Antigen presentation capacity of nucleofected DCs. Non-transfected iDCs (Nil). Nucleofected 
iDCs without RNA or DNA with program X1 (X1). Nucleofected iDCs with GFP IVT RNA and program 
X1 (R-X1). Transfected iDCs with GFP IVT RNA and TTR (R-TTR). 
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3.4.6 Comparison of DNA and RNA transfection methods 
To compare the different approaches for transfection with plasmid DNA and IVT RNA 
directly, we selected the best conditions for each method based on statistical analyses in terms of 
efficiency, intensity, and viability and compared them to IVT RNA nucleofection with the X1 
program at 72 h after transfection (Fig. 3.10). The efficiency was higher after nucleofection of 
IVT RNA with the X1 program than after nucleofection of plasmid DNA (P<0.01), transfection 
of IVT RNA by conventional electroporation (P<0.05) or transfection of IVT RNA with TTR (P 
<0.01), but equivalent to nucleofection of IVT RNA with the U2 program (Fig 3.10a).  In 
contrast, the protein expression level was equivalent to that achieved with nucleofection of 
plasmid DNA or transfection of IVT RNA with TTR, but higher than the level achieved by 
conventional electroporation or nucleofection of IVT RNA with the U2 program (P<0.05) (Fig. 
3.10b). The viability after nucleofection of IVT RNA with the X1 program was higher than after 
nucleofection of plasmid DNA (P<0.01) but equivalent to the viability achieved with program 
U2, conventional electroporation or transfection with TTR (Fig. 3.10c). Overall, nucleofection of 
IVT RNA with the X1 program resulted in extremely efficient transfection, with good long-term 
viability and comparable or higher levels of protein expression to other methods. Although 
transfection with TTR was less efficient than nucleofection with IVT RNA with the X1 program, 
this method resulted in strong protein expression as well as maturation of iDCs. 
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Figure 3.8. Evaluation of the capacity of fast-generated iDCs to secrete cytokines before and after 
nucleofection. a. IFN-γ. b. IL-12 (p70). c. IL-10. Day 3 iDCs were nucleoporated without or with GFP 
IVT mRNA using program X1 (X1 and R-X1 respectively) and non-nucleofected iDCs (Nil) were used as 
control. Four hours after nucleofection 10 μg/ml LPS was added to stimulate cytokine secretion and cells 
were incubated for an additional 20 h. Supernatants were checked for cytokine secretion (-LPS = No LPS, 
+LPS = LPS added).  
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Figure 3.9. Human iDCs transfected on day 3 and analyzed 8 h after transfection: a. Nucleofection 
(program U2) with GFP plasmid DNA (D-U2). b. Nucleofection (program X1) with GFP IVT RNA (R-
X1) c. Transfection of GFP IVT RNA with TTR (R-TTR). Left panels: Phase contrast (× 40). Middle 
panels: Fluorescence (× 40). Right panels: analysis of GFP expression by flow cytometry on the FL1 
channel.  
b. R-X1 
c. R-TTR 
a. D-U2 
Phase-contrast        Fluorescence                FACS 
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Figure 3.10.  Comparison of transfection methods for DNA and RNA. The optimal conditions for the 
different transfection methods were selected and compared with respect to transfection efficiency, 
transfection intensity, and cell viability after 72 h. D-U2 and D-X1: Nucleofection of GFP plasmid DNA 
using programs U2 and X1, respectively. R-U2 and R-X1: Nucleofection of GFP IVT RNA using 
programs U2 and X1, respectively. R-ELD: electroporation of IVT RNA at 300 V, 500 μF, and 400 Ω. 
R-TTR: transfection of IVT RNA with TTR. a: Transfection efficiency expressed as percentage of iDCs 
expressing GFP. b: Intensity calculated as in Fig. 3.4 and expressed as a percentage of the strongest 
fluorescence achieved with the Nucleofector program X1 with GFP IVT RNA. c: Cell viability expressed 
as percentage of live iDCs (P<0.05 and P< 0.01 are shown as * and **, respectively). 
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3.5 Discussion 
Transfer of genetic material into DCs has become a major focus of research having 
applications to the development of DC-based vaccines for treatment of cancer or chronic 
infectious diseases. It is also an important requirement for in vitro evaluation of the effects of 
different microbial genes on DCs. Although viral transduction is efficient, increased 
immunogenicity of transfected DCs due to viral proteins and the risk of oncogenesis from the 
insertion of the viral genome into host cells in vivo have encouraged efforts to establish non-viral 
transfection methods. We hypothesized that if we generate iDCs more rapidly, this may result in 
higher viability after transfection, so we established a new protocol to generate iDCs. Although 
there is one report on direct differentiation and maturation of monocytes into mDCs in 48 h 
(Dauer, Obermaier et al. 2003), this protocol is faster than previous reports in terms of generating 
iDCs. These “fast” iDCs showed high endocytic ability and low antigen-presenting capacity, 
comparable to conventional iDCs generated in 7-14 days. Furthermore, after addition of 
maturation cocktail the iDCs matured as expected, with an increase in antigen presenting ability.   
Since GM-CSF alone drives monocytes toward macrophages (Xu, Roos et al. 2006; Xu, 
Schlagwein et al. 2007) we hypothesized that IL-4 plays a key role in differentiation toward 
DCs. Indeed, when we checked the individual effects of GM-CSF and IL-4 we observed that IL-
4 was responsible for the reduction in CD14 expression, enhanced CD209 expression and 
maintained MHC-II expression on the iDCs, confirming that IL-4 is a critical component for the 
fast differentiation of monocytes to iDCs. This may be due to the fact that IL-4 operates through 
STAT6, (the primary STAT pathway activated in response to IL-4 (Nelms, Keegan et al. 1999)), 
which is critical in the activation of many IL-4 responsive genes, including those for MHC class 
II molecules.  Since  IL-4 has been demonstrated to enhance the survival of haematopoietic cells 
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(Dancescu, Rubio-Trujillo et al. 1992; Illera, Perandones et al. 1993; Zamorano, Wang et al. 
1996) and to play a role in prolonging T and B cell survival in cultures (Hu-Li, Shevach et al. 
1987), IL-4 may also be responsible for better viability of DCs after nucleofection. Activation of 
PI-3K pathways by IL-4 may enhance cell survival through the production of phosphoinositides 
and the subsequent activation of kinases critical for cell survival (Nelms, Keegan et al. 1999).  
With respect to other culture conditions including higher glutamine, according to the 
Media Expert in Sigma-Aldrich glutamine is a very important amino acid for highly active cells 
and can replace serum in culture media. The use of glutamine could promote the differentiation 
because the cells need a high source of energy and better culture conditions due to being very 
active during the differentiation process. Finally, the use of higher glutamine and IL-4 resulted in 
healthier cells, which would also reduce the chance of driving monocytes toward macrophages. 
 In order to optimize the transfection efficiency of the “fast” iDCs with plasmid DNA we 
evaluated a number of transfection reagents. However, regardless of the reagent or conditions 
used, the transfection efficiency was low, whereas the reagents were frequently toxic to the DCs. 
Therefore, we selected electroporation as an alternative method. Conventional electroporation 
resulted in very low transfection efficiency and cell viability, whereas nucleofection with 
plasmid DNA was an effective method with good viability during the first 24 h (Lenz, Bacot et 
al. 2003). Unfortunately, the viability of the iDCs decreased progressively between 24 and 48 h. 
We hypothesized that the excess amount of DNA might be an important factor affecting cell 
viability, so we decreased the amount of DNA and indeed obtained better viability but 
significantly reduced efficiency. We concluded that using IVT RNA instead of DNA in 
combination with conventional electroporation or nucleofection might provide a solution. 
Moreover, since RNA does not need to be transferred through the large pores within the cell 
 82 
membrane or across the nuclear membrane, gentler electroporation conditions can be used, 
which should result in better viability and fewer functional defects in the DCs.  Transfection with 
IVT RNA would also be of benefit if the DCs are to be used for DC-based vaccination, either 
against infectious agents or in cancer patients, because there is no danger of possible integration 
in cellular genetic material. However, although transfection with IVT RNA by electroporation 
resulted in good efficiency and viability with some of the conditions, protein expression was low, 
so transfection of DCs with conventional electroporation and IVT RNA would only be useful for 
proteins that have to be expressed at low amounts.  
Nucleofection of IVT RNA resulted in a mean transfection efficiency of 93%, which to our 
knowledge is the highest rate reported for a non-viral transfection method, as well as excellent 
protein intensity, and long-term viability. A concern with IVT RNA would be short stability in 
the cell cytoplasm; however, GFP was detected for at least five days after transfection with IVT 
RNA, which would be long enough for assays such as MLR. Although this may be due to high 
protein stability or high protein expression levels after transfection, there are some explanations 
supporting enhanced mRNA stability with the nucleofection method. First, there is a possibility 
that the reagent (patented) used for nucleofection may protect mRNA from degradation in the 
cytoplasm. Secondly, since the company claims that the nucleofection method transfers the 
genetic material directly to the nucleus, there is a possibility that mRNA will be directed to the 
nucleus, where it could be protected from degradation and released gradually to the cytoplasm. 
Although nucleofection with IVT RNA generally led to equivalent levels of protein compared to 
transfection with DNA, with program X1 higher amounts of protein were produced which is one 
of the major advantages of this method, especially where stable and high-enough antigen 
concentration of TAA is needed (Ochsenbein 2002; Breckpot, Heirman et al. 2004; Ribas 2005). 
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In addition, high protein expression was detected as early as two hours after nucleofection of 
IVT RNA, so the iDCs can be collected and used for further assays or immunotherapy very soon 
after transfection. This approach may provide a solution to poor protein production, which may 
result in a weak, not-sustained immune response leading to repeated vaccination in cancer 
immunotherapy trials (Batchu, Moreno et al. 2003; Nencioni and Brossart 2004). Another 
advantage of transfection with IVT RNA is the uniform and consistent level of protein 
expression in each cell and for each donor, which implies that all IVT RNA-transfected DCs 
have similar characteristics.  
Importantly, the iDCs nucleofected with IVT RNA remained immature unless maturation 
cocktail was added.  After maturation, the mDCs were capable of antigen presentation as shown 
in a MLR assay, which demonstrated that they were functional. In contrast, transfection of iDCs 
with IVT RNA and TTR induced maturation of the iDCs, so TTR may affect the functional 
properties of the DCs and would not be suitable for in vitro studies. However, as this method 
resulted in strong protein expression as well as maturation of iDCs, it is useful when mDCs, 
which appear to be more effective for cancer immunotherapy (Liao, Li et al. 2004) are required 
immediately after transfection without further induction of maturation. 
In summary, we established a method for the generation of functionally active iDCs from 
CD14
+
 monocytes in three days, after only one treatment with cytokines. This approach reduces 
the time required for in vitro functional assays and provides more viable iDCs for transfection. In 
addition, we developed two methods for transfection of human Mo-iDCs. Nucleofection led to 
high efficiency, as well as high protein expression and long-term viability, and thus can be 
applied to in vitro studies, cancer immunotherapy and DC-based vaccination. Transfection with 
IVT RNA and TTR was less efficient, but resulted in strong protein expression, good long-term 
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viability, and maturation of the iDCs, so this method might be useful in cancer immunotherapy 
or DC-based vaccines.  
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4 Dendritic cells matured by a prostaglandin E2-containing 
cocktail are phenotypically and functionally more mature and 
transcriptionally more Th1-biased than dendritic cells treated by 
TNF-α or LPS 
 
In preparation for publication 
 
4.1 Abstract 
Dendritic cells (DCs) are an important component of the immune system and crucial in 
the initiation of an immune response. There currently is significant interest in the use of DCs in 
cancer immunotherapy. As maturation is critical for effective antigen presentation to naïve T 
cells, different methods have been used to generate mature DCs (mDCs) carrying target antigens 
ex vivo. The use of a maturation cocktail (MC) consisting of IL-1β, IL-6, TNF-α, and 
prostaglandin E2 (PGE2) initially showed promising results, but then was challenged based on 
the potential for induction of Th2-type immune responses. To investigate this contention, we 
compared MC with two of the most commonly used maturation factors, TNF-α and LPS. 
Maturation cocktail was superior to TNF-α and LPS with respect to enhancement of mDC-
specific surface marker expression (CD83, CD86, HLA-DR), induction of T cell proliferation by 
mDCs, and directional motility of mDCs toward CCL19. These results were supported by 
increased expression of a significant number of additional maturation-related genes by MC in 
comparison to TNF-α and LPS. In addition, we did not observe a Th2-biased shift in the gene 
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expression profile of mDCs generated by MC. Conversely, MC induced more Th1-promoting 
transcriptional changes than LPS or TNF-α. This included increased transcript levels of Th1-type 
cytokines such as IL-15, IL-12β, EBI3 (IL-27β), which normally precedes the secretion of IL-12 
during maturation, and an IL-12-induced gene, PSCDBP, as well as Th1-promoting changes in 
the transcripts of CXCL16, CCL13, and CCL18. Interestingly, these changes were accompanied 
by increased transcript levels of MHC class I molecules HLA-A and HLA-F, combined with a 
reduction in the expression of MHC class II molecules such as HLA-DQA1, HLA-DRB5, HLA-
DRA, and HLA-DMA. Finally, MC treatment reduced the transcript levels of TLR2, which was 
recently suggested to be involved in Th2-type immune responses. These results provide support 
for the presence of PGE2 in the cocktail used for maturation of DCs. 
 
4.2 Introduction 
Dendritic cells (DCs) constitute a family of immune cells that play a central role in the 
induction of immune responses. They originate from bone marrow and are dispersed throughout 
the body, but localized more specifically at the sentinel barriers such as skin and respiratory or 
gastrointestinal mucosa, thus providing protection from pathogens. In these locations, where they 
are highly exposed to potential harmful non-self antigens, they remain immature (Cella, Sallusto 
et al. 1997; Banchereau and Steinman 1998; Mellman and Steinman 2001). Considering non-self 
recognition as the major and initial trigger for a specific immune response, the unique role of 
DCs to professionally identify and process the characteristic peptide for a specific target gives 
them a significant role in linking innate and adaptive immunity for an antigen-specific immune 
response.  
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Maturation is one of the important characteristics of the DC family and crucial for 
successful antigen presentation to naïve T cells. After taking up antigens, immature DCs (iDCs) 
change their morphology and surface marker expression and start the maturation process. In this 
process, they lose most of their endocytic ability, gain a high capacity for antigen presentation, 
and switch their migratory potential toward the lymph nodes (LNs) in response to a high 
concentration of CCL19 (Willimann, Legler et al. 1998) and CCL21 (Ohl, Mohaupt et al. 2004). 
This process eventually results in effective contact with T cells (Mellman and Steinman 2001), 
which are also selectively attracted to the LNs (Savina and Amigorena 2007).   
Currently, maturation is becoming a more important concept as many studies suggest 
impairment of DC maturation as the main reason for infectivity or chronicity of several 
infectious agents, as well as escape of TAAs. When used for cancer immunotherapy, DCs need 
to have a sufficient level of maturation, as clinical data have shown that mDCs may provide 
greater therapeutic benefits than iDCs as cancer therapy (Chen, Moyana et al. 2001; Schuler-
Thurner, Schultz et al. 2002; Schuler, Schuler-Thurner et al. 2003; Banchereau and Palucka 
2005). Thus, the maturation protocol and level of maturity could in fact determine the efficacy 
and type of the immune response (Liao, Li et al. 2004; Gilboa 2007).  
In previous studies, different maturation methods caused differences in the type and 
characteristics of mDCs generated; indeed, the maturation signal can determine the bias of the 
immune response (Krause, Singer et al. 2007; Savina and Amigorena 2007; Ten Brinke, Karsten 
et al. 2007; Xia, Dai et al. 2008). Among all methods, TNF-α and bacterial lipopolysacharide 
(LPS) at different concentrations are the most frequently used single agents for maturation of 
DCs in vitro. In addition to an increasing number of other single agents, different combinations 
of cytokines have been used for maturation of DCs as a means to provide highly competent 
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mDCs. The introduction of a cytokine combination of IL-1β, IL-6, and TNF-α in simulation of 
the originally used monocyte-conditioned medium (O'Doherty, Steinman et al. 1993) seemed to 
be more effective in DC maturation. Subsequently, addition of prostaglandin E2 (PGE2) to this 
cocktail provided good migration efficiency, another crucial mDC characteristic (Jonuleit, Kuhn 
et al. 1997). This maturation cocktail (MC) has become the most widely used method of 
maturation (Gilboa 2007; Boullart, Aarntzen et al. 2008), and is now considered the gold 
standard (Ten Brinke, Karsten et al. 2007). However, based on low production of IL-12 by the 
mDCs, the role of PGE2, which may result in the potential for Th2-biased immune responses has 
been challenged (Kalinski, Vieira et al. 2001; McIlroy, Caron et al. 2006; Ten Brinke, Karsten et 
al. 2007). Other studies, however, support retaining PGE2 in the MC because of several positive 
effects. For instance, a unique role for PGE2 was demonstrated in dissolution of podosomes and 
facilitation of mDC motility (van Helden, Krooshoop et al. 2006). The ability of PGE2-generated 
mDCs to stimulate an optimal T cell response, as well as chemokine and cytokine secretion, 
provides more support for the use of PGE2 in the MC (Jefford, Schnurr et al. 2003; Rubio, 
Means et al. 2005). In addition, it was shown that although PGE2 inhibits IL-12 production by 
LPS, it induces IL-12 secretion in synergy with TNF-α (Rieser, Bock et al. 1997). The 
importance of PGE2 in maturation of DCs is further supported by the fact that LPS, TNF-α, and 
IL-1β induce secretion of PGE2 during maturation (Harizi and Gualde 2005). In a recent study 
the effect of PGE2 in induction of tolerance due to expression of indoleamine 2-3 dioxygenase 
(IDO), an enzyme involved in T-cell tolerance (Braun, Longman et al. 2005), was contradicted 
by the fact that the T cell-stimulating capacity of PGE2 overrides the IDO activity (Krause, 
Singer et al. 2007).  
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In summary, the exact biology of DC maturation is yet to be discovered and there is a 
need for more in-depth investigation of different maturation methods, with a more molecular 
focus. Here, we compared three different populations of mDCs generated by TNF-α, LPS, or a 
MC containing PGE2 with respect to their gene expression profile, phenotype, and functional 
properties. Our results show that the level of maturity differed depending on the treatment and 
that MC-generated mDCs (MC-mDCs) are phenotypically and functionally more mature than 
those treated by TNF-α or LPS. These results were confirmed at the transcriptional level, as MC 
appeared to have a more significant effect on transcripts of Th1-related genes than LPS or TNF-
α.  
 
4.3 Materials and methods 
4.3.1 Generation of monocyte-derived immature and mature dendritic cells 
Fast iDCs were generated as described previously (Landi, Babiuk et al. 2007). Briefly, 
human peripheral blood mononuclear cells were collected by density gradient separation, and 
monocytes were isolated using paramagnetic MicroBeads (Miltenyi Biotech, Auburn, CA, USA). 
The monocytes were then cultured in complete RPMI (CRPMI; RPMI 1640 [Invitrogen] 
supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 μM non-essential amino 
acids, 1 mM sodium pyruvate, 50 μM 2ME, 10 mM HEPES, and 50 μg/ml gentamycin), in the 
presence of recombinant human (rh)GM-CSF (100 ng/ml, Peprotech Inc., NJ, USA) and rhIL-4 
(200 ng/ml, Peprotech). To generate mDCs, iDCs were collected on day 3, washed, and 
resuspended in CRPMI containing 50 ng/ml rhGM-CSF and 100 ng/ml rhIL-4. The cells were 
then dispensed in a 6-well plate and matured for 48 h using three different methods of 
maturation: rhTNF-α (Peprotech) at a concentration of 50 ng/ml, LPS (Sigma-Aldrich Canada 
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Ltd., Oakville, ON, Canada) at a concentration of 10 μg/ml, and a MC consisting of 20 ng/ml 
rhIL-1β (Peprotech), 10 ng/ml rhIL-6 (Peprotech), 50 ng/ml rhTNF-α, and 1 μg/ml PGE2 
(Sigma-Aldrich). Immature DCs without addition of any maturation agent were used as control. 
To optimize the concentration of TNF-α and LPS, CD83 and CD86 marker expression was used 
as an indicator for the level of maturity. The concentrations resulting in the highest percentage of 
CD83 and CD86 expressing cells were chosen for further studies (data not shown).  
 
4.3.2 Array analysis 
After 48 h of incubation with different maturation factors, mDCs were washed in 
phosphate buffered saline pH 7.2 (PBS), and total RNA was extracted from the cells using a 
RNA/Protein Isolation NucleoSpin RNA/Protein Kit (MACHEREY-NAGEL, Bethlehem, PA, 
USA) according to the manufacturer’s instructions. To make biotin-integrated cRNA, a 
SuperArray (SuperArray Biosciences, Frederick, MD, USA) reagent kit was used according to 
the instructions, and 3 μg of cRNA was hybridized to a specific Dendritic Cell and Antigen-
presenting cell array with 288 spots of DC-specific genes (OHS-406; SuperArray). All steps 
were performed according to the protocol recommended by the supplier. However, for labeling 
and detection we optimized a one-step infrared labeling procedure using an infrared dye 
conjugated to streptavidin called IRDye CW800-SA (Perkin Elmer). Arrays were scanned using 
an Odyssey infrared scanner. The intensities were calculated using software Odyssey v.3, and 
raw integrated intensity values were loaded into GeneSpring software Version 7.3. Data were 
normalized based on GAPDH housekeeping genes on the array and median polishing was done 
as the second step for normalization. 
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4.3.3 Flow cytometry 
DCs were washed in PBS and resuspended in FACS buffer (PBS, pH 7.2 with 0.2% 
gelatin and 0.03% sodium azide) in a round-bottom 96-well plate (Corning Incorporated, 
Corning, NY, USA). Subsequently, fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-
conjugated monoclonal antibodies (Becton Dickinson Biosciences, Oakville, ON, Canada) were 
added to each well, and the plate was incubated on ice for 30 min. After incubation, cells were 
washed with FACS buffer, resuspended in cold PBS and analyzed by FACScan (BD 
Biosciences).  The cells were gated electronically for Forward Scatter and Side Scatter properties 
to include the main population of the cells and exclude dead cells, and more than 10,000 events 
were analyzed. Cell Quest software (BD Biosciences) was used for analysis of flow cytometry 
data. 
 
4.3.4 Phagocytosis assay 
A phagocytosis assay was performed as described previously (Landi, Babiuk et al. 2007). 
Briefly, DCs were collected, washed in PBS, and resuspended in CRPMI. The cell suspension 
was dispensed in a 1.5 ml eppendorf tube, and FITC-conjugated dextran (DX) (Sigma-Aldrich) 
in PBS (1 mg/ml) was added to the DCs. The treatment tubes were incubated at 37ºC and the 
control ones were incubated on ice for 2 h in the dark. After incubation, the cells were collected, 
washed with cold PBS, and checked by flow cytometry for FITC-DX fluorescence as an 
indicator of phagocytosis. 
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4.3.5 Allostimulatory mixed leukocyte reaction (MLR) 
Immature and mature DCs were collected, washed in PBS, and resuspended in CRPMI. 
The cell suspension was dispensed in the wells of a round-bottom 96-well plate. Subsequently, 
isolated CD4
+ 
cells (CD4
+ 
T cell isolation kit [Miltenyi]) with a purity of more than 95% from a 
different, HLA-mismatched healthy donor were added to each well, and the plate was incubated 
at 37ºC. After 3-5 days, 
3[H] thymidine was added to each well at 0.5 μCi, and the cells were 
incubated for an additional 16-18 hours. Subsequently, the plates were frozen at -20 ºC and at the 
appropriate time were thawed, harvested and read by a Packard microplate scintillation and 
luminescence counter (Packard BioScience Company, Meriden, CT, USA). 
 
4.3.6 Chemotaxis assay 
Chemotaxis assays were performed using a 24-well Transwell system (Corning 
Incorporated). After 2 days of incubation with maturation factors, mDCs were collected, washed 
and resuspended at 1 ×10
6
 cells/ml in chemotaxis buffer (XRPMI; RPMI with 0.1% BSA, 10mM 
HEPES, 20 μM 2ME, 20 μg/ml gentamycin, 50 μg/ml GM-CSF, and 100 μg/ml IL-4). 
Chemokine CCL19 was diluted to different concentrations in XRPMI, and dispensed in a low-
attachment 24-well plate (Corning Incorporated). Medium without any chemokine was used as a 
control. Transwell inserts were placed on each well, and 150 μl of cell suspensions from different 
treatments were added to the insert. Subsequently, the plate was incubated at 37 ºC for 2 h. Cells 
in each well were harvested, concentrated to 200 μl, and counted by FACScan for 1 min.  
 
 93 
4.3.7 Statistical analysis 
Data were analyzed using statistical software (GraphPad Prism Version 5.00). As variables 
were not normally distributed, the medians between pairs of groups were compared using the 
Mann-Whitney U test. Differences were considered significant if the two-tailed P value was 
lower than 0.05 with confidence intervals of 95%.   
 
4.4 Results 
4.4.1 Mature dendritic cells generated by different treatments vary significantly in their 
gross morphology 
Immature DCs were treated with TNF-α, LPS or MC and 48 h later their morphology was 
examined under a light microscope. Mature DCs generated by TNF-α treatment (TNF-mDCs) 
were starting to develop thick dendrites with an irregular shape and were relatively non-adherent 
in comparison to iDCs. In contrast, DCs matured by LPS (LPS-mDCs) were elongated irregular 
large cells with a high tendency to attach to the culture plate; they resembled fibroblasts and 
were difficult to harvest. Finally, MC-mDCs were smaller and relatively round cells in 
comparison to TNF- and LPS-mDCs, and completely non-adherent with many small dendrites 
(Fig. 4.1). 
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Figure 4.1. Immature DCs treated with different maturation agents or not treated; iDCs: immature DCs, 
TNF-mDCs: mDCs generated using TNF-α, LPS-mDCs: mDCs generated using LPS, and MC-mDCs: 
mDCs generated using maturation cocktail containing IL-1β, IL-6, TNF-α, and PGE2 (magnification of 
×40).  
 
 
4.4.2 Treatment of dendritic cells with maturation cocktail results in significant changes 
in gene expression 
To further investigate the effects of different maturation methods, the transcriptional 
changes in iDCs incubated with TNF-α, LPS or MC were examined after 48 h, using non-treated 
iDCs as control. Although expression of many genes may be change during the first hours, the 48 
h time-point was chosen to investigate more stable changes in gene expression in fully matured 
DCs, which persist even after degradation of cytokines and maturation stimuli. One and half-fold 
TNF-mDCs 
MC-mDCs LPS-mDCs 
iDCs 
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changes in expression (based on normalized values) in comparison to control were used as 
cutoff. MC was found to change the expression of 86 genes, which corresponded to 95% of the 
changes (90 genes) observed for any treatment (Fig. 4.2a). In contrast, TNF-α induced a change 
in expression of only 29 genes (32%), which with exception of two genes were all in common 
with those changed by MC. Lipopolysacharide altered expression of 41 genes (45%), 90% of 
which were included in the MC list. Taking the additional 42 genes altered by MC into 
consideration, this indicates that MC treatment has more radical effects on the transcriptional 
profile of DCs in comparison to TNF-α and LPS.  
To investigate the changes induced by each treatment in more detail, up- and down-
regulated genes were compared separately. Of the 50 up-regulated genes, 40 genes were affected 
by MC, which was higher in number in comparison to the 30 genes changed by LPS and the 21 
genes altered by TNF-α (Fig. 4.2b). Indeed, the MC-affected genes included 66% and 81% of the 
genes up regulated by LPS and TNF-α, respectively. Of the down-regulated genes, in addition to 
the 8 and 11 genes altered by LPS and TNF-α, respectively, MC was also found to distinctively 
reduce the expression of another 33 genes (Fig. 4.2c). Overall, the number of genes down-
regulated by MC appeared to be significantly higher than the number of up-regulated ones.  
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Figure 4.2. Gene expression changes in non-treated iDCs and TNF-, LPS-, or MC-mDCs. (a) Total 
number of genes changed after treatment. (b) Up-regulated genes. (c) Down-regulated genes. Only genes 
that changed in expression level by 1.5-fold in comparison to the iDCs are shown. iDCs: immature DCs, 
TNF: mDCs generated using TNF-α, LPS: mDCs generated using LPS, and MC: mDCs generated using 
maturation cocktail containing IL-1β, IL-6, TNF-α, and PGE2. 
LPS > iDCs TNF > iDCs 
MC > iDCs 
12 
0 4 6 
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4.4.3 Maturation cocktail has more significant effects on dendritic cell maturation than 
TNF-α and LPS 
Among the genes that were up-regulated by all treatments, CD83, CD86, CCR7, 
lymphocyte antigen 75 (LY75 or CD205), Epstein-Barr virus induced gene 3 (EBI3), IL-1β, and 
CCL22 are well-known maturation markers or mDC-associated cytokines/chemokines (Fig. 
4.3a). The nuclear factor-kappa B1 (NFKB1), NFKB2, and proline-rich nuclear receptor 
coactivator 1(PNRC1) genes, which are components of the NFKB pathway were also up 
regulated by all treatments (Fig. 4.3a). The NFKB pathway has been reported to be involved in 
DC maturation (Lindstedt, Johansson-Lindbom et al. 2002; Ju, Hacker et al. 2003; Platzer, Jorgl 
et al. 2004; Valentinis, Capobianco et al. 2008). However, the increase in these transcripts was 
significantly higher in DCs treated by MC than DCs treated by TNF-α or LPS, with exception of 
IL-1β, which was higher in LPS-mDCs, and CCL22, which was almost equally increased by all 
treatments (Fig. 4.3a). 
When compared in pairs, there were eight common genes between MC-mDCs and LPS-
mDCs (IL-8, CXCL1, CXCL2, IL-6, CXCL5, CXCL16, CXCR4, and interferon stimulate gene 
20 [ISG20 or CD25]), and five common genes between MC-mDCs and TNF-mDCs 
(reticuloendotheliosis viral oncogene homolog B [RELB], myristoylated alanin-rich protein 
kinase C substrate [MARCKS] L1, a disintegrin and metalloprotease domain [ADAM19], 
lysosomal-associated membrane protein 3 [LAMP3 or CD208] and B cell translocation gene 1 
[BTG1]) (Fig. 4.3b). Although the gene expression levels for IL-8, IL-6, CXCL1, and CXCL2 
was higher in LPS-mDCs than in MC-mDCs, the transcripts of most mDC-specific genes 
including CXCL16, CXCR4, ISG20, RELB, LAMP3, MARCKSL1,  and BTG1 were found to 
be significantly higher after MC treatment than LPS or TNF-α treatments (Fig. 4.3b).  
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Among the genes up-regulated by TNF-α and/or LPS, but not by MC, a series of 
chemokines (CCL3L1, CCL4, CCL5, CCL7, and CCL8) involved in attraction of 
polymorphonuclear cells (PMN), T cells and iDCs, as well as ADAMDEC1, transmembrane 7 
superfamily member 4 (TM7SF4 or DCSTAMP), low affinity immunoglobulin gamma Fc region 
receptor III-B (FCGR3B), and high affinity immunoglobulin E receptor, gamma chain 
(FCER1G) were observed (Fig. 4.3c). Surprisingly, the last two genes are involved in 
phagocytosis, which is normally reduced during maturation.  
In addition to these genes, there was a list of 15 additional genes distinctively up-
regulated by MC treatment, including several important ones such as IL-12β, IL-15, pleckstrin 
homology Sec7 and coiled-coil domains binding protein (PSCDBP), HLA-A, HLA-F, CD58, 
intercellular adhesion molecule 1 (ICAM1 or CD54), MARCKS, and PIM2 (Fig. 4.3d). A more 
detailed analysis of this gene list shows that most of these additional genes affected by MC are 
involved in DC maturation. 
Of the down-regulated genes, all the common genes have been reported to be down-
regulated in mDCs; however, the reduction in expression of CCL13, F13A1, and S100A4 was 
more significant in MC-mDCs than LPS-mDCs and TNF-mDCs (Fig. 4.3a). MC also more 
significantly reduced the transcript levels of ARHGDIB, CD1a, CD1c, CSF1R, FCER1A and 
VCL than LPS or TNF treatmens (Fig. 4.3b). In addition, the reduction in expression of 20 of the 
33 MC-specific genes that are negatively regulated during maturation also favors DC maturation. 
This list includes CCL18, iDC-specific markers (CCR1 and CCR5), adhesion molecules 
(CLEC4A, ITGAX, and ITGB2), phagocytosis-related molecules (FCER1G, FCER2, FCGR2B, 
FCGR3B, and PDIA1), a series of the HLA class II molecules (HLA-DQA1, HLA-DRB5, HLA-
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DRA, and HLA-DMA), HSP90AB1, machrophage migration inhibitory factor (MIF), TLR2, 
CD1b, and LIPA (Fig. 4.3d).  
Taken together, although there was a slight difference between the effects of TNF-α and 
LPS on the gene expression of DCs, it is clear that MC had a significant additional effect on the 
level of transcripts related to DC maturation. This suggests MC to be a superior cocktail for 
maturation of DCs.  
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Figure 4.3. Changes in gene expression levels of iDCs after treatment with TNF-α, LPS, or MC, shown 
by condition tree. (a) Maturation-related genes, which are commonly changed in all treatments. (b) 
Maturation-related genes, which are commonly changed between MC and LPS treatments, or MC and 
TNF-α treatments. (c) Genes that are changed by TNF-α and/or LPS, but not MC treatments. (d) 
Maturation-related genes, which are distinctively changed by MC treatment. iDCs: immature DCs, TNF: 
mDCs generated using TNF-α, LPS: mDCs generated using LPS, and MC: mDCs generated using 
maturation cocktail containing IL-1β, IL-6, TNF-α, and PGE2. The level of gene expression was 
normalized to non-treated iDCs. The color bar on the right shows the range of colors based on the level of 
gene expression. Yellow was set as normal (equal to 1), blue as low, and red as high level of gene 
expression, respectively. Results from three biological replicates are shown.  
 
 
4.4.4 Maturation cocktail induces a Th1-favored transcriptional profile in mDCs 
When the changes in the expression of Th1- and Th2-related genes were examined, MC 
induced a significantly higher increase in transcripts of Th1-related genes, with the exception of 
heat shock 90kDa protein 1 alpha class B (HSP90AB1) (Fig. 4.4). This included CXCL16, EBI3, 
and LAMP3, commonly up-regulated by all treatments, as well as the MHC class I molecules 
HLA-A and HLA-F, Th1-type cytokines IL-12β, IL-15, and the IL-12-induced gene PSCDBP. 
Conversely, the expression levels of Th2-related genes was lower in MC-mDCs than in LPS-
mDCs or TNF-mDCs. Chemokine CCL13 was down-regulated by all treatments, and six 
additional genes were distinctively down-regulated by MC, including CCL18, TLR2, and the 
MHC class II molecules HLA-DQA1, HLA-DRB5, HLA-DRA, and HLA-DRM. The level of 
HLA-DQB1 transcript, a MHC class II molecule, was equally reduced by all treatments. 
Interestingly, expression of CCL22, an mDC-specific Th2-type chemokine was equally up-
regulated by all treatments. Overall, MC appeared to be capable of generating Th1-promoting 
mDCs, by inducing Th1-biased changes in the transcripts of 16 out of 18 Th1/Th2-related genes.   
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Figure 4.4. Changes in gene expression levels of 18 Th1- or Th2-related genes after treatment with TNF-
α, LPS, and MC in comparison to non-treated iDCs.  iDCs: immature DCs, TNF: mDCs generated using 
TNF-α, LPS: mDCs generated using LPS, and MC: mDCs generated using maturation cocktail 
containing IL-1β, IL-6, TNF-α, and PGE2. The level of gene expression was normalized to non-treated 
iDCs. The color bar on the right shows the range of colors based on the level of gene expression. Yellow 
was set as normal (equal to 1), blue as low, and red as high level of gene expression, respectively. Results 
from three biological replicates are shown. 
iDCs       TNF         LPS         MC 
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4.4.5 Mature dendritic cells generated by maturation cocktail express higher levels of 
maturation markers 
Since mDCs generated by different methods varied significantly in gross morphology and 
gene expression, we further characterized their phenotypes by evaluating the expression levels of 
known maturation markers (CD83, CD86, and HLA-DR). Flow cytometry data confirmed that 
MC-mDCs were most mature among all treated mDCs (Fig. 4.5). For instance, CD83, the 
characteristic functional marker for maturation was expressed on 75% of the MC-mDCs in 
comparison to an average of 36% of the LPS-mDCs and 22% of the TNF-mDCs (Fig. 4.5a, b). 
Cluster of differentiation 86 (CD86) expression, a co-stimulatory molecule that plays a role in 
antigen presentation, was also higher on MC-mDCs (Fig. 4.5c, d). For HLA-DR expression, the 
mean fluorescent intensity (MFI) was compared as the amount of this marker on each individual 
cell, but not the number of cells expressing HLA-DR, increases during maturation due to 
translocation from an intra-cytoplasmic location to the surface of the cell membrane. The MFI of 
HLA-DR in MC-mDCs was significantly higher than that of TNF- and LPS-mDCs (Fig. 4.5e, f). 
In summary, MC-mDCs showed significant surface marker changes by FACS analysis 
compatible with a mature phenotype.  
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Figure 4.5. Phenotypic marker expression on non-treated iDCs and DCs 48 h after treatment with TNF-α, 
LPS, or MC. (a) Representative FACS dot plot for each marker. Numbers in the upper right quadrants 
represent the percentage of positive cells for CD83 and CD86 and the mean fluorescent intensity for 
HLA-DR. (b) Percentage of cells expressing CD83, (c) Percentage of cells expressing CD86, (d) Mean 
fluorescent intensity (MFI) of HLA-DR. iDCs: immature DCs, TNF-mDCs: mDCs generated using 
TNF-α, LPS-mDCs: mDCs generated using LPS, and MC-mDCs: mDCs generated using maturation 
cocktail containing IL-1β, IL-6, TNF-α, and PGE2. Bars with different letters are statistically different 
from each other and those with the same letters are not statistically different from each other. Bars and 
error bars represent median with interquartile range.  
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4.4.6 Mature dendritic cells generated by maturation cocktail function more effectively 
than TNF- and LPS-mDCs 
In order to check the functionality of the mDCs generated by the different treatments, they 
were checked in an in vitro phagocytosis assay. Tumor necrosis factor- and LPS-mDCs had 
similar phagocytic abilities, which however were significantly lower than that of iDCs; the MC-
mDCs showed an even more significant reduction in their endocytic ability in comparison to the 
other treatments (Fig. 4.6a). Furthermore, TNF-, LPS-, and MC-mDCs were evaluated in an 
allostimulatory MLR assay, using CD4
+
 T cells as responder cells. As shown in Fig. 4.6b, MC-
mDCs induced enhanced T cell proliferation in comparison to all other DCs, which is compatible 
with improved antigen presentation, an important characteristic of mDCs. The difference 
between TNF- and LPS-mDCs was also significant suggesting that LPS likely has a stronger 
effect on the level of maturity with respect to antigen presentation. Finally, a chemotaxis assay 
using the chemokine CCL19, a ligand for CCR7, showed a very significant increase in the level 
of motility in MC-mDCs in comparison to TNF- and LPS-mDCs (Fig. 4.6c). In spite of their 
adherence in culture, LPS-mDCs showed a better motility than TNF-mDCs in the chemotaxis 
assay. 
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Figure 4.6. Functional characterization of non-treated iDCs and DCs after treatment with TNF-α, LPS, or 
MC. (a) Phagocytosis assay. (b) MLR assay. Stimulation index (SI) was calculated with the formula: 
Radioactive count per minute (CPM) for culture of T cells (R) and DCs (I) : CPM in R, the control group 
(T cells culture alone). (c) Chemotaxis assay. CCL19 was used as chemoattractant in the bottom well of a 
Transwell system. T cells: T cells only, iDCs: immature DCs, TNF-mDCs: mDCs generated using TNF-
α, LPS-mDCs: mDCs generated using LPS, and MC-mDCs = mDCs generated using maturation 
cocktail. The vertical axis (Y) shows the number of cells counted by flow cytometry in 1 min after 
concentration of the samples to 200 μl after harvesting. Bars with different letters are statistically different 
from each other and those with the same letters are not statistically different from each other. Bars and 
error bars represent median with interquartile range. 
 
 
4.5 Discussion 
Different methods of maturation have been used to generate mDCs for in vitro studies or 
clinical trials. A cocktail of IL-1β, IL-6, TNF-α and PGE2 has been widely used, but the 
presence of PGE2 in this cocktail was recently challenged because of the potential for induction 
of a Th2-biased immune response. In this study, we compared this cocktail with two common 
single agents, TNF-α and LPS, with respect to their effects on the maturation of DCs at the 
molecular and functional level. Our data showed that mDCs generated using these methods are 
very different in their morphology, gene expression profile, surface marker expression, and 
functional properties. In addition to the gene expression changes induced by TNF-α and LPS, 
MC modulated the transcription of a significant number of other genes, which are mostly related 
to maturation. Moreover, we did not observe any changes in gene expression profile 
corresponding to a Th2-bias in MC-mDC; conversely, MC induced Th1-promoting changes in 
the transcript levels of both Th1- and Th2-related genes in mDCs (Fig. 4.4).  
 109 
Based on a comprehensive analysis of the functional properties of the genes affected by 
MC, the changes agreed with functions expected of mDCs. Several genes involved in antigen 
presentation (CD83, CD86, LY75, LAMP3, MARCKS, MARCKSL1, PSCDBP, ICAM1, CD58, 
HLA-A and HLA-F) were significantly or distinctively up-regulated by MC, while genes related 
to phagocytosis (CSF1R, FCER1A, FCER1G, FCER2, FCGR2B, FCGR3B, MIF, and PDIA3) 
were down-regulated. Genes favoring high directional motility (CCR7, CXCR4, ARHGDIB, 
MARCKS, MARCKSL1, ADAM19, BTG1, ICAM1, MIF), and lower adhesion properties 
(FCER1A, F13A1, S100A4, CLEC4A, ITGAX, ITGB2, VCL, and CSF1R) were up- or down-
regulated as expected. These changes were mostly more significant after MC treatment than LPS 
or TNF-α treatments. The migration capacity is a crucial property of mDCs as in vivo injected 
DCs were reported to not leave the site of injection unless PGE2 had been added to the 
maturation cocktail (Morse, Coleman et al. 1999; Luft, Jefford et al. 2002; Scandella, Men et al. 
2002; Scandella, Men et al. 2004; Legler, Krause et al. 2006). Consequently, the migration 
ability of mDCs is currently the focus of vaccine delivery techniques (Verdijk, Aarntzen et al. 
2008). Maturation cocktail also significantly up-regulated several genes related to the NFKB 
pathway (NFKB1, NFKB2, PNRC1, RELB, and PIM2), which has been reported to be involved 
in DC maturation (Lindstedt, Johansson-Lindbom et al. 2002; Ju, Hacker et al. 2003; Platzer, 
Jorgl et al. 2004; Valentinis, Capobianco et al. 2008).  
Finally, the gene expression profile of MC-mDCs was evaluated for a possible shift 
toward transcripts of Th1- or Th2-related genes. Interestingly, the transcript levels of MHC class 
I (HLA-A and HLA-F) and MHC class II (HLA-DQA1, HLA-DRB5, HLA-DRA, and HLA-
DMA) molecules were distinctively up- and down-regulated, respectively, by MC. In contrast, 
no changes were detected for these transcripts in LPS-mDCs and TNF-mDCs. In addition, the 
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transcript levels of three Th1-type cytokines, IL-12β, IL-27β, and IL-15, were significantly or 
distinctively up-regulated by MC. As a subunit of the Th1-type cytokine IL-27, EBI3 is an early 
product of activated antigen-presenting cells and drives rapid clonal expansion of naive CD4
+
 T 
cells. Moreover, the expression of IL-27 mRNA precedes that of IL-12 and strongly synergizes 
with IL-12 to trigger IFN-γ production of naive CD4+ T cells (Pflanz, Timans et al. 2002). This 
agrees with a report indicating the induction of a rapid in vivo Th1 response by MC-mDCs 
(Schuler-Thurner, Schultz et al. 2002). 
The secretion of IL-12β (IL-12p40) is tightly regulated and restricted to the cells 
producing bioactive IL-12p70, whereas IL-12α (IL-12p35) is constitutively expressed in many 
cell types (D'Andrea, Rengaraju et al. 1992; Trinchieri 2003). The detection of IL-12p40 
homodimer in DCs treated by PGE2 suggested an antagonist role against IL-12p70 (Kalinski, 
Vieira et al. 2001). However, since the production of IL-12p40 homodimer has never been 
observed by non-transfected human cells (Carra, Gerosa et al. 2000), even under conditions in 
which a large amount of free IL-12p40 chain was produced, an extensive review on IL-12 
suggested that the IL-12 p40 homodimer is not a physiological antagonist of bioactive IL-12p70 
in humans (Trinchieri 2003). Conclusively, the production of IL-12p40 by MC is likely an early 
event in the process of maturation providing the ability of subsequent production of bioactive IL-
12p70 by mDCs.  
As a Th1-type cytokine expressed by maturing DCs (Ohteki, Tada et al. 2006; Lucas, 
Schachterle et al. 2007), IL-15 increases the secretion of IFN-γ by NK and activated T cells 
(Borger, Kauffman et al. 1999), as well as generation of CTLs (Kuniyoshi, Kuniyoshi et al. 
1999). In addition, IL-15 is required for type I IFN-mediated expression of MHC class I 
molecules on DCs, mediating effective induction of NKs (Jinushi, Takehara et al. 2003). 
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Impaired production of IL-15 is suggested to be an immune evasion mechanism in HCV 
infection, a well-known chronic infection combined with a weakened Th1-type immune 
response. Furthermore, the MC-mDCs showed a significantly higher level of expression of 
LAMP3, PSCDBP, and CXCL16, in comparison to LPS-mDCs and TNF-mDCs. As an 
important mDC marker, accumulation of LAMP3
+
 mDCs was reported to be involved in 
induction of proliferation of memory effector CTLs and regression of metastatic melanoma 
(Elliott, Scolyer et al. 2007), a Th1-type immune response. The PSCDBP is an IL-12-induced 
gene in activated DCs and was reported to regulate DC-T cell adhesion by mediating DC-T cell 
de-attachment after antigen presentation (Hofer, Pfeil et al. 2006) indicating a programmed 
change compatible with mDC characteristics. The Th1-type chemokine CXCL16, a TNF-α- and 
IFN-γ-induced chemokine (Abel, Hundhausen et al. 2004), is produced by mDCs found in the T 
cell zones of lymphoid organs, where mDCs are supposed to interact with T cells (Matloubian, 
David et al. 2000). Expression of CXCL16 in LNs attracts several subsets of T cells and NKTs 
favoring better antigen presentation.  
In contrast, MC dramatically reduced the transcripts of CCL13 and CCL18, two well-
known Th2-type chemokines, supporting the notion of driving the immune response away from a 
Th2-type. Chemokine CCL13 is a well-known biomarker of asthma, a well-known Th2-driven 
immune-related disease (Kalayci, Sonna et al. 2004). The secretion of CCL18 is reported to be 
induced by IL-10 (a Th2-biased cytokine) in myeloid DCs (Vulcano, Struyf et al. 2003) resulting 
in generation of Tregs (Adema, Hartgers et al. 1997; Vulcano, Struyf et al. 2003). Moreover, it is 
well known that CCL18 is one of the most abundant chemokines produced by iDCs and 
selectively down-regulated during the maturation process. Finally, the reduction in TLR2 
transcript might be supportive of a Th1-type shift in the transcriptional profile of MC-mDCs as 
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TLR2 appears to promote Th2/Th17 responses by human DCs through TLR4 and TLR8 by 
abrogating the type-1 IFN amplification loop (Wenink M. 2009). This agrees with previous 
studies demonstrating the production of IL-10 by monocytes in response to in vitro stimulation 
of TLR2 (Dolganiuc, Chang et al. 2006), and  the impairment of DCs in cross-presentation due 
to the systemic activation of TLR2 (Wilson, Behrens et al. 2006). The only detected potential 
Th2-biased change in the transcriptional profile of MC-mDCs was a 2-fold reduction in the 
expression of HSP90AB1; however, considering the series of Th1-biased transcriptional 
changes, this does not independently support the notion of Th2-biased mDCs generated by 
PGE2-containing MC.  
Finally, the level of CCL22 transcript, an mDC-specific chemokine and ligand for CCR4 
expressed on activated Th2 T cells, was similarly up regulated by all treatments. This 
observation is important as the increase in CCL22 production by PGE2 was suggested as further 
evidence for a Th2-biased immune response (McIlroy, Caron et al. 2006) . Our results, however, 
contradict this by showing comparable up-regulation of CCL22 transcript by TNF-α, a well-
known inducer of CCL22 secretion (Soumelis, Reche et al. 2002), LPS, and MC, and agrees with 
other reports (Godiska, Chantry et al. 1997; Vulcano, Albanesi et al. 2001; Penna, Vulcano et al. 
2002; Bonecchi, Locati et al. 2004). There are several additional issues disputing the conclusion 
made by this report (McIlroy, Caron et al. 2006). First, the effect of PGE2 used individually, and 
not in a MC combination, on CCL22 production was evaluated. Secondly, the report showed that 
CCL22 prodution was reduced in iDCs by IL-10. As IL-10 is a well-known Th2-type cytokine, 
this observation supports the notion that the production of CCL22 in DCs is not necessarily 
associated with Th2-type immune responses. Third, the increase in CCL22 transcript in our study 
was combined with higher transcript levels of Th1-type cytokines/chemokines IL-12β, IL-27β, 
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IL-15, CXCL16, and a reduction in transcript levels of two Th2-type chemokines, CCL13 and 
CCL18. 
Taken together, considering the changes in transcripts of the cytokines IL-12β, IL-27β, 
IL-15, the chemokines CCL13, CCL18, CCL22, CXCL16, as well as PSCDBP, LAMP3, and 
TLR2, combined with Th1-promoting changes in expression of the MHC class I and II genes, it 
appears that MC-mDCs tend to skew the immune response less toward a Th2 type than TNF-α, 
and LPS, a known inducer of IL-12. Conversely, it may even promote a shift toward a Th1-type 
transcriptional profile. Of the other genes dramatically altered by MC, ISG20 (CD25) is a 
specific marker for mDC, while CCR1 and CCR5 are considered iDC markers. For most of the 
additional genes that were solely up-regulated by MC, there is clear evidence that they are 
important and involved in DC maturation.  
In conclusion, there is no strong evidence at the gene expression level that PGE2-
containing MC generates Th2-promoting mDCs, or permanently blocks the capability of the 
generated mDCs to secrete IL-12. In fact, they may preserve this capacity for the next maturation 
step process called licensing, which is happening in the LNs (Gilboa 2007), where they 
encounter the CD40L signal on T cells in a proper microenvironment. This environment may 
include specific TLR ligands as it has been recently shown that the primary inhibitory effect of 
PGE2 on IL-12 secretion can be overcome with TLR ligands (Boullart, Aarntzen et al. 2008). In 
other words, in vitro generated mDCs may benefit from lack of IL-12 secretion at the time of 
maturation as long as they preserve this potential, as it should happen in the licensing phase of 
maturation in the LNs (Reis e Sousa 2001). In addition, IL-12 secretion during maturation may 
even result in exhaustion of mDCs and failure of further IL-12 secretion (Langenkamp, Messi et 
al. 2000). This contention is in agreement with a comprehensive review (Gilboa 2007) 
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suggesting that DCs need to be generated in vitro such that they undergo optimal maturation but 
not licensing, because full activation of DCs ex vivo might be counterproductive. Moreover, 
although early exposure of mDCs to signals such as CD40L or TLR ligands may increase 
production of IL-12, it reduces the migratory capacity of mDCs supporting the necessity of a late 
trigger for IL-12 secretion (Luft, Maraskovsky et al. 2004; Shi, Harrison et al. 2004; Boullart, 
Aarntzen et al. 2008). This agrees with the reports suggesting IL-12 to be a late-phase cytokine 
in DC maturation which is secreted under tight regulation based on a combination of multiple 
TLR ligands and CD40L (Schulz, Edwards et al. 2000), while a single stimulus is insufficient to 
induce secretion of IL-12 (Snijders, Kalinski et al. 1998; Schulz, Edwards et al. 2000). 
Moreover, the Th1-promoting transcriptional profile observed in MC-mDCs indicates that an IL-
12 based assessment of the abilities of MC-mDCs to generate a Th1- or Th2-type immune 
response might not be necessarily conclusive. 
To our knowledge, this is the first study that compares the effect of several maturation 
agents on the gene expression profiles and functional abilities of the resulting mDCs showing a 
Th1-promoting effect of PGE2-containing cocktail on mDCs combined with advanced mDC-
specific characteristics. In conclusion, we suggest retaining this agent in the cocktail, because of 
its significant effects on all functional aspects of maturation combined with the induction of a 
Th1-biased transcriptional profile in mDCs, while re-evaluating the effects of PGE2 on DC 
maturation with respect to IL-12 production. 
 115 
5 Human dendritic cells expressing hepatitis C virus core protein 
display transcriptional and functional changes consistent with 
maturation 
 
Submitted for publication. 
 
5.1 Abstract 
Hepatitis C virus (HCV) causes a chronic liver infection, which may result in cirrhosis and 
hepatocellular carcinoma. Impairment of the maturation process in dendritic cells (DCs) may be 
one of the mechanisms responsible for immune evasion of HCV. The core and NS3 proteins are 
among the most conserved proteins of HCV and play a key role in viral clearance. To evaluate 
the effects of these proteins on DCs, monocyte-derived immature DCs (iDCs) were transfected 
with in vitro transcribed (IVT) HCV core or NS3 RNA. While these HCV genes had no 
inhibitory effect on DC maturation, transfection of DCs with IVT core RNA appeared to result in 
changes compatible with maturation. To investigate this in more detail, the transcriptional 
profiles of DCs transfected with IVT core, NS3 or green fluorescent protein (GFP) RNA were 
examined using a DC-specific membrane array. Of the 288 genes on the array, 46 genes were 
distinctively up- or down-regulated by transfection with IVT core RNA in comparison to NS3 or 
GFP RNA treatments. Forty-two of these genes are involved in DC maturation. The effects of 
core on maturation of DCs were further confirmed by a significant increase in surface expression 
of CD83 and HLA-DR, a reduction of phagocytosis, as well as an increase in proliferation and 
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IFN-γ secretion by T cells in a mixed leukocyte reaction assay. These results show that HCV 
core does not have an inhibitory effect on human DC maturation; but could be a target for the 
immune system. 
 
5.2 Introduction 
Hepatitis C Virus (HCV), a member of the Flaviviridae family, is the causative agent of a 
blood-borne hepatitis becoming persistent in more than 70% of cases, and continuing as a 
chronic-active hepatitis, which then results in liver cirrhosis and/or hepatocellular carcinoma 
(HCC) (Alter 1997; Alter and Seeff 2000). After the development of a hepatitis B vaccine, HCV 
is becoming the leading cause of liver transplantation and HCC, as one of the confirmed 
oncogenic viruses (El-Serag and Mason 2000; Hassan, Hwang et al. 2002; Rosen 2002; Koike 
2005). According to a World Health Organization (WHO) report in 1999 
(http://www.who.int/en/), at least 3.1% of the world population is chronically infected with this 
virus. It is estimated that each year 3 to 4 million people are newly infected (WHO, 2000 report), 
who play important roles as carriers and reservoirs of the disease (Major and Feinstone 1997; 
Moradpour, Brass et al. 2002; Meylan, Curran et al. 2005). There is no vaccine to prevent HCV 
infection, and while the existing therapy is expensive, it is not effective against all subtypes of 
HCV, and causes serious side effects. Overall, with a five times higher prevalence (3.1%) in 
comparison to HIV infection (0.6%; UNAIDS 2008 Report; http://www.unaids.org/en/), a further 
increased rate in mortality from HCC associated with chronic hepatitis C can be expected during 
the next 20-25 years.  
Viruses use multiple mechanisms to evade the host’s immune defence and become 
persistent. One of the strategies non-cytopathic viruses like HCV use to establish a chronic 
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disease is to infect immune cells. Dendritic cells (DCs), the most potent antigen presenting cells, 
have been suggested to be targets for HCV and impaired in chronic hepatitis C patients. This has 
been attributed to either reduced numbers of circulating DCs or functional impairment of 
circulating or monocyte-derived DCs (Mo-DCs) (Kanto, Hayashi et al. 1999; Auffermann-
Gretzinger, Keeffe et al. 2001; Bain, Fatmi et al. 2001; Kanto, Inoue et al. 2004; Tsubouchi, 
Akbar et al. 2004; Szabo and Dolganiuc 2005; Averill, Lee et al. 2007; Della Bella, Crosignani et 
al. 2007; MacDonald, Semper et al. 2007; Miyatake, Kanto et al. 2007; Miyazaki, Kanto et al. 
2008). Furthermore, inhibition of maturation or allostimulatory ability of in vitro generated DCs 
from healthy donors transfected with HCV genes or exposed to HCV proteins has been reported 
(Sarobe, Lasarte et al. 2002; Dolganiuc, Kodys et al. 2003; Waggoner, Hall et al. 2007; Saito, 
Ait-Goughoulte et al. 2008; Zimmermann, Flechsig et al. 2008). These observations have been 
confirmed in murine models (Hiasa, Horiike et al. 1998; Large, Kittlesen et al. 1999; Kim, Lee et 
al. 2002; Sarobe, Lasarte et al. 2003). 
In contrast, other studies produced contradictory results showing normal functional 
properties of DCs in chronic HCV patients or DCs expressing HCV genes (Sun, Bodola et al. 
2001; Longman, Talal et al. 2004; Longman, Talal et al. 2005; Piccioli, Tavarini et al. 2005; Li, 
Krishnadas et al. 2006; Li, Li et al. 2006; Zhou, Lukes et al. 2007; Barnes, Salio et al. 2008; 
Thumann, Schvoerer et al. 2008). Furthermore, DCs transfected with HCV genes were shown to 
be good candidate vaccines because of their in vitro and in vivo stimulatory effects (Li, 
Krishnadas et al. 2006; Li, Li et al. 2006; Yu, Huang et al. 2006; Yu, Babiuk et al. 2007; Yu, 
Babiuk et al. 2008). However, the use of a viral adenovirus as vectors in some of these studies is 
questionable as adenovirus itself may be able to mature DCs (Morelli, Larregina et al. 2000; 
Philpott, Nociari et al. 2004; Basner-Tschakarjan, Gaffal et al. 2006). Even if the empty vector is 
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used as a control, there is a concern about a potential synergic effect of the combination of HCV 
and vector proteins in inducing maturation, which may not occur when HCV or vector genes are 
expressed individually.  
In this study, we used an efficient non-viral method (Landi, Babiuk et al. 2007) to transfect 
human DCs with in vitro transcribed (IVT) core or NS3 RNA, and then analyzed their functional 
properties. Overall, our data suggest that these HCV genes do not inhibit DC maturation. In 
contrast, according to transcriptional profiles and functional assays, core appeared to induce 
maturation of immature DCs (iDCs). These IVT core RNA-transfected DCs secreted IL-12p70 in 
response to LPS or poly I:C treatment and induced proliferation and IFN-γ secretion by T cells in 
a mixed leukocyte reaction (MLR) assay. In conclusion, by reporting induction of DC maturation 
by HCV core protein, we propose core as a strong immunogenic component of HCV with the 
potential to induce Th1-type immune responses, which suggests core to be a target antigen for 
the immune defence.  
 
5.3 Materials and methods 
5.3.1 Generation of monocyte-derived immature dendritic cells 
Immature DCs were generated as described previously (Landi, Babiuk et al. 2007). 
Briefly, peripheral blood mononuclear cells were collected from human venous blood by density 
gradient separation, and subsequently monocytes were isolated by positive selection on LS 
columns (Miltenyi Biotech, Auburn, CA, USA) using a CD14-specific antibody conjugated to 
paramagnetic MicroBeads (Miltenyi). The cells were resuspended in complete RPMI (CRPMI; 
RPMI 1640 [Invitrogen] supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 
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μM non-essential amino acids, 1 mM sodium pyruvate, 50 μM 2ME, 10 mM HEPES, and 50 
μg/ml gentamycin) prepared with phenol red-free RPMI 1640 (Invitrogen Canada Inc., 
Burlington, ON, Canada) as described previously (Landi, Babiuk et al. 2007). Recombinant 
human (rh) GM-CSF (100 ng/ml, Peprotech Inc., NJ, USA) and rhIL-4 (200 ng/ml, Peprotech) 
were added, and then the CD14
+
 monocytes were dispensed into the wells of a 6-well plate 
(Corning Incorporated, Corning, NY, USA). On day 3, iDCs were harvested, washed, counted, 
and used in subsequent experiments. 
 
5.3.2 Construction of plasmids containing HCV genes 
The pGEM4Z-5’UT-eGFP-3’UT-64A vector (pGEM) was kindly provided by Dr. E. 
Gilboa (Duke University Medical Centre, Durham, NC, USA). This plasmid contains the GFP 
gene flanked by the 5’ and 3’ un-translated regions and a poly A tail. To construct pGEM 
plasmids containing HCV genes, a core DNA fragment was generated by polymerase chain 
reaction (PCR) using genomic DNA isolated from HCV BK strain and a NS3 DNA fragment 
was amplified from pHCVrep1bl. Designed primers, plasmids pGEM4Z-5’UT-core-3’UT-64A 
and pGEM4Z-5’UT-NS3-3’UT-64A, and gene sequences of core and NS3 are displayed in Fig. 
5.7. The PCR products were purified and cloned into the pGEM vector, from which the GFP 
gene was excised by appropriate restriction enzyme digestion. The insertion of the subcloned 
HCV genes was confirmed by sequencing.  
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5.3.3 Nucleofection of immature dendritic cells with HCV genes 
The plasmids containing one of the HCV genes or green fluorescent protein (GFP) were 
used to make IVT RNA using the mMESSAGE mMACHINE Kit (Ambion, Austin, TX, USA) 
according to the manufacturer’s instructions. Nucleofection of iDCs was performed according to 
the manufacturer’s instructions with some modifications (Amaxa Company, Köln, Germany). 
Briefly, the iDCs were collected on day 3, washed twice, and resuspended in 100 μl of Human 
Dendritic Cell Nucleofection Solution (Amaxa). Five μg of IVT RNAs were added per 1×106 
cells, and the samples were nucleofected using program K2. The iDCs were then collected and 
dispensed in the wells of a 24-well plate (Corning Incorporated) containing pre-warmed CRPMI 
supplemented with 50 ng/ml rhGM-CSF and 200 ng/ml rhIL-4. The plate was incubated at 37ºC, 
and DCs and supernatants were collected at appropriate time points for further analysis or assays. 
To induce maturation, the iDCs were treated for 48 h with rhTNF-α (Peprotech) at 50 ng/ml, 
LPS (Sigma-Aldrich Canada Ltd., Oakville, ON, Canada) at 10 μg/ml, or a maturation cocktail 
(MC) consisting  of 20 ng/ml rhIL-1β (Peprotech), 10 ng/ml rhIL-6 (Peprotech), 50 ng/ml 
rhTNF-α, and 1 μg/ml PGE2 (Sigma).  The iDCs and supernatants were collected 48 h after 
nucleofection for further analysis. 
 
5.3.4 Detection of core, NS3 and GFP protein expression in dendritic cells by western 
blotting 
After nucleofection of iDCs and transfection of Cos7 cells with IVT core, NS3 or GFP 
RNA, the cells were centrifuged at 300 x g for 5 min, and resuspended in 200 μl of sodium 
dodecyl sulfate (SDS) loading buffer containing 2-mercapto-ethanol. Subsequently, the cell 
lysates were boiled for 5 min, and loaded on a 12% reducing SDS-polyacrylamide gel. The 
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proteins were transferred to a nitrocellulose membrane, which was then incubated with core-, 
NS3- or GFP-specific monoclonal antibody (Anogen, YES Biotech Laboratories Ltd., 
Mississauga, ON, Canada), followed by secondary antibody conjugated to an infrared dye 
(IRDye CW800, LI-COR Biosciences, Lincoln, Nebraska USA), and scanned on an infrared 
scanner (Odyssey, LI-COR).  
 
5.3.5 Array analysis 
After nucleofection, the iDCs were washed twice in PBS (pH 7.2, Invitrogen), and total 
RNA was extracted from the cells using a RNA/Protein Isolation NucleoSpin RNA/Protein Kit 
(MACHEREY-NAGEL, Bethlehem, PA, USA) according to the manufacturer’s instructions. 
This kit was used in order to simultanously isolate proteins from the same sample for proteomic 
study. Total RNA samples were checked on a bioanalyzer for quality assurance and kept at -80ºC 
until use. Biotin-integrated complementary RNA (cRNA) was generated using a reagent kit from 
SuperArray Biosciences (SuperArray Biosciences, Frederick, MD, USA) according to the 
manufacturer’s instructions.  Three biological replicates were used, and all cRNA samples were 
made simultaneously and hybridized under the same conditions to reduce the technical 
variability.  A final amount of 3 μg of cRNA was used to hybridize on a specific Dendritic Cell 
and Antigen-presenting Cell Array (OHS-406) membrane (SuperArray). All hybridization steps 
were performed according to the protocol provided by the supplier with exception of the labeling 
and detection steps. To be able to scan the arrays with an infrared scanner, we optimized a one-
step method to label streptavidin with IRDye CW800-SA (Perkin Elmer, Waltham, 
Massachusetts, USA). After incubation with CW800-SA-streptavidin, the arrays were washed, 
and scanned using the Odyssey scanner (LI-COR). The settings were optimized to get the best 
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images with a broad range of intensities within the limits of the equipment. A customized grid 
with circle-shape features was designed, and before calculation of the intensities, every spot on 
the array was visually checked, and noises and artifacts were excluded using Odyssey software 
V.3 (LI-COR). The intensities were calculated and raw integrated intensity values were loaded 
into GeneSpring software Version 7.3 (Agilent Technologies, Santa Clara, California, USA). 
Data normalization was performed based on GAPDH housekeeping genes on the array, and only 
median polishing was added as the second step for normalization. Changes of 1.5-fold (based on 
normalized values) in comparison to non-transfected or IVT NS3- or GFP-transfected iDCs were 
used as cutoff. 
 
5.3.6 Flow cytometry 
DCs were washed in PBS, and resuspended in FACS buffer (PBS, pH 7.2 with 0.2% 
gelatin and 0.03% sodium azide) in a round-bottom 96-well plate (Corning Incorporated). 
Subsequently, FITC- or PE-conjugated monoclonal antibodies specific for CD83 or HLA-DR, as 
well as appropriate isotype controls (Becton Dickinson [BD] Biosciences, Oakville, ON, 
Canada) were added to each well, and the plate was incubated on ice for 30 min. After 
incubation, the cells were washed three times with FACS buffer, resuspended in cold PBS and 
analyzed by FACScan (BD Biosciences). The cells were gated electronically for Forward Scatter 
(FSC) and Side Scatter (SSC) properties and more than 10,000 events were analyzed by 
FACScan using Cell Quest software (BD Biosciences). 
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5.3.7 Phagocytosis assay 
A phagocytosis assay was performed as described previously (Landi, Babiuk et al. 2007). 
Briefly, DCs were collected, washed once in PBS, resuspended in CRPMI at 1×10
6
 cells/ml, and 
then incubated at 37 ºC or on ice with FITC-conjugated dextran (FITC-DX, Sigma, 1 mg/ml of 
PBS) for 2 h in the dark. After incubation, the cells were collected, washed three times with cold 
PBS, and checked by flow cytometry for FITC-DX uptake. 
 
5.3.8 Allostimulatory mixed leukocyte reaction (MLR) 
Carboxyfluorescein diacetate succininidyl ester (CFSE) (CellTrace™ CFSE Cell 
Proliferation Kit, Molecular Probes, Invitrogen) was used to label responder CD4
+
 T cells as 
described previously (Lyons and Parish 1994). Using a CD4
+ 
T cell isolation kit (Miltenyi), 
CD4
+ 
T cells were isolated from a different, HLA-mismatched healthy donor with a purity of 
more than 95% based on CD3 and CD4 markers. After incubation with CFSE and washes 
according to the manufacturer’s instructions, CD4+ T cells were resuspend in CRPMI, and added 
to each well of a round-bottom 96-well plate (Corning Incorporated) at 3 × 10
5
 cells/well. 
Dendritic cells were harvested, washed in PBS, resuspended in CRPMI, and dispensed in the 
wells at 3 × 10
4
 cells/well. The plate was incubated at 37 ºC. On days 3, 5, and 8, the 
supernatants were collected for cytokine analysis and the cells were collected and analyzed by 
FACScan. The T cell populations were gated electronically for further analysis on the FL1 
channel. Based on the fluorescent intensities for CFSE, dividing T cells were gated separately 
from non-dividing T cells and their ratio used to compare the magnitude of T cell proliferation. 
 
 124 
5.3.9 Cytokine secretion analysis 
Transfected iDCs were collected 24 h after nucleofection and stimulated by LPS (Sigma) 
or poly I:C (Sigma) to check their ability to secrete IL-12p70 and/or IL-10. After incubation for 
24 h, the plates were centrifuged at 400 x g, and the supernatants were collected, and analyzed 
for production of IL-12p70 and IL-10 using ELISA Sets (BD biosciences). The supernatants 
from the MLR assays were also collected on days 3, 5, and 8, and checked for IFN-γ and IL-10 
secretion by ELISA (BD biosciences). 
 
5.3.10 Statistical analysis 
Data were analyzed using statistical software (GraphPad Prism Version 5.00, Prism 
Software Corporation, Irvine, CA, USA). Variables were assumed to not be normally distributed; 
thus, the median values between pairs of groups were compared using the Mann-Whitney U test. 
Differences were considered significant if the two-tailed P value was lower than 0.05 with 
confidence intervals of 95%. For the array data only genes up- or down-regulated in the same 
direction in all three replicates in core-nucleofected DCs were considered to be relevant. After 
normalization of the fold-change values of these genes, only those genes that showed statistical 
significance between the core and GFP or NS3 treatments with a p value of <0.05 or lower based 
on a parametric student t-Test were considered significant and discussed as genes distinctively 
affected by core. 
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5.4 Results 
5.4.1 Transfection of immature dendritic cells with IVT core or NS3 RNA does not 
impair dendritic cell maturation 
To evaluate the effects of core or NS3 expression on human DCs, monocyte-derived 
iDCs (Mo-iDCs) were transfected with IVT core, NS3 or GFP RNA, treated with LPS, TNF-α or 
maturation cocktail, and then phenotypically and functionally characterized.  As shown in Fig. 
5.1a, iDCs nucleofected with IVT core, NS3 or GFP RNA expressed the respective proteins at 
levels comparable to those in transfected Cos-7 cells, which confirms the intracellular expression 
of the target proteins, and supports the efficiency of nucleofection of Mo-DCs (90-98%) (Landi, 
Babiuk et al. 2007).  Based on expression of CD83 and MLR, core and NS3 did not show an 
inhibitory effect on DC maturation (Fig. 5.1b, c, and d). Furthermore, IVT core and NS3 RNA-
transfected DCs retained their ability to secrete high levels of IL-12p70 in response to LPS or 
poly I:C stimulation (Fig. 5.1e), while similar levels of IL-10 secretion were induced, regardless 
of the DC treatment (Fig. 5.1f). Interestingly, in the absence of maturation factors, transfection 
with IVT core RNA appeared to result in induction of maturation (Fig. 5.2b). 
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Figure 5.1. Effects of transfection with IVT core, NS3 or GFP RNA on iDCs treated with maturation 
factors. (a) Expression of HCV core, NS3 and GFP proteins in iDCs after nucleofection with IVT core, 
NS3, or GFP RNA and in Cos-7 cells after electroporation with IVT core, NS3, or GFP RNA.  Molecular 
weight markers are shown in the left margin. (b) CD83 expression without treatment with maturation 
factors in iDCs transfected with IVT core (N+core), NS3 (N+NS3) or GFP (N+GFP) RNA on iDCs after 
48 h. N: nucleofected only. Nil: No treatment. (c) CD83 expression after treatment with maturation 
cocktail (MC) in iDCs transfected with IVT core (N+core), NS3 (N+NS3) or GFP (N+GFP) RNA on 
iDCs after 48 h. N: nucleofected only. Nil: No treatment. (d) MLR of iDCs transfected with IVT core, 
NS3, or GFP RNA, and either treated with LPS or MC, or left untreated (nil). Stimulation index was 
calculated with the formula: Radioactive count per minute (CPM) for culture of T cells (R) and DCs (I) : 
CPM in R, the control group (T cells culture alone). (e) IL-12 p70 and (f) IL-10  production by DCs 
transfected with IVT core, NS3 or GFP RNA and non-transfected DCs, 24 h after induction with LPS or 
poly I:C. Nil on the X-axis refers to untreated DCs. Bars represent median values (n = 5).  
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5.4.2 Transfection of immature dendritic cells with IVT core RNA results in significant 
changes in gene expression 
To examine the effects of core at the transcriptional level, iDCs were nucleofected with 
IVT core RNA, without addition of any maturation factors, and collected 8, 24 or 48 h later. 
Total RNA was extracted, and cRNA was made and analyzed using DC-specific arrays. IVT 
NS3 or GFP RNA-transfected, and non-transfected were included as controls. Furthermore, non-
transfected iDCs were treated with TNF-α to compare the effect of core to a commonly used 
maturation factor. Since the changes in gene expression at 48 h were highly representative of 
changes at 8 and 24 h (Fig. 5.2a) and likely representative of specific and stable effects due to 
foreign protein expression within DCs and not from immediate effects of the nucleofection itself, 
the 48 h time-point was selected for further studies. This time point was also most relevant, 
because mDCs are usually characterized 48 h after incubation with maturation agents.  
When a 1.5-fold change in gene expression over non-transfected iDCs was used as cutoff to 
evaluate the effects of IVT core, NS3, or GFP RNA on iDCs after 48 h, core was found to induce 
changes in expression of 71 genes, which corresponds to 89% of the changes observed after any 
of the treatments (Table 5.1). In contrast, NS3 induced changes in expression of 27 genes (34%), 
while GFP changed expression of 29 genes (36%) and TNF-α altered expression of 26 genes 
(33%). A more detailed analysis of the gene list suggested that a significant number of the genes 
affected by core are involved in DC maturation. 
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Figure 5.2. Gene expression changes in IVT core, NS3, or GFP RNA-transfected iDCs. (a) Number of 
up- and down-regulated genes in IVT core, NS3, or GFP RNA-transfected iDCs in comparison to non-
nucleofected iDC at different time points after transfection. (b,c) Comparison of gene expression changes 
after nucleofection with IVT core, NS3 and GFP RNA. (b) Up-regulated genes. (c) Down-regulated 
genes. Only genes that changed in expression level by 1.5-fold in comparison to the non-nucleofected 
iDCs (Nil) treatment are shown. (d,e) Comparison of changes in expression of maturation-related genes 
after nucleofection with IVT core RNA and treatment with TNF-α. (d) Up-regulated genes. (e) Down-
regulated genes. For core-affected genes, only genes that were significantly up- or down-regulated in 
comparison to IVT NS3 or GFP RNA-transfected iDCs are used for comparison. Only genes that changed 
in expression level by 1.5-fold in comparison to the non-nucleofected iDCs (Nil) treatment are shown.   
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Table 5.1. List of 80 genes up- or down-regulated by ≥1.5-fold in IVT core-, NS3- and GFP RNA-
transfected and TNF-α-treated iDCs, in comparison to non-transfected iDCs. 
 
 
 
Gene GFP Core NS3 TNF Gene GFP Core NS3 TNF 
ADAMDEC1 2.2 3.4 2.0 1.5 FCER1G 1.7 1.2 1.4 -1.1 
ADAR 1.7 1.7 1.5 1.1 FCER2 1.3 -2.1 1.0 -1.4 
ARHGDIB -1.4 -5.2 -1.3 -1.0 GBP3 1.1 1.6 1.3 -1.0 
B2M-1 1.7 2.2 1.8 1.3 GPX4 -1.0 -1.0 1.1 1.8 
BASP1 -1.3 1.3 -1.3 1.8 HLA-A 2.0 4.0 2.3 1.5 
BTG1 1.0 2.5 1.1 1.6 HLA-DPB1 -1.0 -1.5 -1.0 -1.0 
CCL1 1.0 1.5 -1.0 1.0 HLA-DQA1 1.1 -1.6 -1.1 -1.1 
CCL13 -1.1 1.2 -1.2 -2.4 HLA-DQB1 1.4 -1.6 1.2 -1.1 
CCL2 2.1 4.8 1.9 -1.6 HLA-F 2.1 3.5 1.8 1.5 
CCL22 -1.0 1.2 1.1 1.6 HLA-G 1.4 1.7 1.6 1.4 
CCL3L1 1.9 5.3 2.3 1.3 HSP90B1 1.4 1.1 1.5 1.1 
CCL4 1.6 4.0 2.7 1.5 IFI16 1.8 2.0 1.7 -1.1 
CCL5 2.7 8.3 2.4 3.5 IFI27 4.1 12.2 2.2 -1.1 
CCL7 1.1 3.1 -1.1 -1.3 IFI35 3.3 5.7 2.4 1.0 
CCL8 2.6 14.7 1.9 -1.6 IFI44 2.3 3.5 2.3 -1.1 
CCR1 1.8 1.6 1.5 -1.3 IFI6 4.1 4.3 2.9 -1.2 
CCR5 1.6 1.2 1.4 1.1 IFIT1 8.0 30.0 4.7 -1.3 
CCR7 1.3 9.1 1.3 3.7 IL8 1.2 3.7 1.9 1.5 
CD1A -1.2 -3.7 -1.0 -1.2 INHBA 1.3 2.3 1.1 1.4 
CD1B 1.3 -1.5 1.6 1.2 ISG15 14.0 20.0 7.0 1.0 
CD1C 1.2 -2.6 1.2 -1.0 ISG20 5.1 33.6 2.5 1.7 
CD209 -1.2 -1.6 -1.1 -1.1 ITGAX 1.2 -1.7 -1.1 1.1 
CD33 -1.0 -1.6 1.1 -1.3 ITGB2 1.6 -1.7 1.2 1.2 
CD4 -1.5 -2.3 -1.4 -1.1 LAMP3 -1.1 1.5 -1.0 1.6 
CD52 -1.0 -2.0 -1.1 -1.3 LIPA -1.1 -2.2 1.0 1.0 
CD74 -1.1 -1.6 -1.2 -1.0 LY75 -1.3 1.6 1.0 2.5 
CD80 1.2 1.9 1.2 -1.1 MARCKSL1 -1.2 2.0 1.0 1.6 
CD83 1.1 2.7 1.2 1.9 MIF -1.5 -2.6 -1.2 -1.3 
CD86 2.0 3.4 1.8 1.3 NFKB1 1.2 2.3 -1.0 1.9 
CD8A -1.3 -1.6 -1.2 -1.1 NFKB2 -1.0 1.4 -1.1 1.5 
CLEC4A -1.4 -2.1 -1.0 1.2 PDIA3 1.5 1.7 2.1 1.2 
CSF1R -1.0 -2.1 -1.1 -1.4 PLAUR 1.1 1.7 1.3 1.3 
CST3 -1.4 -2.9 -1.4 -1.4 PNRC1 -1.6 2.1 -1.1 2.0 
CXCL10 -1.0 3.1 1.1 -1.2 PRG1 1.9 2.1 2.2 1.3 
CXCL16 1.3 1.7 1.1 -1.0 PSCDBP 1.2 2.4 1.3 1.6 
CXCR4 -1.2 1.8 -1.3 1.3 RELB 1.2 1.8 1.0 1.7 
EBI3 -1.0 1.8 -1.1 2.5 S100A4 -1.1 -4.8 1.1 -2.2 
ECGF1 1.9 1.7 1.4 -1.0 SOD2 1.5 3.7 1.4 1.4 
F13A1 -3.6 -8.5 -2.2 -4.1 TRAP1 1.1 -1.8 -1.1 1.0 
FCER1A -1.5 -3.6 -1.1 -1.2 VCL -1.4 -3.1 -1.4 -1.0 
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5.4.3 Transfection of immature dendritic cells with IVT core RNA has distinctive effects 
on the expression of maturation-related genes in comparison to dendritic cells 
transfected with GFP or NS3 
When analyzed in more detail, of the 50 up-regulated genes in transfected DCs (Fig. 
5.2b), 22 genes were common for core, NS3 and GFP. However, the increase in expression of 10 
of these genes was consistently higher in IVT core RNA-transfected DCs than in DCs transfected 
with IVT NS3 or GFP RNA. This increase was observed in all replicates and was statistically 
significant (student t-Test) (Fig. 5.3a). With the exception of CCL3L1, all of these genes have 
been reported as up-regulated during DC maturation, including genes encoding chemokines 
involved in T cell attraction (CCL5 and CCL8), the co-stimulatory molecule CD86, MHC-I 
molecules HLA-A and HLA-F, and IFN-stimulated genes (ISGs), such as IFI27, IFIT1 and 
ISG20.  Detailed information regarding these genes and their role in DC maturation is provided 
in Table 5.2. Furthermore, the expression of mitochondrial superoxide dismutase 2 (SOD2), one 
of two genes up-regulated by both core and GFP, but not NS3 treatment, was significantly higher 
in IVT core RNA-transfected DCs than in IVT GFP RNA-transfected DCs, whereas the 
expression levels of IL-8, a gene up-regulated by both core and NS3, but not GFP treatment, was 
significantly higher in IVT core RNA-transfected DCs than in IVT NS3 RNA-transfected DCs 
(Fig. 5.3a). These two genes have also been frequently reported as up-regulated during DC 
maturation (Dietz, Bulur et al. 2000; Le Naour, Hohenkirk et al. 2001; Moschella, Maffei et al. 
2001; Lindstedt, Johansson-Lindbom et al. 2002; Messmer, Messmer et al. 2003; Bles, 
Horckmans et al. 2007). Since only two respectively three genes were specifically up-regulated 
by IVT NS3- and GFP RNA treatment (Fig. 5.2b), expression of NS3 did not appear to have any 
significant effect on DCs when compared to GFP. Interestingly, three of these genes (FCER1, 
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ITGB2, and CD1b) are members of the families down- regulated during maturation, while CCR5 
is a known iDC marker.  
Of the 19 genes up-regulated in IVT core RNA-transfected DCs (Fig. 5.2b), 16 genes 
were significantly increased in expression when compared to non-transfected DCs (Fig. 5.3b). 
Fourteen of these 16 genes are clearly up-regulated during DC maturation (Table 5.2).  In 
summary, of the 28 genes significantly up-regulated after transfection with IVT core RNA in 
comparison to transfection with IVT NS3 and GFP RNA, 25 genes (89%) have been reported as 
up-regulated in mDCs. This suggests that induction of maturation is one of the in vitro effects of 
core on human DCs. Figure 5.4a shows the actual images for several of these up-regulated genes 
supporting the reproducibility and quality of these arrays. 
Of the 27 down-regulated genes in transfected DCs, 25 genes were specific for core (Fig. 
5.2c). Seventeen of these genes were significantly down-regulated when compared to non-
transfected, as well as IVT NS3 and GFP RNA-transfected DCs. In contrast, only one gene 
(PNRC1) was down-regulated by GFP, while F13A1 was down-regulated by core, NS3 and 
GFP. However, the level of F13A1 gene expression was significantly lower in IVT core RNA-
nucleofected DCs for all replicates in comparison to other treatments, so we consider F13A1 a 
gene distinctively down-regulated by core treatment. Interestingly, PNRC1, which is up-
regulated during maturation, was down-regulated by GFP. Overall, of the 18 genes significantly 
down-regulated by transfection with IVT core RNA in comparison with IVT NS3 or GFP RNA 
transfected DCs or non-nucleofected DCs (Fig. 5.3c), 17 are down-regulated during DC 
maturation (Table 5.2).  The actual images for several of the down-regulated genes are shown in 
Fig. 5.4b. 
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Figure 5.3. Changes in gene expression levels after transfection with IVT core, NS3 or GFP RNA. (a) 
Genes up-regulated in iDCs after transfection with IVT core, NS3 or GFP RNA in comparison to non-
nucleofected iDCs. SOD2 was common between core and GFP, and IL-8 was common between core and 
NS3 only. The changes induced were significantly higher in IVT core RNA-treated iDCs when compared 
to IVT NS3 or GFP RNA-treated iDCs. (b) Genes significantly up-regulated in iDCs transfected with 
IVT core RNA in comparison to IVT NS3 and GFP RNA-treated iDCs, and non-nucleofected iDCs. (c) 
Genes significantly down-regulated in iDCs transfected with IVT core RNA in comparison with IVT NS3 
and GFP RNA-treated iDCs and non-nucleofected iDCs. F13A1 gene expression was down-regulated in 
all transfected groups. Squares: IVT core RNA-transfected iDCs. Triangles: IVT NS3 RNA-transfected 
iDCs. Circles: IVT GFP RNA-transfected iDCs. Each data point is representative of one biological 
replicate. The dotted line at 1.5 fold change shows the cutoff point for analysis.  
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Table 5.2. Functional categorization and description of genes significantly changed in expression levels 
by IVT core RNA in the direction expected for DC maturation.    
 
 
Gene Name and Description 
Fold 
change 
Phagocytosis: 
CD209: A cell surface receptor involved in the primary interaction between host and pathogens, which acts as cell-
adhesion and pathogen-recognition receptor (Barreiro, Patin et al. 2005). 
CSF1R: A receptor for which down-regulation is associated with loss of phagocytic and adhesive properties of DCs 
(Takashima and Kitajima 1998). 
FCER1A: A high affinity receptor for IgE which plays a role in uptake of antigens bound to IgE by LCs (Mudde, Hansel 
et al. 1990). 
FCER2: A low-affinity receptor for IgE, which is down-regulated in mDCs (Hashimoto, Suzuki et al. 2000; Lindstedt, 
Johansson-Lindbom et al. 2002), and considered an iDC marker (Shin, Jin et al. 2008). 
 
-1.6 
 
-2.1 
 
-3.6 
 
-2.1 
Antigen Processing and Presentation: 
ADAMDEC1: A secreted protein in the disintegrin metalloproteinase family, which is involved in cell migration, cell 
adhesion, cell-cell and cell-matrix interactions, and signal transduction. It is predominantly expressed in DCs located in 
germinal centers of the lymphatic tissue (where mDCs are supposed to interact with T cells) and absent in iDCs. High 
levels of gene expression upon DC maturation were observed (Mueller, Rissoan et al. 1997; Fritsche, Muller et al. 2003). 
HLA-A:  and 
HLA-F: Members of the MHC-I family involved in antigen presentation, and up-regulated during DC maturation 
(Hashimoto, Suzuki et al. 2000; Bleharski, Niazi et al. 2001; Messmer, Messmer et al. 2003). 
CD80: A co-stimulatory molecule involved in antigen presentation. 
CD83: A functional maturation marker involved in antigen presentation 
CD86: A co-stimulatory molecule involved in antigen presentation. 
CD205 A member of the MMR family mediating the capture, endocytosis and subsequent processing and presentation of 
antigens by DCs. It can deliver antigens into both the MHC- I and II presentation pathways, indicating that CD205-
mediated endocytosis might be coupled to a mechanism for cross-presentation (Bonifaz, Bonnyay et al. 2002). It is up-
regulated upon DC maturation suggesting two distinct functions for this molecule in iDCs and mDCs (Messmer, 
Messmer et al. 2003; Butler, Morel et al. 2007).   
MARCKSL1: Myristoylated alanine-rich C-kinase substrate-like 1 playing important roles in cell shape, cell motility, 
cell secretion, transmembrane transport, and regulation of the cell cycle. It is consistently up-regulated during DC 
maturation (Dietz, Bulur et al. 2000; Hashimoto, Suzuki et al. 2000; Le Naour, Hohenkirk et al. 2001; Lindstedt, 
Johansson-Lindbom et al. 2002; Tureci, Bian et al. 2003). 
PSCDBP: An IL-12-induced gene, regulating DC-T cell adhesion by mediating DC-T cell de-attachment after antigen 
presentation (Hofer, Pfeil et al. 2006). It is up-regulated during DC maturation (Bleharski, Niazi et al. 2001; Messmer, 
Messmer et al. 2003; Tureci, Bian et al. 2003), which is indicative of a programmed change compatible with the 
characteristics of mDCs. 
CST3: Encodes human Cystatin C, which is an endogenous cysteine proteinase inhibitor in the Golgi system (Mussap 
and Plebani 2004). A reduction in expression level during DC maturation (Zavasnik-Bergant, Repnik et al. 2005) has 
suggested an increase in the activity of antigen processing in the cytoplasm compatible with an mDC state. 
CD1a: and 
CD1b: and 
CD1c: Members of the CD1 family, mediating the presentation of lipid antigens to T cells. They are down-regulated 
during DC maturation (Palucka, Taquet et al. 1998; Yanagihara, Komura et al. 1998; Hashimoto, Suzuki et al. 2000; Le 
Naour, Hohenkirk et al. 2001; Messmer, Messmer et al. 2003). 
LIPA: Lipase A, a crucial enzyme for the intracellular hydrolysis of taken-up lipoprotein particles. It is expressed at high 
levels in iDCs (Dietz, Bulur et al. 2000; Hashimoto, Suzuki et al. 2000; Ahn, Lee et al. 2002) and decreased in mDCs 
matured by LPS (Messmer, Messmer et al. 2003). This is suggestive of an enzyme activity focused at the early stages of 
maturation. 
 
3.4 
 
 
 
4 
3.5 
 
1.9 
2.7 
3.4 
1.6 
 
 
 
 
2 
 
 
 
2.4 
 
 
 
-2.9 
 
 
-3.7 
-1.5 
-2.6 
 
 
-2.2 
Cell Motility: 
ADAMDEC1: Described above. 
MARCKSL1: Described above. 
CCR7: A specific receptor for CCL19 and CCL21 involved in directional migration of mDCs and T cells toward lymph 
nodes, selectively expressed on mDCs and T cells.  
CXCR4: A specific receptor for CXCL12 involved in directional migration of mDCs and LCs toward lymph nodes, 
selectively expressed on mDCs and migrating LCs. 
ARHGDIB: A well-known anti-metastatic gene (Harding and Theodorescu 2007) (Schunke, Span et al. 2007), which 
 
3.4 
2 
9.1 
 
1.8 
 
-5.2 
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may also have an inhibitory effects on DC motility  (Messmer, Messmer et al. 2003). 
Cell Adherence: 
CSF1R: Described above. 
ITGAX (CD11c): and 
ITGB2 (CD18): Leukocyte adhesion receptors, involved in cellular attachment. Indeed, podosomes are linked to the 
extracellular matrix through these receptors, a critical process for cell adhesion (Gaidano, Bergui et al. 1990; Burns, 
Hardy et al. 2004). 
VCL: A membrane cytoskeletal protein, which is required for strong cell adhesion (Demali 2004). 
F13A1: An important coagulation factor, which cross-links between fibrin chains and stabilizes the fibrin clot. With its 
role in coagulation cascades and consistent and extensive reduction in its expression during DC maturation (Hashimoto, 
Suzuki et al. 2000; Messmer, Messmer et al. 2003), it could be a molecule needed to be down regulated during DC 
maturation. 
 
-2.1 
-1.7 
-1.7 
 
 
-3.1 
-8.5 
 
T cell Attraction: 
CCL5: Ligand for CCR1, CCR3, and CCR5, and  
CCL8: Ligand for CCR1, CCR2, CCR3, and CCR5 (Lindstedt, Johansson-Lindbom et al. 2002; Messmer, Messmer et 
al. 2003; Skelton, Cooper et al. 2003; Tureci, Bian et al. 2003). They play an important role in attracting naïve CD8+ 
through the CCR5 receptor to the site where DCs are interacting with CD4+ cells (Castellino, Huang et al. 2006). These 
would favour better DC-T cell contact resulting in stronger antigen presentation. 
CXCL10: A specific ligand for CXCR3 (expressed on Th1-type T cells and NK cells). It attracts CD8+ T cells and is 
secreted during induction of DC maturation by IFN-α2a (Padovan, Spagnoli et al. 2002). 
CXCL16: A specific ligand for CXCR6. It is produced by DCs found in the T cell zones of lymphoid organs, where 
mDCs are supposed to be located and interact with T cells (Matloubian, David et al. 2000). Expression of CXCL16, 
which attracts several subsets of T cells and natural killer T (NKT) cells, is induced by TNF-α and IFN-γ (Abel, 
Hundhausen et al. 2004). 
EBI3: Epstein-barr virus induced gene 3, an early product of activated antigen-presenting cells, driving rapid clonal 
expansion of naive CD4+ T cells (Pflanz, Timans et al. 2002). It is up-regulated during DC maturation (Ngo, Tang et al. 
1998; Yanagihara, Komura et al. 1998; Tureci, Bian et al. 2003). 
 
8.3 
14.8 
 
 
 
3.1 
 
1.7 
 
 
 
1.8 
Other: 
IFI27: and 
IFIT1: and 
ISG20: An important part of the IFN defense mechanism against viruses. Their expression is up-regulated during DC 
activation and maturation (Hashimoto, Suzuki et al. 2000; Liang, Ristich et al. 2008) (Hashimoto, Suzuki et al. 2000; 
Messmer, Messmer et al. 2003; Velten, Rambow et al. 2007). ISG20 is even proposed as a maturation marker for DCs.  
SOD2: A mitochondrial antioxidant enzyme, which is suggested to have a role in the immune response as it is up-
regulated in cells phagocytosing virus in other species (Zhang, Li et al. 2007).  
IL-8: A ligand for CXCR1 and CXCR2 attracting PMN to the site of infection. 
BTG1: B-cell translocation gene 1, which positively alters the migration capacity of DCs. 
NFKB1: Nuclear factor κB (NFKB) is a transcriptional regulator, which was recently suggested to be involved in partial 
maturation of DCs (Valentinis, Capobianco et al. 2008). 
PNRC1: Proline-rich nuclear receptor coactivator 1, a transcriptional regulator playing a role in signal transduction. It 
was also up-regulated as a result of NFKB signaling in response to LPS stimulation in a monocyte cell line (Carayol, 
Chen et al. 2006).  
RELB: V-reticulo-endotheliosis viral oncogene homolog B, a member of the NFKB family. It is suggested to have a 
critical role in maturation of DCs (Valentinis, Capobianco et al. 2008). Its up-regulation and nuclear translocation during 
DC maturation is considered a hallmark for maturation (Lindstedt, Johansson-Lindbom et al. 2002; Ju, Hacker et al. 
2003; Platzer, Jorgl et al. 2004).  
CD52:  An MHC-II-related gene, down-regulated in mDCs (Hashimoto, Suzuki et al. 2000). 
S100A4: S100 calcium binding protein A4, down-regulated during DC maturation.   
TRAP1: TNF receptor-associated protein 1, down regulated during DC maturation (Bles, Horckmans et al. 2007). 
 
12.2 
30 
32.6 
 
 
3.7 
 
3.7 
3.7 
2.3 
 
2.1 
 
 
1.8 
 
 
 
-2 
-4.8 
-1.8 
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Figure 5.4. Dendritic Cell and Antigen-presenting Cell Arrays (OHS-406) (SuperArray) incubated with 3 
μg of cRNA from iDCs after transfection with IVT core, NS3 or GFP RNA or treatment with TNF-α, or 
from untreated iDCs (Nil); R1, R2 and R3 represent three biological replicates. (a) Up-regulated genes. 
(b) Down-regulated genes. 
CD1a CD52 FCER1
A 
F13A1 CST3 S100A
4 
CD1c 
ITGAX 
Nil   GFP  Core   NS3  TNF Nil   GFP  Core   NS3  TNF Nil   GFP  Core   NS3  TNF 
Nil   GFP  Core   NS3  TNF Nil   GFP  Core   NS3  TNF Nil   GFP  Core   NS3  TNF Nil   GFP  Core   NS3  TNF 
Nil   GFP  Core   NS3  TNF 
R1 
R2 
R3 
R1 
R2 
R3 
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SOD2 IFIT1 ISG20 BTG1 
CCL8 CCR7 CXCL10 
R1 
R2 
R3 
CCL5 
Nil   GFP  Core   NS3  TNF Nil   GFP  Core   NS3  TNF Nil   GFP  Core   NS3  TNF 
EBI3 
Nil   GFP  Core   NS3  TNF 
MARCKSL1 
Nil   GFP  Core   NS3  TNF 
PSCDBP 
Nil   GFP  Core   NS3  TNF 
CD80 
Nil   GFP  Core   NS3  TNF 
Nil   GFP  Core   NS3  TNF Nil   GFP  Core   NS3  TNF Nil   GFP  Core   NS3  TNF Nil   GFP  Core   NS3  TNF 
Nil   GFP  Core   NS3  TNF 
R1 
R2 
R3 
R1 
R2 
R3 
a 
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Collectively, 91% (42 out of 46 genes) of all genes distinctively up- or down-regulated 
by core behaved according to changes expected during DC maturation, which suggests a function 
for core in DC maturation. To further confirm the differences in the effects of core, NS3 and 
GFP on iDCs, the genes 1.5-fold up- or down-regulated by core in comparison to GFP or NS3 
treatment were identified. This approach demonstrated that of the 42 genes described above only 
two (CD209, and CXCL16) were not included; however, even though not changed by 1.5-fold, 
the expression levels of these genes were still significantly different in IVT core RNA-
transfected DCs in comparison with IVT NS3 or GFP RNA-transfected DCs.   
 
5.4.4 The effects of core on the gene expression profile of dendritic cells are similar to 
those of TNF-α as one of the most common maturation agents 
To compare the effects of core to those induced by TNF-α, a routinely used maturation 
agent, the maturation-related genes up-regulated after IVT core RNA treatment were pooled with 
the genes altered during TNF-α treatment. Of 25 mDC-specific genes up-regulated by core (Fig. 
5.2d), 15 were also up-regulated by TNF-α. This accounts for 71% of all genes up-regulated 
during TNF-α treatment and 60% of all genes up-regulated by core. Indeed, this strongly 
suggests that there is a significant effect of core on DC maturation with a similar pattern to that 
of TNF-α. When the 17 mDC-specific genes down-regulated by core were pooled with the genes 
down-regulated by TNF-α in a Venn diagram (Fig. 5.2e), 2 common genes (F13A1 and S100A4) 
were identified, while 15 genes were down-regulated during nucleofection with IVT core RNA, 
but not by TNF-α.  
In summary, the effects of core were similar to the changes occurring during maturation 
of DCs by TNF-α, specifically with respect to the up-regulated genes. However, core promoted 
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the maturation process of DCs more extensively by shutting down a significant number of 
additional genes, mostly involved in endocytosis and cell adhesion, thus facilitating cell motility. 
These data strongly suggest that transfection of DCs with IVT core RNA results in stimulation of 
maturation, which could result in more efficient antigen presentation by mDCs followed by a 
more effective immune response.  
 
5.4.5 Transfection of immature dendritic cells with core induces phenotypic changes 
suggestive of maturation 
Expression of CD83, a functional maturation marker involved in antigen presentation, 
and HLA-DR, which translocates from the cytoplasm to the cell surface during maturation was 
examined. The number of IVT core RNA-transfected DCs expressing CD83 was equivalent to 
the number of TNF-α-treated DCs expressing CD83 (Fig. 5.5a), but significantly higher than the 
number of IVT NS3 or GFP RNA-transfected or non-nucleofected iDCs expressing CD83. 
Interestingly, the effect of NS3 was similar to that of the control treatments and significantly 
different from that of core. In addition, the cellular expression level of HLA-DR (shown by mean 
fluorescent intensity = MFI) was significantly increased after transfection with IVT core RNA, 
but not by IVT NS3 or GFP RNA (Fig. 5.5b). Although a significant increase was observed in 
MFI of HLA-DR in TNF-α-treated iDCs in comparison to untreated iDCs, the MFI of HLA-DR 
was significantly lower in TNF-α-treated iDC when compared to IVT core RNA-transfected 
iDCs, while there was no difference in comparison to the IVT NS3 or GFP RNA-transfected 
iDCs. 
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Figure 5.5. Phenotypic marker expression of iDCs 48 h after transfection with IVT core, NS3 or GFP 
RNA or treatment with TNF-α, or from untreated iDCs (Nil). The percentage of cells expressing CD83 
(a) and the mean fluorescent intensity (MFI) of HLA-DR (b) are shown, respectively. Bars represent 
median values (n = 5); bars with different letters are statistically different from each other and those with 
the same letters are not statistically different from each other. The star (*) is representative of a p value of 
< 0.05. 
b 
a 
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5.4.6 Transfection with core induces functional changes in immature dendritic cells 
compatible with maturation 
A reduction in phagocytic ability is a characteristic of mDCs, so the transfected DCs 
were examined in an in vitro phagocytosis assay. Transfection with IVT core RNA induced a 
significant reduction in the endocytic ability of the iDCs in comparison to all other treatments 
including TNF-α. In contrast, transfection with IVT NS3 RNA did not show any effect on the 
endocytic ability of the iDCs (Fig. 5.6a) suggesting that NS3 does not influence DC maturation. 
Furthermore, IVT core, NS3 and GFP RNA-transfected DCs were evaluated in an 
allostimulatory MLR assay, using CFSE-incubated T cells as responder cells. As shown in Fig. 
5.6b, iDCs nucleofected with IVT core RNA induced enhanced T cell proliferation in 
comparison to all other iDCs, which is compatible with improved antigen presentation, an 
important characteristic of mDCs. The difference between IVT core RNA-transfected DCs and 
IVT GFP RNA-transfected or untreated DCs was statistically significant on days 3, 5 and 8, 
whereas the IVT core RNA-transfected DCs were different from IVT NS3 RNA-transfected DCs 
on day 8. Representative FACS plots of this assay on day 8 are shown in Fig. 5.6c. 
In addition to their ability to promote proliferation of T cells, IVT core RNA-transfected 
DCs induced T cells to secrete IFN-γ at significantly higher levels when compared to iDCs 
transfected with IVT NS3 or GFP RNA, or non-transfected iDCs (Fig. 5.6d), while there were no 
differences in IL-10 production between the treatments (Fig. 5.6e). These data show that HCV 
core might promote the induction of a Th1-type immune response.   
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Figure 5.6. Functional characterization of DCs nucleofected with IVT core or NS3 RNA or incubated 
with TNF-α. Non-transfected iDCs (Nil) or GFP-transfected iDCs were also included. (a) Phagocytosis 
assay. (b) MLR assay. Stimulation index was calculated with the formula: Dividing T cells : Non-
dividing T cells in each treatment group / Dividing T cells : Non-dividing T cells in the control group (T 
cells culture). (c) FACS dot plot representative of the day 8 reading of the MLR assay. R3 and R4 show 
the population of non-divided and divided T cells, respectively. (d) IFN-γ secretion and (e) IL-10 
secretion by T cells induced by different treatments of iDCs.  T: T cells only; T+iDC: T cells incubated 
with iDCs; T+ GFP, core or NS3: T cells incubated with transfected iDCs. Bars represent median values 
(n = 5); bars with different letters are statistically different from each other and those with the same letters 
are not statistically different from each other. The stars (*) and (**) represent a p value of < 0.05 and < 
0.01, respectively. 
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Core primers : 
5’ primer           5’   GAATACGGATCCACCATGAGCACGAATCCTAAACC     3’ 
3’ primer:          5’   TAGCATCGAATTCTCTTAAGCGGAAGCTGGGGTGGT   3’ 
NS3 primers: 
 5’ primer          5’   ACGATGGATCCACCATGGCGCCTATTACGGCCTA        3’ 
3’ primer           5’    TAGCATCGAATTCACTCAGGTGCTCGTGACGACCTC  3’  
pGEM4Z/5'UT-Core-3'UT/A64
3464 bps
SpeI
T7 promoter
5' UTR 
Core
3' UTR 
A64
pGEM4Z5'UT-NS3-3'UT A64
4793 bps
SpeI
T7 promoter5' UTR 
NS3
3' UTR A64
 
Core gene sequences including T7 promoter and A64 regions: 
 
TAATACGACTCACTATAGGGAGACAAGCTTGCTTGTTCTTTTTGCAGAAGCTCAGAA
TAAACGCTCAACTTTGGCAGATCTGCAGGTCGACTCTAGAGGATCCACCATGAGCAC
GAATCCTAAACCTCAAAGAAAAACCAAACGTAACACCAACCGCCGCCCACAGGACG
TCAAGTTCCCGGGCGGTGGTCAGATCGTTGGTGGAGTTTACCTGTTGCCGCGCAGGG
GCCCCAGGTTGGGTGTGCGCGCGCCCAGGAAGACTTCCGAGCGGTCGCAACCTCGT
GGAAGGCGACAACCTATCCCCAAGGCTCGCCGGCCCGAGGGCAGGACCTGGGCTCA
GCCCGGGTACCCTTGGCCTCTCTATGGCAATGAGGGCTTAGGGTGGGCAGGATGGCT
CCTGTCACCCCGCGGCTCCCGGCCTAGTTGGGGCCCCACGGACCCCCGGCGTAGGTC
GCGTAATTTGGGTAAGGTCATCGATACCCTCACATGCGGCTTCGCCGATCTCATGGG
GTACATTCCGCTCGTCGGCGCCCCCCTGGGGGGCGCTGCCAGGGCCCTGGCACATGG
TGTCCGGGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATCTGCCCGGTTGCTC
TTTCTCTATCTTCCTCTTGGCTCTGCTGTCCTGCCTGACCACCCCAGCTTCCGCTTAA
GAGAATTCTAGTGACTGACTAGGATCTGGTTACCACTAAACCAGCCTCAAGAACACC
CGAATGGAGTCTCTAAGCTACATAATACCAACTTACACTTACAAAATGTTGTCCCCC
AAAATGTAGCCATCGTATCTGCTCCTAATAAAAAGAAAGTTTCTTCACATTCTTTAA
TTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAA 
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NS3 gene sequence including T7 promoter and A64 regions: 
 
TAATACGACTCACTATAGGGAGACAAGCTTGCTTGTTCTTTTTGCAGAAGCTCAGAA
TAAACGCTCAACTTTGGCAGATCTGCAGGTCGACTCTAGAGGATCCACCATGGCGCC
TATTACGGCCTACTCCCAACAGACGCGAGGCCTACTTGGCTGCATCATCACTAGCCT
CACAGGCCGGGACAGGAACCAGGTCGAGGGGGAGGTCCAAGTGGTCTCCACCGCA
ACACAATCTTTCCTGGCGACCTGCGTCAATGGCGTGTGTTGGACTGTCTATCATGGT
GCCGGCTCAAAGACCCTTGCCGGCCCAAAGGGCCCAATCACCCAAATGTACACCAA
TGTGGACCAGGACCTCGTCGGCTGGCAAGCGCCCCCCGGGGCGCGTTCCTTGACACC
ATGCACCTGCGGCAGCTCGGACCTTTACTTGGTCACGAGGCATGCCGATGTCATTCC
GGTGCGCCGGCGGGGCGACAGCAGGGGGAGCCTACTCTCCCCCAGGCCCGTCTCCT
ACTTGAAGGGCTCTTCGGGCGGTCCACTGCTCTGCCCCTCGGGGCACGCTGTGGGCA
TCTTTCGGGCTGCCGTGTGCACCCGAGGGGTTGCGAAGGCGGTGGACTTTGTACCCG
TCGAGTCTATGGAAACCACTATGCGGTCCCCGGTCTTCACGGACAACTCGTCCCCTC
CGGCCGTACCGCAGACATTCCAGGTGGCCCATCTACACGCCCCTACTGGTAGCGGCA
AGAGCACTAAGGTGCCGGCTGCGTATGCAGCCCAAGGGTATAAGGTGCTTGTCCTG
AACCCGTCCGTCGCCGCCACCCTAGGTTTCGGGGCGTATATGTCTAAGGCACATGGT
ATCGACCCTAACATCAGAACCGGGGTAAGGACCATCACCACGGGTGCCCCCATCAC
GTACTCCACCTATGGCAAGTTTCTTGCCGACGGTGGTTGCTCTGGGGGCGCCTATGA
CATCATAATATGTGATGAGTGCCACTCAACTGACTCGACCACTATCCTGGGCATCGG 
CACAGTCCTGGACCAAGCGGAGACGGCTGGAGCGCGACTCGTCGTGCTCGCCACCG
CTACGCCTCCGGGATCGGTCACCGTGCCACATCCAAACATCGAGGAGGTGGCTCTGT
CCAGCACTGGAGAAATCCCCTTTTATGGCAAAGCCATCCCCATCGAGACCATCAAG
GGGGGGAGGCACCTCATTTTCTGCCATTCCAAGAAGAAATGTGATGAGCTCGCCGC
GAAGCTGTCCGGCCTCGGACTCAATGCTGTAGCATATTACCGGGGCCTTGATGTATC
CGTCATACCAACTAGCGGAGACGTCATTGTCGTAGCAACGGACGCTCTAATGACGG
GCTTTACCGGCGATTTCGACTCAGTGATCGACTGCAATACATGTGTCACCCAGACAG
TCGACTTCAGCCTGGACCCGACCTTCACCATTGAGACGACGACCGTGCCACAAGAC
GCGGTGTCACGCTCGCAGCGGCGAGGCAGGACTGGTAGGGGCAGGATGGGCATTTA
CAGGTTTGTGACTCCAGGAGAACGGCCCTCGGGCATGTTCGATTCCTCGGTTCTGTG
CGAGTGCTATGACGCGGGCTGTGCTTGGTACGAGCTCACGCCCGCCGAGACCTCAGT
TAGGTTGCGGGCTTACCTAAACACACCAGGGTTGCCCGTCTGCCAGGACCATCTGGA
GTTCTGGGAGAGCGTCTTTACAGGCCTCACCCACATAGACGCCCATTTCTTGTCCCA
GACTAAGCAGGCAGGAGACAACTTCCCCTACCTGGTAGCATACCAGGCTACGGTGT
GCGCCAGGGCTCAGGCTCCACCTCCATCGTGGGACCAAATGTGGAAGTGTCTCATAC
GGCTAAAGCCTACGCTGCACGGGCCAACGCCCCTGCTGTATAGGCTGGGAGCCGTT
AAAACGAGGTTACTACCACACACCCCATAACCAAATACATCATGGCATGCATGTCG
GCTGACCTGGAGGTCGTCACGAGCACCTGAGTGAATTCTAGTGACTGACTAGGATCT
GGTTACCACTAAACCAGCCTCAAGAACACCCGAATGGAGTCTCTAAGCTACATAAT
ACCAACTTACACTTACAAAATGTTGTCCCCCAAAATGTAGCCATCGTATCTGCTCCT
AATAAAAAGAAAGTTTCTTCACATTCTTTAATTAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
 
Figure 5.7. Designed primers, pGEM-core and pGEM-NS3 plasmids and gene sequences. 
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5.5 Discussion 
The effect of HCV infection on DC maturation has been the subject of controversy in the 
past few years. To test the effects of HCV proteins on human DCs, iDC generated from healthy 
volunteers were transfected with IVT core or NS3 RNA and evaluated for their capacity to 
mature in comparison to non-transfected iDCs or IVT GFP RNA-transfected iDCs. The core and 
NS3 proteins are among the most conserved proteins of HCV and are thought to play a key role 
in viral clearance. Transfection of DCs by these HCV genes did not show an inhibitory effect on 
DC maturation. In contrast, we obtained evidence for induction of DC maturation by transfection 
with IVT core RNA. Therefore, the effects of core on DC maturation were further investigated at 
the transcriptional and functional level.  
Core appeared to induce radical changes in gene transcripts. When the 71 genes affected 
by core were compared to the number affected by other treatments, 46 were significant and 
distinctive to core in all three replicates. Forty-two of these genes (91%) were changed at the 
transcriptional level in agreement with maturation of DCs. By categorizing these 42 genes 
according to functional properties (Table 2), the changes agreed with the functions expected of 
mDCs. Several known phagocytic genes (CD209, CSF1R, FCER1A, and FCER2) were down-
regulated and at the same time the transcript levels of genes involved in antigen processing and 
presentation (ADAMDEC1, HLA-A, HLA-F, CD80, CD83, CD86, and CD205) were increased. 
A reduction in gene expression of CST3, an inhibitor of proteinase activity in the Golgi system, 
suggested an increase in the level of antigen processing in the cytoplasm compatible with an 
mDC state. An increase in expression of an IL-12-induced gene, PSCDBP, which plays a role in 
de-attachment of DCs from T cells, is indicative of a programmed change compatible with the 
characteristics of mDCs. Although CD1 receptors (CD1a, CD1b, and CD1c) are involved in 
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presentation of lipid antigens, the slight reduction in gene expression during DC maturation is in 
agreement with other studies (Palucka, Taquet et al. 1998; Yanagihara, Komura et al. 1998; 
Hashimoto, Suzuki et al. 2000; Le Naour, Hohenkirk et al. 2001; Messmer, Messmer et al. 
2003). A reduction was also consistently observed in cell surface expression of CD1a on mDCs 
(data not shown) and might have occurred in compensation of the up-regulation of the other 
important receptors involved in presentation of peptides, especially when this occurs with 
reduced levels of Lipase A (LIPA) enzyme in order to adopt higher levels of processing and 
presentation of peptide antigens. In fact, the expression of LIPA, which is a crucial enzyme for 
the intracellular hydrolysis of lipoprotein particles after uptake, was shown to be high in iDCs 
(Dietz, Bulur et al. 2000; Hashimoto, Suzuki et al. 2000; Ahn, Lee et al. 2002) and decreased in 
response to LPS (Messmer, Messmer et al. 2003). This might suggest that LIPA enzyme activity 
is highest in the early stages of maturation. 
As high motility of mDCs is required, the increased gene expression of the ADAMDEC1 
and MARCKSL1 genes and decreased expression of ARHGDIB, CSF1R, ITGAX, ITGB2, VCL 
and F13A1 genes, which are involved in cell motility and cell adherence, respectively, are 
interesting, while the increased gene expression of the chemokine receptors CCR7 and CXCR4 
favours motility toward the lymph nodes. A consistent increase in the level of EBI3 gene 
expression, an IL-12 related gene involved in clonal expansion of naïve T cells, as well as an 
increase in the expression of a number of chemokine genes (CCL5, CCL8, CXCL10, and 
CXCL16) involved in attraction of different subtypes of T cells and NK cells facilitate a 
potential interaction between mDCs and T cells, which supports the induction of immune 
responses. The high CCL5 and CCL8 gene expression may play a role in attraction of iDCs, 
which would also boost the immune response. In addition to these changes, the involvement of 
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components of the NFKB pathway, suggested to be related to DC maturation by adenoviruses, 
could indicate a role of this important pathway in DC maturation by core. 
Although there are insufficient data on the functions of the other genes affected by 
transfection with IVT core RNA, the expression levels of these genes changed in the same 
direction as reported for maturation elsewhere. Some of these genes are well known antiviral 
factors (IFI27, IFIT1, ISG20), which, as an early event in the immune defense, are not expected 
to impede the maturation process. SOD2, an important mitochondrial antioxidant enzyme, is also 
suggested to play a role in the immune response as it is up-regulated in cells phagocytosing virus 
in other species (Zhang, Li et al. 2007).  
Transfection with core changed the expression of most of the genes affected by TNF-α in a 
similar manner, which supports the contention of core inducing maturation of human iDCs. In 
addition, the spotted complementary oligonucleotides on the arrays are 60 nucleotides in length 
(considered long oligonucleotides), which recognize 3’-biased sequences of each gene with 
enough distance from 3’ end of transcript. This makes the results of this 288-spot array very 
reliable and thus conclusive, especially with consistency in the three biological replicates (Fig. 
5.4). Most importantly, these maturation-compatible changes in the transcriptional profiles of the 
DCs were confirmed with phenotypic and functional studies, which showed that the effects of 
core were stronger than those of TNF-α, resulting in higher levels of CD83 and HLA-DR 
expression. Furthermore, IVT core RNA-transfected iDCs showed a reduction in endocytosis, 
while the induction of T cell proliferation was enhanced, suggesting an augmented antigen 
presentation capacity, as expected of mDCs.  Finally, IVT core RNA-transfected DCs retained 
the capacity to secrete IL12-p70, and induced IFN-γ production by T cells in a MLR assay, in 
agreement with the increased gene expression of the IL-12-related proteins PSCDBP and EIB3. 
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Collectively, HCV core did not inhibit the maturation of DCs, but appeared to have the ability to 
mature DCs with a type-1 cytokine profile. 
Although this seems surprising in view of the reports suggesting inhibition of maturation 
by HCV genes, induction of DC maturation by core is indeed in agreement with the 
physiological process expected from an intact and competent immune system when encountering 
a viral antigen. This effect on maturation agrees with the contention that core might decrease the 
viral load and maintain a low steady state dose of HCV in infected cells in order to escape from 
antigen presentation (Kato 2001). Transfection with IVT RNA has the advantage of being very 
efficient without the presence of other viral genes.  Although signalling through TLR7/8 may 
contribute to maturation of iDCs transfected with ssRNA, this did not appear to be a major 
contributing factor, as very few gene expression changes were observed in IVT NS3 or GFP 
RNA-transfected iDCs. The secondary structure in core RNA (Tuplin, Wood et al. 2002) might 
have led to activation of TLR3 and type I IFNs; however, this is not necessary due to induction 
of TLR3 by dsRNA, as core protein could have effects on the downstream steps of the TLR3 
signalling pathways as reported for other HCV proteins. Moreover, TLR3 is an intracytoplasmic 
receptor and usually induced by constitutive replication of viral RNA while the IVT core RNA 
has a very short half-life, as it is rapidly degraded in the cytoplasm. Finally, in spite of 
similarities in the changes in gene profile (Avril, de Tayrac et al. 2009), several genes changed 
differently in the presence of core in comparison to TLR3. For example, adhesion molecules that 
are down-regulated due to core favouring increased DC motility are up regulated by TLR3 
signalling (Lee, Hooper et al. 2007; Liu, Kimura et al. 2008), while CXCR4, which is up-
regulated by core is down regulated by TLR3 agonists (Zhang, Sun et al. 2009). As a result, 
HCV core protein might not only be a factor in immune evasion, but could also be an excellent 
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immunogenic antigen to induce a strong immune response through maturing DCs. However, 
since the inhibitory effects of HCV proteins may only occur when the viral genome is replicated 
during the natural course of infection, HCV may still evade the immune system by interfering 
with the maturation process in vivo. This hypothesis is supported by two recent studies, showing 
that infection of in vitro generated DCs with the full HCV genome results in some degree of DC 
impairment in culture (Saito, Ait-Goughoulte et al. 2008; Shiina and Rehermann 2008), although 
other reports are not in agreement (Ebihara, Shingai et al. 2008). 
To our knowledge, this is the first study of the effects of HCV core and NS3 on gene 
expression profiles of DCs. The results, which suggest that core induces DC maturation, were 
confirmed by phenotypic and functional assays. Core is one among the most conserved HCV 
proteins, and thus is expected to elicit immune responses to a broad range of virus variants 
(Lechner, Wong et al. 2000). This proposes core as a target for the immune system, and as such, 
a good candidate to induce a Th1-type immune response. 
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6 General discussions and conclusions 
This work was based on evidence suggesting inhibition of DC maturation by HCV. Our 
initial goal was to evaluate the effect of HCV on DCs from patients at different stages of chronic 
infection; however, limited access to patients led us to evaluate the effects of HCV genes on in 
vitro generated DCs from healthy donors. Since the maturation process was the focus of our 
study, iDCs were generated, transfected by HCV genes, matured, and evaluated for changes in 
their functional charcteristics and gene expression profiles indicating inhibition of maturation 
due to the presence of HCV proteins.  
Our first objective was to optimize the generation of DCs from monocytes. We had to 
work with human primary DCs since there is no appropriate DC cell line available to be used as 
a prototype and stimulation of available monocyte cell lines such as THP-1 is not generating 
fully qualified DCs for our study. Since there is a limited number of human DCs in the peripheral 
circulation, we generated DCs in vitro through the isolation and stimulation of monocytes. 
Particular attention was paid to this process as different culture conditions may result in different 
DC subtypes, which potentially behave differently in response to expression of HCV proteins. 
After optimization of DC generation, we mainly focused on transfection of DCs. In this regard, 
two parameters were crucial, the efficiency of transfection and the viability of the DCs after 
transfection. As DCs have short life span, we hypothesized that if we generate DCs more rapidly, 
this may enhance their viability after transfection. To achieve this goal, attention was paid to 
avoid stimulation of monocytes during the isolation process, as it could drive them toward MФs, 
which in turn could delay the process of differentiation to DCs. Several key variables were 
optimized. First, as the PBMC suspension was to be incubated with CD14
+
 MicroBeads at 4 ºC, 
the temperature was gradually reduced to avoid stimulation of monocytes. Secondly, very gentle 
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pipetting techniques with widebore pipette tips were practiced. Thirdly, the culture media was 
modified by reducing and replacing FBS with L-glutamine favoring less stimulation of 
monocytes. Finally, the concentration of IL-4 was increased as it has been reported to be the 
crucial cytokine in differentiation of monocytes to DCs, and to be responsible for better survival 
of hematopoietic cells. Indeed, higher levels of IL-4 in combination with the changes mentioned 
above resulted in faster conversion of monocytes to iDCs. The role of IL-4 in differentiation of 
monocytes to iDCs was confirmed as we observed a dramatic appearance of DC markers in 
differentiating monocytes when IL-4 was used in isolation. This eventually led to the 
development of a new method allowing fast generation of iDCs (Chapter 3). Although a report 
had been published on the generation of mDCs within 48 h, our protocol was the first one on fast 
generation of iDCs. When these iDCs were compared to conventionally generated iDCs, they 
shared all phenotypic and functional characteristics, and were equally capable of converting to 
functional mDCs. 
Although this method of iDC generation is a significant advancement in in vitro 
generation of DCs, future studies could be designed to compare different cytokine cocktails as an 
approach to better understand DC biology. In addition, different subtypes of DCs may be 
generated and their characteristics compared, as it is not known whether pre-programmed 
subtypes of DCs determine the type of immune response based on the expression of different 
PRRs on their surface such as TLRs, or whether each DC population has the ability to generate 
both types of Th1 versus Th2 immune responses based on the nature of the pathogen they 
encounter or the presence of cytokines secreted by other immune cells involved in this process 
(Maldonado-Lopez, De Smedt et al. 1999; Kapsenberg 2003). 
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Since most of the previously reported non-viral approaches to transfect DCs have failed 
or ended in significant damage and death of the DCs, our next objective was to develope an 
efficient method to transfect iDCs while retaining high viability. The previous failures are likely 
due to the fact that DCs are professional APCs and strictly control the trafficking of molecules 
across their cell membranes making it difficult to artificially transfer genes into their nucleus. 
Although viral vectors were successfully used for this purpose (Hiasa, Horiike et al. 1998; Jooss, 
Yang et al. 1998; Ponnazhagan, Mahendra et al. 2001; Dullaers, Breckpot et al. 2004; 
Siavoshian, Abraham et al. 2005), potential effects on DC function and maturation due to the 
presence of vector genes have been reported for several viral vectors (Engelmayer, Larsson et al. 
1999; Salio, Cella et al. 1999; Drillien, Spehner et al. 2000; Jenne, Hauser et al. 2000; Kruse, 
Rosorius et al. 2000; Morelli, Larregina et al. 2000; Philpott, Nociari et al. 2004; Basner-
Tschakarjan, Gaffal et al. 2006). Therefore, we sought non-viral approaches to transfect DCs. 
Furthermore, for clinical use, there is a need for DC-based immunotherapy without the risk of 
exposing individuals to other viral genes or integration of the viral genome. Non-viral 
approaches of gene transfer have been used in recent years; however, inefficient gene transfer to 
DCs, low levels of gene expression or low cell viability by non-viral transfection methods have 
limited studies on DCs (Chamarthy, Jia et al. 2004; Dullaers, Breckpot et al. 2004; Erhardt, 
Gorschluter et al. 2005; Tan, Beutelspacher et al. 2005). 
By investigating different methods of transfection, we successfully established a new 
method of nucleofection for iDCs with high efficiency and viability (Chapter 3). First, we 
evaluated reagents that seemed to be less harmful to DC survival. Although acceptable viability 
was achieved, the efficiency and more importantly the level of protein expression was generally 
too low. Conventional electroporation of DNA plasmids on the other hand resulted in much 
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lower viability, while it did not also show acceptable transfection efficiency. By using IVT 
RNAs with conventional electroporation combined with optimized parameters (such as voltage, 
capacitance, and resistance), we observed up to 80% transfection efficiency and acceptable 
viability for DCs; however, the level of protein expression was still insufficient for functional 
studies and transient. Nevertheless, these optimized methods might be valuable when temporary 
and low expression levels of the target protein are preferred. The use of TTR with IVT RNA 
resulted in high efficiency and viability with an interesting stimulatory effect on DC maturation, 
which is an advantage if the generation of mDCs is desired. Although it is not clear but the effect 
on maturation could be a result of lipid-based formulation of TTR. Finally, we were able to 
optimize a new method of nucleofection, which resulted in the highest efficiency reported for 
DCs, as well as long-term viability and high levels of protein expression in DCs. This method is 
based on the X1 program of an Amaxa nucleofection device as optimal setting in combination 
with IVT RNA. An important feature of this approach was that DCs keep their immature status, 
making them suitable for studying the effects of HCV genes on the maturation process. In 
addition, they showed normal potential to secrete IL-12 in response to LPS stimulation. In 
conclusion, this newly established transfection method could be considered as a milestone in DC 
research since transfection of DCs has been a significant barrier for a long time. 
To extend this work, we propose to investigate potentially gentler methods of gene 
delivery into DCs, as the nucleofection method still uses electrical shock, which may affect DC 
functionality. One approach could be the use of cationic or anionic micro particles for transfer of 
genes or proteins into the DCs. A relatively stable combination of candidate genetic material 
(DNA or RNA) or proteins with micro particles of different sizes could be evaluated for the 
potential to passively enter DCs via phagocytosis. The current problem with this approach is low 
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efficiency, but if the efficiency improves, this method may also induce DC maturation, which is 
an additional advantage for in vivo application of DCs when mDCs are needed. Another 
interesting approach could be delivery of target antigens via specific receptors on the DC 
surface, which are normally taken up after interacting with their ligands (Boscardin, Hafalla et al. 
2006). Members of the MMR receptor family such as CD205 are good candidates for this 
approach. Genes of microbial proteins can be genetically engineered into anti-receptor antibodies 
plasmids, transcribed in vitro while attached to given antibodies, which could easily interact with 
their receptor on the cell surface and deliver the proteins into the cell through the natural 
mechanism of phagocytosis. This method is indeed the most natural way of antigen delivery for 
extracellular proteins and could increase the antigen presentation efficiency by more than 100-
fold relative to non-targeted antigens (Bozzacco, Trumpfheller et al. 2007). Other candidates for 
this kind of approach include MMR/CD206 and DC-SIGN/CD209 receptors. A disadvantage of 
phagocytic receptor-associated antigen transfer into DCs is the type of the immune response 
induced as exogenously-obtained antigens are generally presented in MHC class II pathways; 
however, this possibility could be investigated and addressed in light of cross-presentation 
capabilities of DCs. 
After establishing successful transfection of iDCs, we intended to evaluate the effects of 
HCV genes on the process of DC maturation. By reviewing studies on the generation of mDCs 
for in vitro assays or in vivo purposes, we noticed that insufficient attention was paid to the 
method used for maturation and thought that the controversial reports on the effects of HCV on 
DC maturation could be due to this issue. Thus, prior to evaluating the effects of HCV genes on 
DC maturation, we performed an extensive study on the characteristics of mDCs generated by 
different methods of maturation (Chapter 4). Our data showed that mDCs generated with 
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different methods varied significantly in their morphology and level of maturity leading to 
different functional abilities as mDCs. A cytokine cocktail containing IL-1β, IL-6, TNF-α, and 
PGE2 proved to be a superior maturation agent in comparison to TNF-α and LPS, based on the 
induction of phenotypic and functional characteristics compatible with mDCs. The PGE2-
containing cocktail also induced transcriptional changes in a significant number of additional 
genes in comparison to the other two methods. These genes were mostly involved in DC 
maturation and corresponded to changes expected of mDCs. Although the quality of the immune 
response induced by the PGE2-containing cocktail has been questioned, based on the 
transcriptional profile of MC-mDCs, there was no evidence for a Th2-type immune response. In 
contrast, we observed an increase in transcript levels of IL-12β, IL-27β, which normally 
precedes the secretion of IL-12 during maturation, IL-15, and an IL-12-induced gene, PSCDBP, 
as well as Th1-promoting changes in the transcripts of chemokines CXCL16, CCL13, and 
CCL18. IL-12 and IL-15 are Th1-type cytokines, and IL-27β is a Th1-biased cytokine, which is 
usually an early-secreted cytokine in the process of maturation, preceding secretion of IL-12. 
This sequential order of cytokine secretion resembles the licensing phase in LNs in vivo and 
provides support for retaining PGE2 in the MC cocktail, especially for DCs matured for clinical 
use, as under physiological conditions the secretion of IL-12 at later stages in the LNs is crucial. 
Moreover, the in vitro secretion of IL-12 during maturation is not beneficial as it may result in 
exhaustion or paralysis of DCs after a transient production of IL-12 during maturation (Reis e 
Sousa, Yap et al. 1999; Langenkamp, Messi et al. 2000). More interestingly, these changes were 
accompanied by increases in the transcript levels of MHC class I molecules HLA-A and HLA-F, 
combined with reduction in the expression of MHC class II molecules such as HLA-DQA1, 
HLA-DRB5, HLA-DRA, and HLA-DMA. Finally, the transcript levels of TLR2, which was 
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recently suggested to be involved in Th2-type immune responses, was reduced. Thus, we suggest 
retaining of PGE2 in the cocktail for maturation of DCs. 
As an extension of the maturation study, a more extensive analysis of different 
combinations of maturation factors, in particular TLR ligands, is worth performing. A full panel 
of DC markers could be applied, and some of the interesting genes should be studied using 
quantitative real time PCR. By using larger gene arrays, there is a chance of finding new genes 
and proteins involved in maturation, which could be considered new markers for mDCs.  
Although achieving effective maturation of DCs ex vivo has not been a major problem, in 
vivo migration of DCs, which is a critical parameter for successful immunotherapy has been a 
challenge (Verdijk, Aarntzen et al. 2008). This aspect of mDCs was initially underestimated, as 
in preliminary in vivo trials, DCs loaded with target antigens did not leave the site of injection 
and were not able to trigger an immune response. If DCs do not migrate toward LNs, where they 
can interact with T cells, they cannot deliver the antigen for presentation and the immune 
response will be aborted. In addition, as ex vivo generated DCs may not be as healthy as in vivo 
ones, they might be rapidly cleared from the body before getting to the point of antigen 
presentation. Thus, faster and more effective motility of DCs bearing target antigens is required. 
In this regard, in vitro maturation stimuli should result in a high level of CCR7 expression, the 
selective receptor for homeostatic chemokines CCL19 and CCL21 constitutively produced in 
secondary lymphatic tissues (Willimann, Legler et al. 1998; MartIn-Fontecha, Sebastiani et al. 
2003). In complementary studies, transfected mDCs can be labeled with radioactive compounds, 
fluorochrome-conjugated antibodies, or paramagnetic beads and be traced. Carboxyfluorescein 
diacetate succininidyl ester (CFSE), which passively diffuses into the cells and becomes 
impermeant and stable for a long time, could be a potential dye to label and follow DCs in vivo.   
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In summary, maturation is not a simple one-step event; conversely, it is a progressive 
well-programmed process with a high level of complexity, the details of which are mostly yet to 
be discovered. To simplify and quantify this concept, and to compare results from different 
laboratories, we suggest a definition of a maturity index for the level of maturity based on a 
mathematical model. Based on a maturity index, mDCs generated in different studies could be 
properly compared and the results could potentially be predicted in experiments or trials. This 
may also indentify the level of DC maturity as the reason for the controversial reports on the 
effects of HCV on DCs in different studies. Defining a maturity index is part of an ongoing 
interdisciplinary study in collaboration with mathematicians. Although to mathematically define 
a biological concept is in its initial phase, modeling of maturation could be a starting point to 
engage mathematical modeling in conceptual aspects of immunology.  
 As our ultimate objective, we proceeded to evaluate the effects of HCV genes on DCs. 
Fast iDCs were transfected with different HCV genes individually or in various combinations 
and checked for their characteristic in the presence or absence of different maturation agents. 
Interestingly, we did not observe any inhibitory effect on DC maturation by individual or 
combinations of HCV genes transferred to DCs generated from healthy donors. In contrast, we 
observed a considerable increase in CD83 expression due to core expression in DCs, without 
addition of any maturation agent. Thus, we designed experiments to compare the effects of core 
protein on iDCs with those induced by a common maturation agent, TNF-α. Non-structural 
protein 3 was included as a HCV gene that had no effects on DC maturation in our preliminary 
studies. Our data showed that not only did core not impair the maturation of DCs, it actually 
induced maturation of DCs (Chapter 5). According to transcriptional profiles, core altered the 
expression levels of a significant number of genes related to the process of DC maturation. The 
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core-transfected DCs also developed a mature phenotype based on the expression of CD83 and 
HLA-DR, as well as characteristics of mDCs in phagocytosis and MLR assays. These effects 
were similar to, but much stronger than those of TNF-α. Furthermore, contrary to other reports 
core-transfected DCs still retained their ability to secrete significant amounts of IL-12 in 
response to LPS or poly I:C stimulation and induced proliferation and IFN-γ secretion by T cells 
in a MLR assay. The fact that IVT GFP and NS3 RNAs did not induced DC maturation 
confirmed that this effect is not due to TLR7/8 receptor stimulation by IVT ssRNAs. In addition, 
several genes involved in adhesion and motility of DCs has changed differently in core 
transfected DCs in comparison to TLR3 signalling (Lee, Hooper et al. 2007; Liu, Kimura et al. 
2008; Avril, de Tayrac et al. 2009; Zhang, Sun et al. 2009). This shows that the double-stranded 
secondary structure of IVT core RNA (Tuplin, Wood et al. 2002) is not likely responsible for 
maturation induction. To further support this notion, an experiment with point mutations in core 
RNA could be designed to rule out a possible TLR3 stimulation as a contributing factor in 
maturation instead of the expression of core protein. 
Overall, by reporting induction of DC maturation by HCV core protein, we proposed core 
as a strong immunogenic component of HCV with the potential to induce Th1-type immune 
responses, which suggests core to be a target antigen for the immune defense. This conclusion 
agrees with previous reports on the induction of humoral and cellular immune responses by core 
(Iwata, Wakita et al. 1995; Lasarte, Garcia-Granero et al. 1998; Alisi, Giambartolomei et al. 
2003). Based on these results, core could possibly be used as a target antigen to formulate 
vaccines with appropriate adjuants in in vivo systems. An alternative would be the evaluation of 
DCs loaded with core protein or genes expressing core in initiating an appropriate immune 
response in in vivo.  
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To our knowledge, this is the first study evaluating the effects of HCV genes on DC 
maturation based on gene expression in addition to phenotypic and functional characteristics. 
The results strongly suggest that core protein can induce DC maturation, while NS3 had no effect 
on DCs. This may not necessarily contradict results obtained with DCs generated from CHC 
patients, as inhibitory effects may only occur when the whole viral genome is replicated, 
resulting in evasion of HCV via interference with the maturation process. Indeed, there are 
several reasons, which may explain the contradictory observations.  
To address the discrepancies between studies with patients’ DCs and those with in vitro 
tranfected DCs from healthy individuals, the first potential reason might be the introduction of 
the virus or viral genes in two different manners (Kanto, Hayashi et al. 1999; Kanto, Inoue et al. 
2004; Li, Li et al. 2006). Typically, DCs in patients are exposed to the virus such that the whole 
genome is replicated during natural infection, which may be optimal condition for the expression 
of viral proteins leading to successful evasion from immune system. In contrast, the presence of 
a complete set of defense strategies may effectively limit viral replication in vivo, while in vitro 
infected or transfected cells may fail to overcome the viral effects. In conclusion, the results from 
studies on DCs generated from patients cannot be compared to the results from studies on DCs 
that are infected or transfected in vitro.  
To perform complementary studies, infecting DCs from healthy volunteers with a 
recently characterized clinical isolate of HCV (Kato, Furusaka et al. 2001), Japanese fulminant 
hepatitis virus 1 (JFH-1) would be interesting, resembling natural infection in vivo. This 
approach is not straightforward as the virus hardly proliferates in primary DC cultures, except 
under very specific conditions. However, since the results of an in vitro study on the effects of 
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JFH-1 virus on DC maturation might better model a true HCV infection, it would be worth 
improving the replication of JFH-1 in primary DCs.   
Contradictory results obtained in experiments with DCs generated from chronic patients, 
could be due to a difference in the methods of DC generation and maturation. Thus, the results of 
even two similar experiments using patient DCs might still not be in agreement if the same 
method for DC generation and maturation was not used. For similarly in vitro generated and 
matured DCs from healthy volunteers, the use of different methods of loading DCs with viral 
antigens (Dolganiuc, Kodys et al. 2003; Zhou, Lukes et al. 2007; Thumann, Schvoerer et al. 
2008; Zimmermann, Flechsig et al. 2008) might be an additional reason for discrepancies. The 
method of transfection needs to be carefully examined, especially when the use of viral vectors is 
considered, because two separate viral genes could act synergistically with respect to induction 
or inhibition of DC maturation. 
Thus, non-viral methods seem more reasonable to avoid such a effect. However, a 
common disadvantage of electroporation-based non-viral transfection methods is their negative 
effect on the functionality of DCs, which could be due to general damage to the cellular function 
and not necessarily to inhibition of specific pathways of maturation. This may also explain the 
differences in results between a viral method versus a non-viral method or direct exposure of the 
DCs to viral proteins. The solution to this problem was the development of non-viral non-
invasive protocols for gene transfer into DCs. In comparison to other in vitro studies, our study 
had the advantage of not using a viral vector for transfection of DCs supporting that the observed 
effect on maturation is primarily related to HCV core protein. 
  The other issue is whether a combination of two or more genes might have a stronger 
effect on DCs. Although we investigated this possibility and did not observe any inhibitory 
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effects of multiple HCV genes, studies with the complete genome of the virus, VLPs or the use 
of JFH-1 virus could further clarify this matter. The level of expression of each protein is also 
important, as during HCV infection low antigenicity could be one of the evasion mechanisms. 
By using different amounts of IVT RNAs expressing HCV proteins, this effect could be 
investigated. Ideally, transfection of DCs with the whole genome of a virus may result in 
proportionally appropriate amounts of viral proteins, which resembles a natural course of 
infection even if the whole viral replication cycle is not completed. However, these approaches 
should be compared to determine which combination or level of protein expression might have 
effects on DC maturation. 
The genetic material used for transfection might also influence the DCs. For example, 
transfection of DCs using RNA may result in a low level of maturation induction via interacting 
with TLR receptors. Therefore, if RNA is used for transfection and no inhibitory effect is 
observed, weak effects of the viral proteins might have been compromised by the effect of 
introduced RNA in the cells. In our study however, proper controls and complementary work 
such as gene expression profiling ruled out this possibility, as the transcriptional profiles of 
mDCs differed those expected from a TLR-specific pathway (Chapter 5). In summary, although 
there are several ways to explain discrepancies between observed effects of HCV on DC 
maturation, at this stage a definite explanation is not readily available. More studies need to be 
performed, specifically with DCs from hepatitis C patients.  
Therefore, to further extend this study, we have planned to evaluate the response of DCs 
from hepatitis C patients to different maturation stimuli. Chronic, treated versus untreated, and 
spontaneously resolved versus chronic cases will be chosen for this investigation, and 
transcriptional studies will be designed as complementary approaches to functional evaluation of 
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the DCs. Finally, a collective review of all reported studies may lead to a possible conclusion on 
the effects of HCV on DC maturation. 
In conclusion, the most significant results included i) Development of a new method for 
rapid generation of iDCs with minimal handling and high reproducibility in biological replicates. 
ii) Establishment of a new nucleofection method for DC transfection with excellent efficiency 
and viability as well as high level of protein expression. iii) The first extensive and comparative 
study on DC maturation using gene profiling suggesting a different level of maturity of mDCs as 
a possible reason for the controversy of HCV effects on DC maturation. And iv) Induction, but 
not inhibition of maturation of DCs by HCV core protein but not NS3 protein, supported by a 
gene expression study that proposes core as a candidate for vaccine design against HCV. 
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